<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp.: Form 10K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT><BR></B><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT><BR>Washington, D.C.
20549</B></P>
<P align=center><B><FONT size=5>FORM 10-K</FONT></B></P>
<P align=center>(Mark One) </P>
<P align=center><B>[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</B></P>
<P align=center>For the fiscal year ended: <U>September 30, 2010 </U>or</P>
<P align=center><B>[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
</B><B>SECURITIES EXCHANGE ACT OF 1934</B></P>
<P align=center>For the transition period from __________________to
__________________</P>
<P align=center>Commission file number: <U>000-51652 </U></P>
<P align=center><B><U><FONT size=5>ANAVEX LIFE SCIENCES
CORP.</FONT></U><BR></B>(Exact name of registrant as specified in its
charter)</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD align=center><U><B>Nevada </B></U></TD>
    <TD width="50%" align=center><U><B>20-8365999 </B></U></TD></TR>
  <TR vAlign=top>
    <TD align=center>State or other jurisdiction of </TD>
    <TD width="50%" align=center>(I.R.S. Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>incorporation or organization </TD>
    <TD width="50%" align=center>Identification No.) </TD></TR></TABLE>
<P align=center><B><U>50 Harrison Street, Suite 315A, Hoboken, NJ 07030
</U><BR></B>(Address of principal executive offices)( Zip Code) </P>
<P align=center>Registrant&#146;s telephone number, including area code
<B><U>1-800-689-3939</U></B></P>
<P align=center>Securities registered pursuant to Section 12(b) of the Act</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD align=center>Title of each class </TD>
    <TD width="50%" align=center>Name of each exchange on which registered
  </TD></TR>
  <TR vAlign=top>
    <TD align=center><B>Nil </B></TD>
    <TD width="50%" align=center><B>Nil </B></TD></TR></TABLE>
<P align=center>Securities registered pursuant to Section 12(g) of the Act</P>
<P align=center><B><U>Common Stock</U><BR></B>(Title of Class)</P>
<P align=center>Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No [X]
</P>
<P align=center>Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the Act. Yes [ ] No [X]</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_2></A>
<P align=center>ii</P>
<P align=center>Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]</P>
<P align=center>Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation
S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files).
<BR>Yes [ ] No [ ]</P>
<P align=center>Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of Regulation S-K (&#167; 229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant&#146;s
knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]
</P>
<P align=center>Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148;
&#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the
Exchange Act</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD align=center>Large accelerated filer [ ] </TD>
    <TD width="33%" align=center>&nbsp; </TD>
    <TD width="33%" align=center>Accelerated filer [ ] </TD></TR>
  <TR vAlign=top>
    <TD align=center>Non-accelerated filer [ ] </TD>
    <TD width="33%" align=center>(Do not check if a smaller reporting company)
    </TD>
    <TD width="33%" align=center>Smaller reporting company [X]
</TD></TR></TABLE></DIV>
<P align=center>Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Act). Yes [ ] No [X] </P>
<P align=center>State the aggregate market value of the voting and non-voting
common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such
common equity, as of the last business day of the registrant&#146;s most recently
completed second fiscal quarter. $43,134,494<B> (computed by reference to the
closing price of $3.14 per share on March 31, 2010)</B></P>
<P align=center>Indicate the number of shares outstanding of each of the
registrant&#146;s classes of common stock, as of the latest practicable date:
25,127,226 shares of common stock are issued and outstanding as of December 20,
2010.</P>
<P align=center>DOCUMENTS INCORPORATED BY REFERENCE</P>
<P align=center>List hereunder the following documents if incorporated by
reference and the Part of the Form 10-K (e.g., Part I, Part II, etc.) into which
the document is incorporated: (1) Any annual report to security holders; (2) Any
proxy or information statement; and (3) Any prospectus filed pursuant to Rule
424(b) or (c) under the Securities Act of 1933. The listed documents should be
clearly described for identification purposes (e.g., annual report to security
holders for fiscal year ended December 24, 1980). <B>Not applicable.</B></P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_3></A>
<P align=center>iii</P>
<P align=center>TABLE OF CONTENTS</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD bgColor=#eeeeee colSpan=2 align=left ><A
      href="#page_5">PART I </A></TD>
    <TD bgColor=#eeeeee width="10%" align=right><A href="#page_5">1 </A></TD></TR>
  <TR vAlign=top>
    <TD align=left ><A href="#page_5">ITEM 1. </A></TD>
    <TD width="80%" align=left ><A href="#page_5">BUSINESS
</A></TD>
    <TD width="10%" align=right><A href="#page_5">1 </A></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left ><A href="#page_17">ITEM 1A.
      </A></TD>
    <TD bgColor=#eeeeee width="80%" align=left ><A
      href="#page_17">RISK
      FACTORS </A></TD>
    <TD bgColor=#eeeeee width="10%" align=right><A
      href="#page_17">13
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left ><A
      href="#page_29">ITEM
      1B. </A></TD>
    <TD width="80%" align=left ><A
      href="#page_29">UNRESOLVED
      STAFF COMMENTS </A></TD>
    <TD width="10%" align=right><A
      href="#page_29">25
      </A></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left ><A
      href="#page_29">ITEM
      2. </A></TD>
    <TD bgColor=#eeeeee width="80%" align=left ><A
      href="#page_29">PROPERTIES
      </A></TD>
    <TD bgColor=#eeeeee width="10%" align=right><A
      href="#page_29">25
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left ><A
      href="#page_30">ITEM
      3. </A></TD>
    <TD width="80%" align=left ><A
      href="#page_30">LEGAL
      PROCEEDINGS </A></TD>
    <TD width="10%" align=right><A
      href="#page_30">26
      </A></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left ><A
      href="#page_30">ITEM
      4. </A></TD>
    <TD bgColor=#eeeeee width="80%" align=left ><A
      href="#page_30">(REMOVED
      AND RESERVED) </A></TD>
    <TD bgColor=#eeeeee width="10%" align=right><A
      href="#page_30">26
      </A></TD></TR>
  <TR vAlign=top>
    <TD colSpan=2 align=left ><A
      href="#page_30">PART
      II </A></TD>
    <TD width="10%" align=right><A
      href="#page_30">26
      </A></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left ><A
      href="#page_30">ITEM
      5. </A></TD>
    <TD bgColor=#eeeeee width="80%" align=left><A
      href="#page_30">MARKET
      FOR REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER
      PURCHASES OF EQUITY SECURITIES </A></TD>
    <TD bgColor=#eeeeee  width="10%" align=right><A
      href="#page_30">26
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left ><A
      href="#page_32">ITEM
      6 </A></TD>
    <TD width="80%" align=left ><A
      href="#page_32">SELECTED
      FINANCIAL DATA </A></TD>
    <TD width="10%" align=right><A
      href="#page_32">28
      </A></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left ><A
      href="#page_32">ITEM
      7 </A></TD>
    <TD bgColor=#eeeeee width="80%" align=left><A
      href="#page_32">MANAGEMENT&#146;S
      DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION
      </A></TD>
    <TD bgColor=#eeeeee  width="10%" align=right><A
      href="#page_32">28
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left ><A
      href="#page_38">ITEM
      7A </A></TD>
    <TD width="80%" align=left><A
      href="#page_38">QUANTITATIVE
      AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </A></TD>
    <TD  width="10%" align=right><A
      href="#page_38">34
      </A></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left ><A
      href="#page_39">ITEM
      8. </A></TD>
    <TD bgColor=#eeeeee width="80%" align=left ><A
      href="#page_39">FINANCIAL
      STATEMENTS AND SUPPLEMENTARY DATA </A></TD>
    <TD bgColor=#eeeeee width="10%" align=right><A
      href="#page_39">35
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left ><A
      href="#page_40">ITEM
      9. </A></TD>
    <TD width="80%" align=left><A
      href="#page_40">CHANGES
      IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS
      </A></TD>
    <TD width="10%" align=right><A
      href="#page_40">36
      </A></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left ><A
      href="#page_40">ITEM
      9A(T). </A></TD>
    <TD bgColor=#eeeeee width="80%" align=left ><A
      href="#page_40">CONTROLS
      AND PROCEDURES </A></TD>
    <TD bgColor=#eeeeee width="10%" align=right><A
      href="#page_40">36
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left ><A
      href="#page_43">ITEM
      9B </A></TD>
    <TD width="80%" align=left ><A
      href="#page_43">OTHER
      INFORMATION </A></TD>
    <TD width="10%" align=right><A
      href="#page_43">39
      </A></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee colSpan=2 align=left ><A
      href="#page_43">PART
      III </A></TD>
    <TD bgColor=#eeeeee width="10%" align=right><A
      href="#page_43">39
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left ><A
      href="#page_43">ITEM
      10 </A></TD>
    <TD width="80%" align=left ><A
      href="#page_43">DIRECTORS,
      EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </A></TD>
    <TD width="10%" align=right><A
      href="#page_43">39
      </A></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left ><A
      href="#page_49">ITEM
      11. </A></TD>
    <TD bgColor=#eeeeee width="80%" align=left ><A
      href="#page_49">EXECUTIVE
      COMPENSATION </A></TD>
    <TD bgColor=#eeeeee width="10%" align=right><A
      href="#page_49">45
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left ><A
      href="#page_54">ITEM
      12. </A></TD>
    <TD width="80%" align=left><A
      href="#page_54">SECURITY
      OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
      STOCKHOLDER MATTERS </A></TD>
    <TD width="10%" align=right><A
      href="#page_54">50
      </A></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left ><A
      href="#page_56">ITEM
      13. </A></TD>
    <TD bgColor=#eeeeee width="80%" align=left><A
      href="#page_56">CERTAIN
      RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </A></TD>
    <TD bgColor=#eeeeee width="10%" align=right><A
      href="#page_56">52
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left ><A
      href="#page_57">ITEM
      14. </A></TD>
    <TD width="80%" align=left ><A
      href="#page_57">PRINCIPAL
      ACCOUNTING FEES AND SERVICES </A></TD>
    <TD width="10%" align=right><A
      href="#page_57">53
      </A></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee colSpan=2 align=left ><A
      href="#page_57">PART
      IV </A></TD>
    <TD bgColor=#eeeeee width="10%" align=right><A
      href="#page_57">53
      </A></TD></TR>
  <TR vAlign=top>
    <TD align=left ><A
      href="#page_57">ITEM
      15. </A></TD>
    <TD width="80%" align=left ><A
      href="#page_57">EXHIBITS,
      FINANCIAL STATEMENT SCHEDULES </A></TD>
    <TD width="10%" align=right><A
      href="#page_57">53
      </A></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee colSpan=2 align=left ><A
      href="#page_62">SIGNATURES
      </A></TD>
    <TD bgColor=#eeeeee width="10%" align=right><A
      href="#page_62">58
      </A></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_4></A>
<P align=center>iv</P>
<P align=justify><B><I>Forward-Looking Statements</I></B></P>
<P align=justify>This Annual Report on Form 10-K includes forward-looking
statements. All statements other than statements of historical facts contained
in this Annual Report on Form 10-K, including statements regarding our
anticipated future clinical and regulatory milestone events, future financial
position, business strategy and plans and objectives of management for future
operations, are forward-looking statements. The words &#147;believe,&#148; &#147;may,&#148;
&#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect&#148; and similar
expressions, as they relate to us, are intended to identify forward-looking
statements. Such forward-looking statements include, without limitation,
statements regarding the anticipated start dates, durations and completion dates
of our ongoing and future clinical studies, statements regarding the anticipated
designs of our future clinical studies, statements regarding our anticipated
future regulatory submissions and statements regarding our anticipated future
cash position. We have based these forward-looking statements largely on our
current expectations and projections about future events, including the
responses we expect from the U.S. Food and Drug Administration, or FDA, and
other regulatory authorities and financial trends that we believe may affect our
financial condition, results of operations, business strategy, preclinical and
clinical trials and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions including without
limitation the risks described in &#147;Risk Factors&#148; in Part I, Item 1A of this
Annual Report on Form 10-K. These risks are not exhaustive. Other sections of
this Annual Report on Form 10-K include additional factors which could adversely
impact our business and financial performance. Moreover, we operate in a very
competitive and rapidly changing environment. New risk factors emerge from time
to time and it is not possible for our management to predict all risk factors,
nor can we assess the impact of all factors on our business or the extent to
which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements. You should
not rely upon forward-looking statements as predictions of future events. We
cannot assure you that the events and circumstances reflected in the
forward-looking statements will be achieved or occur and actual results could
differ materially from those projected in the forward-looking statements. Except
as required by applicable laws including the securities laws of the United
States and Canada, we assume no obligation to update or supplement
forward-looking statements. </P>
<P align=justify>As used in this annual report, the terms &#147;we&#148;, &#147;us&#148;, &#147;our&#148;, and
&#147;Anavex&#148; mean Anavex Life Sciences Corp., unless the context clearly requires
otherwise.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_5></A>
<P align=center>1</P>
<P align=center><B>PART I</B></P>
<P align=justify><B>ITEM 1. BUSINESS </B></P>
<P align=justify><B><I>Our Current Business </I></B></P>
<P align=justify>We are a biopharmaceutical company engaged in the discovery and
development of novel drug targets to treat serious diseases for which there are
urgent unmet medical needs. The ANAVEX portfolio involves new sigma receptor
compounds (ligands) in the preclinical stage that target neurodegenerative
diseases and cancer. Our lead drug candidate ANAVEX 2-73, targeting Alzheimer&#146;s
disease (AD), is expected to enter first Human Clinical Trials (HCT) in the
first quarter of 2011. Scale-up manufacturing and preclinical development of
ANAVEX 2-73 has been completed. Genesis BioPharma Group LLC and ABX-CRO Advanced
Pharmaceutical Services have been contracted to carry out our phase I and phase
IIa clinical trials. We plan to commence preclinical work on other CNS compounds
such as those targeting epilepsy, depression and neuropathic pain in 2011
provided sufficient capital is available. Additionally, we intend to further
develop compounds in earlier preclinical phases, which target various types of
cancer and continue to develop and expand our Sigmaceptor<SUP>tm
</SUP>platform.</P>
<P align=justify><I>Our Pipeline</I></P>
<P align=justify>Our proprietary SIGMACEPTOR&#153; Discovery Platform has resulted in
and continues to generate small molecule drug candidates with unique modes of
action, by making use of sigma receptors, which represent potential targets for
therapeutic developments in combating many human diseases (such as AD,
depression, epilepsy, pain and cancer). When activated by the appropriate
ligands, these receptors influence the functioning of multiple biochemical
signals that are involved in the pathogenesis (origin or development) of
disease. </P>
<P align=justify>With our SIGMACEPTOR&#153;-N program, we are focused on developing
disease-modifying treatments for CNS conditions using sigma-1 receptor ligands.
Among our lead CNS drug candidates, we have made significant progress with
ANAVEX 2-73, our lead drug candidate for the treatment of Alzheimer&#146;s disease
(AD), and ANAVEX 19-144, a lead drug candidate to treat epilepsy. Preclinical
data reveals that these compounds exhibit significant anti-amnesic,
neuroprotective and anticonvulsant properties in a variety of in vitro systems
and specialized animal models. These activities involve sigma-1 and NMDA
receptor components as well as ion channels, indicating a unique mode of action.
In AD, ANAVEX 2-73 has pharmacological, histological and behavioral evidence as
a potential neuroprotective, anti-amnesic, anti-convulsive and anti depressive
therapeutic agent, due to its potent affinity to sigma-1 receptors and moderate
affinities to M1-4 types muscarinic receptors. In epilepsy, ANAVEX 19-144
controls seizures and the epileptogenesis process in animal models. Moreover,
its neuroprotective properties prevent the process that causes long-term damage
to tissue and cells as well as biochemical and physiological alterations to the
brain from epileptic seizures. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_6></A>
<P align=center>2</P>
<P align=justify>We also have reported promising developments with ANAVEX 1-41,
which is a sigma-1 agonist and a lead compound for depression and a back up
compound for AD. Preclinical tests revealed significant neuroprotective benefits
(i.e. protects nerve cells from degeneration or death) through the modulation of
endoplasmic reticulum, mitochondrial and oxidative stress, which damages and
destroys cells and is believed by some scientists to be a primary cause of AD.
In addition, in animal models, ANAVEX 1-41 prevented the expression of
caspase-3, an enzyme that plays a key role in apoptosis (programmed cell death)
and in the loss of cells in the hippocampus, the part of the brain that
regulates learning, emotion and memory. These activities involve both muscarinic
and sigma-1 receptor systems through a novel mechanism of action. ANAVEX 1-41
may offer disease-modifying options that reverse memory and learning deficits
and protect nerve cells from death through its anti-amnesic and neuroprotective
actions. ANAVEX 1-41 may slow the progression of AD and considerably improve the
quality of life of those impacted by the disease as well as their caregivers.
</P>
<P align=justify>Our SIGMACEPTOR&#153;-C program leverages the unique properties of
sigma-1 and/or sigma-2 receptor ligands, which may allow us to develop a new
class of promising drug candidates designed to combat various types of solid
cancer. Sigma receptors are highly expressed in different tumor cell types and
binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective
apoptosis. In addition, through tumor cell membrane reorganization and
interactions with ion channels, our drug candidates are believed to play an
important role in inhibiting the processes of metastasis (spreading of cancer
cells from the original site to other parts of the body), angiogenesis (the
formation of new blood vessels) and tumor cell proliferation. The compounds in
our oncology program are in pre-clinical testing, and there is no guarantee that
the activity demonstrated in pre-clinical models will be shown in human testing.
</P>
<P align=justify>ANAVEX 7-1037, our lead drug candidate for the treatment of
prostate cancer, is a low molecular weight, synthetic compound exhibiting high
(nanomolar) affinity for sigma-1 and moderate (micromolar) affinity for sigma-2
and sodium channels. In advanced preclinical studies, this compound revealed
antitumor potential with no toxic side effects. It has also been shown to
selectively kill human cancer cells without affecting normal/healthy cells and
also to significantly suppress tumor growth in immune-deficient mice models.
Scientific publications emphasize the promise of sigma receptor ligands,
highlighting the fact that these ligands stop tumor growth and induce selective
cell death in various tumor cell lines, including leukemia, melanoma and cancers
of the colon, breast, prostate, lung, brain, ovary and kidney.</P>
<P align=justify>Numerous additional compounds are currently in the early
discovery and lead optimization stages of our SIGMACEPTOR&#153;-N and SIGMACEPTOR&#153;-C
programs.</P>
<P align=justify><I>Corporate History </I></P>
<P align=justify>We were incorporated in the State of Nevada on January 24,
2004, originally under the name of Thrifty Printing, Inc. From inception to
January 25, 2007, we were in the business of providing on-line photofinishing
services through our website. </P>
<P align=justify>On January 25, 2007, we completed a merger with our
wholly-owned subsidiary, Anavex Life Sciences Corp. As a result, we changed our
name from &#147;Thrifty Printing, Inc.&#148; to &#147;Anavex Life Sciences Corp.&#148; to better
reflect the direction and business of our company. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_7></A>
<P align=center>3</P>
<P align=justify>With the completion of the patent and patent application
acquisition on January 31, 2007, with Dr. Alexandre Vamvakides, we acquired all
rights to three patents and one patent application as well as all inventions
described in those patents as well as eight compounds that were in various
stages of development and which are derivatives of the patents and patent
application. With this acquisition, we changed our business model to the
research and development of pharmaceutical small molecules. </P>
<P align=justify><I>Diseases of the Central Nervous System </I></P>
<P align=justify>We believe that our compounds may be useful for the treatment
of diseases of the central nervous system and cancer. We expect that the market
for treatments for diseases of the central nervous system will grow over the
next several decades. We believe that this expansion will be driven by the
introduction of new technologies and products which will be developed as a
result of a clearer understanding of the underlying biochemical mechanisms that
cause neurological disorders. We believe that this enhanced understanding has
led, and will continue to lead to the development of rationally designed drugs
specifically targeted to the neuropharmacological mechanisms responsible for
central nervous system disorders. </P>
<P align=justify>The market for treatments for diseases of the central nervous
system is expected to be the fastest growing disease area over the next two
decades for several reasons: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>Improved patient and physician awareness of central nervous system
  disorders </P>
  <LI>
  <P>Aging of the general population and greater risk of, for example,
  Alzheimer&#146;s disease and other neurological conditions associated with aging
  </P>
  <LI>
  <P>A better understanding of the neuropharmacological mechanisms underlying
  those disorders. </P></LI></UL>
<P align=justify>Central nervous system disorders include many of the classic
diseases of old age, e.g., Parkinson&#146;s and Alzheimer&#146;s. Central nervous system
disorders also include psychiatric disorders such as depression and
schizophrenia.</P>
<P align=justify><U>Alzheimer&#146;s disease</U></P>
<P align=justify>According to the World Health Organization, dementia currently
affects an estimated 37 million people worldwide and approximately 50% of these
cases are caused by Alzheimer&#146;s disease (AD). The worldwide prevalence of AD was
over 26 million in 2006, as reported by Johns Hopkins University. By 2050, it is
anticipated to quadruple and 1 in 85 people worldwide are anticipated to be
living with the disease. AD is considered to be a healthcare system &#145;time-bomb&#146;.
Medications on the market today only treat the symptoms of AD -- they do not
have the ability to stop its onset or its progression. Meanwhile, the majority
of AD treatments currently in development are focused on reducing or dissolving
amyloid-beta plaques. In 2008, there were several well-publicized failures of
therapies that were highly effective at clearing amyloid-beta plaques but which
had no impact on the disease.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_8></A>
<P align=center>4</P>
<P align=justify><U>Depression</U></P>
<P align=justify>Depression is a major cause of morbidity worldwide according to
the World Health Organization (&#147;WHO&#148;). According to statistics published by the
WHO, lifetime prevalence varies widely, from 3% in Japan to 17% in the US. In
most countries the number of people who would suffer from depression during
their lives falls within an 8&#150;12% range. In North America the probability of
having a major depressive episode within a year-long period is 3&#150;5% for males
and 8&#150;10% for females. Population studies have consistently shown major
depression to be about twice as common in women as in men, although it is
unclear why this happens. The relative increase in occurrence is related to
pubertal development rather than chronological age which reaches adult ratios
between the ages of 15 and 18, and appears associated with psychosocial more
than hormonal factors.</P>
<P align=justify>The depression market is dominated by a large number of
blockbuster brands, with the leading nine brands accounting for approximately
75% of total sales. However, the dominance of the leading brands is waning,
largely due to the effects of patent expiration and generic competition. </P>
<P align=justify><U>Epilepsy</U></P>
<P align=justify>Epilepsy is a common chronic neurological disorder
characterized by recurrent unprovoked seizures. These seizures are transient
signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in
the brain. It has been estimated that about 50 million people worldwide suffer
from epilepsy, according to the International Bureau for Epilepsy, with almost
90% of these people located in developing countries. Epilepsy is more likely to
occur in young children or people over the age of 65 years; however it can occur
at any time. Epilepsy may be controlled, but not cured, with medication,
although surgery may be considered in difficult cases. Nevertheless, over 30% of
people with epilepsy do not have seizure control even with the best available
medications.</P>
<P align=justify>The epilepsy market features two classes of drugs: older
traditional Anti Epileptic Drugs and second generation Anti Epileptic Drugs,
with the former marketed before 1980, and the latter marketed in the early 1990s
and developed through intelligent synthetic design techniques. They are
currently the driving force of the market. However, second generation
anti-convulsants offer limited benefits in terms of efficacy over traditional
anticonvulsants but often confer improvements in side effects and dosing.
Because epilepsy afflicts sufferers in several different ways, there is
considerable need for an array of drugs that can be used in combination with
both traditional Anti Epileptic Drugs and second generations Anti Epileptic
Drugs. Furthermore, with additional benefits in supplementary indications such
as migraine prophylaxis, bipolar disorder and neuropathic pain,
second-generation Anti Epileptic Drugs have greatly expanded the potential of
the market for epilepsy treatments and are the driving force behind sales. </P>
<P align=justify>According to the International Bureau for Epilepsy, the world
market for epilepsy therapies was estimated at US $ 10.4 billion in 2004 while
this number is projected to increase to US $ 13.2 billion by 2010 and to US $
15.3 billion by 2015.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_9></A>
<P align=center>5</P>
<P align=justify><U>Neuropathic Pain</U></P>
<P align=justify>Neuralgia or neuropathic pain can be defined as a pain that is
not related to activation of pain receptor cells in any part of the body.
Neuralgia is a pain produced by a change in neurological structure or function.
Unlike nociceptive pain, neuralgia exists with no continuous nociceptive input.
Neuralgia falls into two categories: central neuralgia and peripheral neuralgia.
This unusual pain is thought to be linked to four possible mechanisms: ion gate
malfunctions; the nerve becomes mechanically sensitive and creates an ectopic
signal; cross signals between large and small fibers; and malfunction due to
damage in the central processor. </P>
<P align=justify>Neuralgia is often difficult to diagnose, and most treatments
show little or no effectiveness. Diagnosis typically involves locating the
damaged nerve by identifying missing sensory or motor function. Neuralgia is
more difficult to be treated than other types of pain because it does not
respond well to normal pain medications. Special medications have become more
specific to neuralgia and typically fall under the category of membrane
stabilizing drugs or antidepressants.</P>
<P align=justify><U>Cancer</U></P>
<P align=justify>Cancer is the second leading cause of mortality worldwide, with
seven million deaths per year globally. In the US, one in two men and one in
three women are anticipated to develop cancer during their lifetime. From
diagnosis, five year survival is estimated at 64% in the US and even lower in
other countries. Currently available treatments are not effective for all
patients, and have limited impact on survival for patients with metastatic
disease. New treatments with novel mechanisms of action that can overcome
resistance mechanisms, inhibit tumor cell proliferation, and trigger tumor cell
death could offer greater therapeutic benefit and improved survival.</P>
<P align=justify>IMS estimates that the market for cancer drugs will reach $ 80
billion annually by 2012, almost double the 2007 value (IMS Global Oncology
Forecast, 2008).</P>
<P align=justify><U>Malignant Melanoma</U> </P>
<P align=justify>Malignant melanoma is due to uncontrolled growth of pigment
cells, called melanocytes. It is predominantly a skin cancer, but can also occur
in melanocytes found in the bowel and the eye. It is one of the less common
types of skin cancer but causes the majority of skin cancer related deaths,
accounting for 75% of all deaths associated with skin cancer. The treatment
includes surgical removal of the tumor, adjuvant treatment, chemo and
immunotherapy, or radiation therapy. Despite many years of intensive laboratory
and clinical research, the sole effective cure is surgical resection of the
primary tumor before it achieves a Breslow thickness greater than 1 mm. Around
160,000 new cases of melanoma are diagnosed each year, and it is more frequent
in males. According to a World Health Organization (WHO) report about 48,000
melanoma related deaths occur worldwide per year. </P>
<P align=justify><U>Prostate Cancer</U></P>
<P align=justify>Prostate cancer is a form of cancer that develops in the
prostate, a gland in the male reproductive system. The cancer cells may
metastasize from the prostate to other parts of the body, particularly the bones
and lymph nodes. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_10></A>
<P align=center>6</P>
<P align=justify>Rates of detection of prostate cancers vary widely across the
world, with South and East Asia detecting less frequently than in Europe, and
especially the United States. </P>
<P align=justify>Over 65% of men over the age of 70 estimated to carry
microscopic evidence of the disease in their bodies. The growth in the number of
cases of prostate cancer is expected to continue to be high in relation to other
cancer types, with the market for treatments projected to reach $7 billion by
2015 as determined by IMS.</P>
<P align=justify><U>Pancreatic Cancer</U></P>
<P align=justify>Pancreatic cancer is a malignant neoplasm of the pancreas. In
the United States approximately 42,000 new cases of pancreatic cancer were
diagnosed and approximately 35,000 patients died in 2009 as a result. The
prognosis is in general poor, as less than 5% of those diagnosed live for more
than five years after diagnosis. Complete remission is extremely rare. About 95%
of exocrine pancreatic cancers are adenocarcinomas. The remaining 5% include
adenosquamous carcinomas, squamous cell carcinomas, and giant cell carcinomas.
Exocrine pancreatic cancers are far more common than endocrine pancreatic
cancers (islet cell carcinomas), which make up about 1% of total cases.</P>
<P align=justify><I>The Market in General </I></P>
<P align=justify>Pharmaceutical companies provide remedies and treatments for
central nervous system diseases and cancer. We believe that as these
technologies are developed and to the extent they are approved and reimbursed,
the central nervous system diseases and cancer drug market will expand, as new
therapeutics become available for currently unmet needs. </P>
<P align=justify>Three approaches are primarily used to treat central nervous
system diseases and cancer: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>Neurosurgery or invasive techniques. </P>
  <LI>
  <P>Pharmacological techniques, including drugs. </P>
  <LI>
  <P>Physiologically based techniques, such as transcytosis. </P></LI></UL>
<P align=justify>Invasive procedures for brain tumors and some severe
neurological conditions utilize catheter-based delivery of the drug directly
into the brain. This technique has proven useful in the treatment of brain
tumors, but is not successful in distributing drugs throughout the entire brain.
Amgen, Inc. recently had clinical trials for the treatment of Parkinson&#146;s
disease using intrathecal delivery through the use of various catheter/pump
techniques. In the trials conducted by Amgen, Inc., improvements were found in
cells at various distances from the end of the catheter, but improvements were
not seen uniformly throughout the brain. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_11></A>
<P align=center>7</P>
<P align=justify>The physiological route is a popular approach to cross the
blood-brain barrier via lipid mediated free diffusion or by facilitated
transport. This is the most common strategy used for the development of new
neuropharmaceuticals, but has experienced limited success as it requires that
the drug have sufficient lipophilic or fat-soluble properties so that it can
pass through lipid membranes. Unfortunately, the current method of delivery by
this route is nonspecific to the brain and side effects are common since most
organs are exposed to the drug. Furthermore, many of the potential lipophilic
therapeutic molecules are substrates for the blood-brain barrier&#146;s multi-drug
resistant proteins, which actively transport the therapeutic agent back into the
blood. Consequently, large doses need to be used so that sufficient amounts of
the drug reach the brain. These high doses can result in significant side
effects as the drug is delivered to essentially all tissues of the body, which
is extremely inefficient as seen with most anticancer drugs and many of the new
central nervous system medications. </P>
<P align=justify><I>Competition</I></P>
<P align=justify>The biopharmaceutical industry is intensely competitive in
general. Furthermore, our business strategy is to target large unmet medical
needs, and those markets are even more highly competitive</P>
<P align=justify>Our competition is other biomedical development companies that
are also trying to discover compounds to be used in the treatment of central
nervous system diseases and cancer. Our research and development is highly
speculative and we may never discover or develop any compounds that we are
capable of selling to pharmaceutical companies for inclusion in their treatments
of central nervous system diseases and cancer. </P>
<P align=justify>Many of our competitors have greater capital resources, larger
overall research and development staffs and facilities, and a longer history in
drug discovery and development, obtaining regulatory approval, and
pharmaceutical product manufacturing and marketing than we do. With these
additional resources, our competitors will be able to respond to the rapid and
significant technological changes in the biotechnology and pharmaceutical
industries faster than we can. Our future success will depend in large part on
our ability to acquire funding for our research and development. To continue to
acquire funding for our research and development, we will likely have to show
progress toward our goals and will eventually be expected to develop a compound
that may result in a transaction with a major pharmaceutical company. </P>
<P align=justify>Rapid technological development, as well as new scientific
developments, may result in our compounds becoming obsolete before we can
recover any of the expenses incurred to develop them.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_12></A>
<P align=center>8</P>
<P align=justify><I>Patents, Trademarks and Intellectual Property </I></P>
<P align=justify>We currently own the following patents:</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee colSpan=3
    align=center>&nbsp;&nbsp;<B>PATENTS</B> </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee
      align=center><B>Title of Application/</B> <BR><B>Patent
      No./Jurisdiction</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="30%"
    align=center><B>Filing/Issue/</B> <BR><B>Expiration</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="40%"
    align=center><BR><B>Claims</B> </TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>Patent No. <BR>1002616/Greece <BR><BR></TD>
    <TD bgColor=#ffffff width="30%" align=left>February 21, 1996 <BR>February
      20, 1997 <BR>February 20, 2017 <BR></TD>
    <TD bgColor=#ffffff width="40%" align=left>
      <P align=justify>Invention related to the synthesis and the method of
      synthesis of molecules of a novel formula. This method is to be applied
      for the obtention of anticonvulsant, antidepressant and nootropic
      pharmaceuticals. </P></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>Patent No. <BR>1004208/Greece
    <BR><BR><BR></TD>
    <TD bgColor=#ffffff width="30%" align=left>October 15, 2001 <BR>April 4,
      2003 <BR>April 4, 2023 <BR><BR></TD>
    <TD bgColor=#ffffff width="40%" align=left>
      <P align=justify>Aminotetrahydrofuran derivatives, muscarinic/sigma/sodium
      channel ligands, with synergic sigma/muscarinic (neuroactivating) and
      sigma/sodium channel (neuroprotective) components, as prototypical
      activating &#150; neuroprotectors and neuroregenerative drugs </P></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>Patent No. <BR>1004868/Greece <BR><BR></TD>
    <TD bgColor=#ffffff width="30%" align=left>April 22, 2003 <BR>April 26,
      2005 <BR>April 26, 2025 <BR></TD>
    <TD bgColor=#ffffff width="40%" align=left>
      <P align=justify>Aminotetrahydrofuran derivatives, muscarinic/sigma/sodium
      channel ligands, ortho-and allo-sterically operating, as prototypical
      neuromodulating and neuroregenerative drugs </P></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>Patent No. <BR>1005865/ Greece </TD>
    <TD bgColor=#ffffff width="30%" align=left>January 17, 2007 <BR>April 7,
      2008 <BR>January 18, 2027 </TD>
    <TD bgColor=#ffffff width="40%" align=left>
      <P align=justify>New sigma (&#245;) receptor ligands with anti-apoptotic and/or
      pro- apoptotic properties over cellular biochemical mechanisms, with
      neuroprotective, anti-cancer, anti- metastatic and anti-(chronic)
      inflammatory action </P></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>Patent No. <BR>1006794/Greece </TD>
    <TD bgColor=#ffffff width="30%" align=left>
      <P>February 26, 2009</P>
      <P>February 27, 2029 </P></TD>
    <TD bgColor=#ffffff width="40%" align=left>
      <P align=justify>Sigma (&#245;) receptor ligands with anti-apoptotic and/or
      pro-apoptotic properties, over cellular mechanisms, exhibiting
      prototypical cytoprotective and also anticancer activity </P></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>Patent Application<BR>201100100140
      <BR>Greece </TD>
    <TD bgColor=#ffffff width="30%" align=left>March 9, 2010 <BR>March 10,
      2030 </TD>
    <TD bgColor=#ffffff width="40%" align=left>
      <P align=justify>Synthesis and method of synthesis of molecules 1-
      methylo-4-[4,4-difainylo-4(Adantylo1-boutylo)] piperzine and its
      structural analogues with anticancer properties </P></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>PCT/ National Phase <BR>- GR 2008000002
      <BR>Filed: <BR>Europe &#150; 08702158.0 <BR>USA &#150; 12/522.761 <BR>India &#150;
      2392/KOLNP/2009 <BR>China &#150; 200880002334.5 <BR>Hong Kong 004800011111
      <BR>Russia - 2009125211 </TD>
    <TD bgColor=#ffffff width="30%" align=left><BR><BR><BR>May 28, 2009
      <BR>July 10, 2009 <BR>June 29, 2009 <BR>July 16, 2009 <BR>July 2, 2010
      <BR>June 26, 2009 </TD>
    <TD bgColor=#ffffff width="40%" align=left>
      <P align=justify>On basis of Greek Patent 1005865 <BR>(Application
      20070100020/17-01-2007) <BR><BR><BR><BR><BR><BR><BR></P></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>PCT Request <BR>International Filing
      <BR>GR2010000009 </TD>
    <TD bgColor=#ffffff width="30%" align=left>February 17, 2010 </TD>
    <TD bgColor=#ffffff width="40%" align=left>
      <P align=justify>On basis of Greek Patent 1006794 <BR>(Application
      20090100115/26-02-2009) </P></TD></TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_13></A>
<P align=center>9</P>
<P align=justify>We regard patents and other proprietary technology rights a key
element in our goal of building a successful biomedical company. Accordingly, we
plan to protect all of our key technology, inventions and improvements to our
inventions by filing patent applications in a timely fashion. We are currently
seeking patent protection in the United States, China, Russia, India and Europe
and intend to seek protection for additional countries on a selective basis for
our compounds or other inventions and improvements. However, we note that filing
and prosecuting patent applications are expensive processes and we have very
limited financial resources. </P>
<P align=justify>We also rely on trade secrets and unpatentable know-how that we
seek to protect, in part, by confidentiality agreements. It is now our policy to
require our employees, consultants, contractors, manufacturers, outside
scientific collaborators and sponsored researchers, board of directors and other
advisors to execute confidentiality agreements upon the commencement of
employment, advisory, or consulting relationships with us. We expect that these
agreements will provide that all confidential information developed or made
known to the individual during the course of the individual&#146;s relationship with
us is to be kept confidential and not disclosed to third parties except in
specific limited circumstances.</P>
<P align=justify>We also intend to require signed confidentiality or material
transfer agreements from any company that is to receive our confidential
information. In the case of employees, consultants and contractors, the
agreements will generally provide that all inventions conceived by the
individual while rendering services to us shall be assigned to us as our
exclusive property. There can be no assurance, however, that all persons who we
desire to sign such agreements will sign, or if they do, that these agreements
will not be breached, that we would have adequate remedies for any breach, or
that our trade secrets or unpatentable know-how will not otherwise become known
or be independently developed by competitors. </P>
<P align=justify>Our patent position, like that of many biomedical companies, is
uncertain and involves complex legal and technical questions for which important
legal principles are unresolved. Much of our intellectual property is still only
filed with the Greek National Office of Industrial Property and we plan to file
additional patent applications in Canada and the U.S. for further inventions. We
may not be successful in obtaining critical claims or in protecting our
potential drug compounds or processes. Even if we do obtain patents, they may
not adequately protect the technology we own or have licensed. In addition,
others may challenge, seek to invalidate, infringe or circumvent any patents we
own or license, and rights we receive under those patents may not provide
competitive advantages to us. Further, the manufacture, use or sale of our
potential drug compounds may infringe the patent rights of others. </P>
<P align=justify>Our success will also depend in part on our ability to commercialize
  our compounds without infringing the proprietary rights of others. We have not
  conducted extensive freedom of use patent searches and no assurance can be given
  that patents do not exist or could not be filed which would have an adverse
  affect on our ability to market our technology or maintain our competitive position
  with respect to our technology. If our compounds or other subject matter are
  claimed under other existing United States or other patents or are otherwise
  protected by third party proprietary rights, we may be subject to infringement
  actions. In such event, we may challenge the validity of such patents or other
  proprietary rights or we may be required to obtain licenses from such companies
  in order to develop, manufacture or market our technology. There can be no assurances
  that we would be able to obtain such licenses or that such licenses, if available,
  could be obtained on commercially reasonable terms. Furthermore, the failure to either develop a commercially viable
  alternative or obtain such licenses could result in delays in marketing all
  of our potential drug compounds based on our drug technology or the inability
  to proceed with the development, manufacture or sale of potential drug compounds
  requiring such licenses, which could have a material adverse affect on our business,
  financial condition and results of operations. If we are required to defend
  ourselves against charges of patent infringement or to protect our proprietary
  rights against third parties, substantial costs will be incurred regardless
  of whether we are successful. Such proceedings are typically protracted with
  no certainty of success. An adverse outcome could subject us to significant
  liabilities to third parties and force us to curtail or cease our research and
  development of our technology. </P>
<hr style="PAGE-BREAK-AFTER: always" align=center color=black size=5
width="100%" noshade>
<!--$$/page=-->
<a name=page_14></a>
<p align=center>10</p>
<P align=justify><I>Government Approval </I></P>
<P align=justify>Regulation by governmental authorities in the United States and
foreign countries is a significant factor in the development, manufacture, and
expected marketing of our potential drug compounds and in our ongoing research
and development activities. The nature and extent to which such regulation will
apply to us will vary depending on the nature of any potential drug compounds
developed. We anticipate that all of our potential drug compounds will require
regulatory approval by governmental agencies prior to commercialization.</P>
<P align=justify>In particular, human therapeutic products are subject to
rigorous non-clinical and clinical testing and other approval procedures of the
FDA and similar regulatory authorities in other countries. Various federal
statutes and regulations also govern or influence testing, manufacturing,
safety, labeling, storage, and record-keeping related to such products and their
marketing. The process of obtaining these approvals and the subsequent
compliance with the appropriate federal statutes and regulations requires
substantial time and financial resources. Any failure by us or our collaborators
to obtain, or any delay in obtaining, regulatory approval could adversely affect
the marketing of any potential drug compounds developed by us, our ability to
receive product revenues, and our liquidity and capital resources. </P>
<P align=justify>The steps ordinarily required before a new drug may be marketed
in the United States, which are similar to steps required in most other
countries, include: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>non-clinical laboratory tests, non-clinical studies in animals, formulation
  studies and the submission to the FDA of an investigational new drug
  application; </P>
  <LI>
  <P>adequate and well-controlled clinical trials to establish the safety and
  efficacy of the drug; </P>
  <LI>
  <P>the submission of a new drug application or biologic license application to
  the FDA; and </P>
  <LI>
  <P>FDA review and approval of the new drug application or biologics license
  application. </P></LI></UL>
<P align=justify>Non-clinical tests include laboratory evaluation of potential
  drug compound chemistry, formulation and toxicity, as well as animal studies.
  The results of non-clinical testing are submitted to the FDA as part of an investigational
  new drug application. A 30-day waiting period after the filing of each investigational
  new drug application is required prior to commencement of clinical testing in
  humans. At any time during the 30-day period or at any time thereafter, the
  FDA may halt proposed or ongoing clinical trials until the FDA authorizes trials
  under specified terms. The investigational new drug application process may be extremely
  costly and substantially delay the development of our potential drug compounds.
  Moreover, positive results of non-clinical tests will not necessarily indicate
  positive results in subsequent clinical trials. The FDA may require additional
  animal testing after an initial investigational new drug application is approved
  and prior to Phase III trials.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_15></A>
<P align=center>11</P>
<P align=justify>Clinical trials to support new drug applications are typically
conducted in three sequential phases, although the phases may overlap. During
Phase I, clinical trials are conducted with a small number of subjects to assess
metabolism, pharmacokinetics, and pharmacological actions and safety, including
side effects associated with increasing doses. Phase II usually involves studies
in a limited patient population to assess the efficacy of the drug in specific,
targeted indications; assess dosage tolerance and optimal dosage; and identify
possible adverse effects and safety risks. </P>
<P align=justify>If a compound is found to be potentially effective and to have
an acceptable safety profile in Phase I and II evaluations, Phase III trials are
undertaken to further demonstrate clinical efficacy and to further test for
safety within an expanded patient population at geographically dispersed
clinical trial sites. </P>
<P align=justify>After successful completion of the required clinical trials, a
new drug application is generally submitted. The FDA may request additional
information before accepting the new drug application for filing, in which case
the new drug application must be resubmitted with the additional information.
Once the submission has been accepted for filing, the FDA reviews the new drug
application and responds to the applicant. The FDA&#146;s requests for additional
information or clarification often significantly extend the review process. The
FDA may refer the new drug application to an appropriate advisory committee for
review, evaluation, and recommendation as to whether the new drug application
should be approved, although the FDA is not bound by the recommendation of an
advisory committee. </P>
<P align=justify><I>The Food and Drug Administration&#146;s Modernization Act</I>
codified the FDA&#146;s policy of granting &#147;fast track&#148; review of certain therapies
targeting &#147;orphan&#148; indications and other therapies intended to treat severe or
life threatening diseases and having potential to address unmet medical needs.
Orphan indications are defined by the FDA as having a prevalence of less than
200,000 patients in the United States. We anticipate that certain
neurodegenerative diseases which could potentially be treated using our
technology could qualify for fast track review under these revised guidelines.
</P>
<P align=justify>Previously, the FDA approved cancer therapies primarily based
on patient survival rates or data on improved quality of life. The FDA
considered evidence of partial tumor shrinkage, while often part of the data
relied on for approval was insufficient by itself to warrant approval of a
cancer therapy, except in limited situations. Under the FDA&#146;s revised policy,
which became effective in 1998, the FDA has broadened authority to consider
evidence of partial tumor shrinkage or other clinical outcomes for approval.
This revised policy is intended to facilitate the study of solid tumor therapies
and shorten the total time for marketing approvals. We intend to take advantage
of this policy; however, it is too early to tell what effect, if any, these
provisions may have on the approval of our potential drug compounds. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_16></A>
<P align=center>12</P>
<P align=justify>Sales outside the United States of potential drug compounds we
develop will also be subject to foreign regulatory requirements governing human
clinical trials and marketing for drugs. The requirements vary widely from
country to country, but typically the registration and approval process takes
several years and requires significant resources. In most cases, if the FDA has
not approved a potential drug compound for sale in the United States, the
potential drug compound may be exported for sale outside of the United States,
only if it has been approved in any one of the following: the European Union,
Canada, Australia, New Zealand, Japan, Israel, Switzerland and South Africa.
There are specific FDA regulations that govern this process. </P>
<P align=justify>We are also subject to various federal, state, local, and
foreign laws, regulations and recommendations relating to safe working
conditions, laboratory and manufacturing practices, and the use and disposal of
hazardous or potentially hazardous substances, including radioactive compounds
and infectious disease agents, used in connection with our research work. We
cannot accurately predict the extent of government regulation that might result
from future legislation or administrative action. </P>
<P align=justify><I>Research and Development Expenses</I></P>
<P align=justify>A significant portion of our operating expenses is related to
research and development, and we intend to maintain a strong commitment to
research and development activities. See Item 8 &#147;Financial Statements and
Supplementary Data&#148; of this Annual Report on Form 10-K for costs and expenses
related to research and development, and other financial information for fiscal
years 2010 and 2009.</P>
<P align=justify><I>Scientific Advisory Board</I></P>
<P align=justify>We maintain a Scientific Advisory Board comprised of scientists
with experience relevant to our company and our product candidates. Members of
our Scientific Advisory Board have agreed to consult and advise us in their
respective areas of expertise. We have placed special emphasis on identifying
members of our Scientific Advisory Board with expertise in the treatment of the
clinical indications targeted by our programs. Our Scientific Advisory Board
consists of the following members:</P>
<P align=justify><I>Alexandre Vamvakides, Ph.D.</I> Dr. Vamvakides has spent 30
years in research, focusing on the therapeutic/pharmacological areas of
anti-neurodegenerative, antiepileptic and anti-depressive molecules. The author
of more than 80 scientific papers, he has worked at the Institut national de la
sant&#233; et de la recherche m&#233;dicale (INSERM), the University of Athens, Ciba-Geigy
(now Novartis), Sanofi (now sanofi-aventis) and many other research laboratories
throughout Europe, for the discovery and development of new concepts in the
therapeutic areas of CNS, oncology and anti-inflammatory diseases.</P>
<P align=justify><I>Mark Smith, Ph.D., FRCPath</I> Dr. Smith is a leading researcher
  and professor in the Department of Pathology at Case Western Reserve University
  School of Medicine, Dr. Smith is one of the world&#146;s most cited researchers
  in the fields of Alzheimer&#146;s disease, free radical biology and neuroscience
  and behavior. He is Executive Director of the American Aging Association and
  Editor-in-Chief of the Journal of Alzheimer&#146;s Disease. Dr. Smith has authored
  over 600 peer reviewed scientific manuscripts and book chapters. He has received
  a number of notable scientific awards in recognition of his scientific research,
  which is currently focused on investigating the pathological mechanisms underlying
  selective neuronal death in neurodegenerative diseases, notably Alzheimer&#146;s
  disease.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_17></A>
<P align=center>13</P>
<P align=justify><I>Tangui Nicolas Maurice, Ph.D</I>. Dr. Maurice has spent 15
  years in the field of neurosciences, including behavioral and molecular neuropharmacology,
  sigma receptors, neuropeptides, neurosteroids, neurotrophic factors, normal/pathological
  aging models for Alzheimer&#146;s and related disorders, and behavioural phenotyping
  of rodent models. Previously, Dr. Maurice held research positions with INSERM
  U710 at Montpellier, CNRS, INSERM U336, the department of neuropsychopharmacology
  and hospital pharmacy at Meijo University (Nagoya, Japan), and Jouveinal Research
  Institute (Fresnes, France). A past recipient of the CNRS bronze medal, Dr.
  Maurice holds a Ph.D. in cellular and molecular biology with a specialty in
  neuropharmacology from Universit&#233; Montpellier.</P>
<P align=justify><I>Jean-Jacques Bourguignon, Ph.D.</I> Dr. Bourguignon has 30
years experience in medicinal chemistry, including expertise in drug design and
optimization as well as organic and physical chemistry and is currently a
Research Director, Centre National de la Recherche Scientifique (CNRS) at the
Faculty of Pharmacy, Strasbourg-Illkrich, France. His background also includes
work as a senior scientist at the Center of Neurochemistry (Strasbourg, France)
and post-doctoral fellow with the department of chemistry at the State
University of New York at Buffalo. </P>
<P align=justify>Dr. Bourguignon holds a Ph.D. in polymer physical chemistry
from the Universit&#233; Louis-Pasteur in Strasbourg.</P>
<P align=justify><I>Officers </I></P>
<P align=justify>We currently engage the services of four consultants who act
for our company in the capacity of executive chairman, president, secretary and
chief operating officer, chief financial officer, and a chief scientific officer
respectively. We have also engaged the services of two consultants to assist in
product research and business development and we have 14 consultants assisting
us in our research and development activities. </P>
<P align=justify><B>ITEM 1A. RISK FACTORS</B></P>
<P align=justify>In addition to other information in this annual report, the
following risk factors should be carefully considered in evaluating our business
because such factors may have a significant impact on our business, operating
results, liquidity and financial condition. As a result of the risk factors set
forth below, actual results could differ materially from those projected in any
forward-looking statements. Additional risks and uncertainties not presently
known to us, or that we currently consider to be immaterial, may also impact our
business, operating results, liquidity and financial condition. If any such
risks occur, our business, operating results, liquidity and financial condition
could be materially affected in an adverse manner. Under such circumstances, the
trading price of our securities could decline, and you may lose all or part of
your investment. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_18></A>
<P align=center>14</P>
<P align=justify><B><I>Risks Related to our Company</I></B></P>
<P align=justify><I>We have had a history of losses and no revenue, which raise
substantial doubt about our ability to continue as a going concern. </I></P>
<P align=justify>Since inception on January 23, 2004, we have incurred aggregate
net losses of $21,345,270 from operations. We can offer no assurance that we
will ever operate profitably or that we will generate positive cash flow in the
future. To date, we have not generated any revenues from our operations. Our
history of losses and no revenues raise substantial doubt about our ability to
continue as a going concern. As a result, our management expects the business to
continue to experience negative cash flow for the foreseeable future and cannot
predict when, if ever, our business might become profitable. We will need to
raise additional funds, and such funds may not be available on commercially
acceptable terms, if at all. If we are unable to raise funds on acceptable
terms, we may not be able to execute our business plan, take advantage of future
opportunities, or respond to competitive pressures or unanticipated
requirements. This may seriously harm our business, financial condition and
results of operations.</P>
<P align=justify><I>We are an early development stage biotechnology research and
development company and may never be able to successfully develop marketable
products or generate any revenue. We have a very limited relevant operating
history upon which an evaluation of our performance and prospects can be made.
There is no assurance that our future operations will result in profits. If we
cannot generate sufficient revenues, we may suspend or cease operations.
</I></P>
<P align=justify>We are an early development stage company and have not
generated any revenues to date and have no operating history. All of our
potential drug compounds are in the concept stage and have not undergone
significant testing in non-clinical studies or in clinical trials. Moreover, we
cannot be certain that our research and development efforts will be successful
or, if successful, that our potential drug compounds will ever be approved for
sales to pharmaceutical companies or generate commercial revenues. We have no
relevant operating history upon which an evaluation of our performance and
prospects can be made. We are subject to all of the business risks associated
with a new enterprise, including, but not limited to, risks of unforeseen
capital requirements, failure of potential drug compounds either in non-clinical
testing or in clinical trials, failure to establish business relationships and
competitive disadvantages as against larger and more established companies. If
we fail to become profitable, we may suspend or cease operations. </P>
<P align=justify><I>We will need additional funding and may be unable to raise
additional capital when needed, which would force us to delay, reduce or
eliminate our research and development activities. </I></P>
<P align=justify>We will need to raise additional funding, but the current economic
  condition will most likely have a negative impact on our ability to raise additional
  needed capital on terms that are favorable to our company or at all. We do not
  anticipate that we will generate significant revenues for several years, if
  at all. Until we can generate significant revenues, if ever, we expect to satisfy
  our future cash needs through equity or debt financing. We cannot be certain
  that additional funding will be available on acceptable terms, or at all. If
  adequate funds are not available, we may be required to delay, reduce the scope
  of, or eliminate one or more of our research and development activities. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_19></A>
<P align=center>15</P>
<P align=justify><I>We may be unable to continue as a going concern in which case
  our securities will have little or no value. </I></P>
<P align=justify>Our independent auditors have noted in their report concerning
our annual financial statements for the fiscal year ended September 30, 2010
that we have incurred substantial losses since inception, which raises
substantial doubt abut our ability to continue as a going concern. In the event
we are not able to continue operations you will likely suffer a complete loss of
your investment in our securities. </P>
<P align=justify><B><I>Risks Related to our Business</I></B></P>
<P align=justify><I>Even if we are able to develop our potential drug compounds,
we may not be able to receive regulatory approval, or if approved, we may not be
able to generate significant revenues or successfully commercialize our
products, which will adversely affect our financial results and financial
condition and we will have to delay or terminate some or all of our research and
development plans and we may be forced to cease operations. </I></P>
<P align=justify>All of our potential drug compounds will require extensive
additional research and development, including non-clinical testing and clinical
trials, as well as regulatory approvals, before we can market them. We cannot
predict if or when any of the potential drug compounds we intend to develop will
be approved for marketing. There are many reasons that we may fail in our
efforts to develop our potential drug compounds. These include: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>the possibility that non-clinical testing or clinical trials may show that
  our potential drug compounds are ineffective and/or cause harmful side
  effects; </P>
  <LI>
  <P>our potential drug compounds may prove to be too expensive to manufacture
  or administer to patients; </P>
  <LI>
  <P>our potential drug compounds may fail to receive necessary regulatory
  approvals from the United States Food and Drug Administration or foreign
  regulatory authorities in a timely manner, or at all; </P>
  <LI>
  <P>even if our potential drug compounds are approved, we may not be able to
  produce them in commercial quantities or at reasonable costs; </P>
  <LI>
  <P>even if our potential drug compounds are approved, they may not achieve
  commercial acceptance; </P>
  <LI>
  <P>regulatory or governmental authorities may apply restrictions to any of our
  potential drug compounds, which could adversely affect their commercial
  success; and </P>
  <LI>
  <P>the proprietary rights of other parties may prevent us or our potential
  collaborative partners from marketing our potential drug compounds.
</P></LI></UL>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_20></A>
<P align=center>16</P>
<P align=justify>If we fail to develop our potential drug compounds, our
financial results and financial condition will be adversely affected, we will
have to delay or terminate some or all of our research and development plans and
may be forced to cease operations. </P>
<P align=justify><I>Our research and development plans will require substantial
additional future funding which could impact our operational and financial
condition. Without the required additional funds, we will likely cease
operations. </I></P>
<P align=justify>It will take several years before we are able to develop
marketable potential drug compounds, if at all. Our research and development
plans will require substantial additional capital, arising from costs to:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>conduct research, non-clinical testing and human studies; </P>
  <LI>
  <P>establish pilot scale and commercial scale manufacturing processes and
  facilities; and </P>
  <LI>
  <P>establish and develop quality control, regulatory, marketing, sales,
  finance and administrative capabilities to support these programs.
</P></LI></UL>
<P align=justify>Our future operating and capital needs will depend on many
factors, including:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>the pace of scientific progress in our research and development programs
  and the magnitude of these programs; </P>
  <LI>
  <P>the scope and results of preclinical testing and human studies; </P>
  <LI>
  <P>the time and costs involved in obtaining regulatory approvals; </P>
  <LI>
  <P>the time and costs involved in preparing, filing, prosecuting, maintaining
  and enforcing patent claims; </P>
  <LI>
  <P>competing technological and market developments; </P>
  <LI>
  <P>our ability to establish additional collaborations; </P>
  <LI>
  <P>changes in our existing collaborations; </P>
  <LI>
  <P>the cost of manufacturing scale-up; and </P>
  <LI>
  <P>the effectiveness of our commercialization activities. </P></LI></UL>
<P align=justify>We base our outlook regarding the need for funds on many
uncertain variables. Such uncertainties include the success of our research
initiatives, regulatory approvals, the timing of events outside our direct
control such as negotiations with potential strategic partners and other
factors. Any of these uncertain events can significantly change our cash
requirements as they determine such one-time events as the receipt or payment of
major milestones and other payments. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_21></A>
<P align=center>17</P>
<P align=justify>Additional funds will be required to support our operations and
if we are unable to obtain them on favorable terms, we may be required to cease
or reduce further research and development of our drug product programs, sell
some or all of our intellectual property, merge with another entity or cease
operations.</P>
<P align=justify><I>If we fail to demonstrate efficacy in our non-clinical
studies and clinical trials our future business prospects, financial condition
and operating results will be materially adversely affected. </I></P>
<P align=justify>The success of our research and development efforts will be
greatly dependent upon our ability to demonstrate potential drug compound
efficacy in non-clinical studies, as well as in clinical trials. Non-clinical
studies involve testing potential drug compounds in appropriate non-human
disease models to demonstrate efficacy and safety. Regulatory agencies evaluate
these data carefully before they will approve clinical testing in humans. If
certain non-clinical data reveals potential safety issues or the results are
inconsistent with an expectation of the potential drug compound&#146;s efficacy in
humans, the regulatory agencies may require additional more rigorous testing,
before allowing human clinical trials. This additional testing will increase
program expenses and extend timelines. We may decide to suspend further testing
on our potential drug compounds if, in the judgment of our management and
advisors, the non-clinical test results do not support further development. </P>
<P align=justify>Moreover, success in non-clinical testing and early clinical
trials does not ensure that later clinical trials will be successful, and we
cannot be sure that the results of later clinical trials will replicate the
results of prior clinical trials and non-clinical testing. The clinical trial
process may fail to demonstrate that our potential drug compounds are safe for
humans and effective for indicated uses. This failure would cause us to abandon
a drug candidate and may delay development of other potential drug compounds.
Any delay in, or termination of, our non-clinical testing or clinical trials
will delay the filing of an investigational new drug application and new drug
application with the Food and Drug Administration and, ultimately, our ability
to commercialize our potential drug compounds and generate product revenues. In
addition, we expect that our clinical trials will involve small patient
populations. Because of the small sample size, the results of these early
clinical trials may not be indicative of future results.</P>
<P align=justify>Following successful non-clinical testing, potential drug
compounds will need to be tested in a clinical development program to provide
data on safety and efficacy prior to becoming eligible for product approval and
licensure by regulatory agencies. From the first human trial through product
approval can take many years and 10-12 years is not unusual.</P>
<P align=justify>If any of our future clinical development potential drug
compounds become the subject of problems, our ability to sustain our development
programs will become critically compromised. For example, efficacy or safety
concerns may arise, whether or not justified, that could lead to the suspension
or termination of our clinical programs. Examples of problems that could arise
include, among others:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>efficacy or safety concerns with the potential drug compounds, even if not
  justified; </P>
  <LI>
  <P>unexpected side-effects; </P></LI></UL>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_22></A>
<P align=center>18</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>regulatory proceedings subjecting the potential drug compounds to potential
  recall; </P>
  <LI>
  <P>publicity affecting doctor prescription or patient use of the potential
  drug compounds; </P>
  <LI>
  <P>pressure from competitive products; or </P>
  <LI>
  <P>introduction of more effective treatments. </P></LI></UL>
<P align=justify>Each clinical phase is designed to test attributes of the drug
and problems that might result in the termination of the entire clinical plan
can be revealed at any time throughout the overall clinical program. The failure
to demonstrate efficacy in our clinical trials would have a material adverse
effect on our future business prospects, financial condition and operating
results.</P>
<P align=justify><I>If we do not obtain the support of qualified scientific
collaborators, our revenue, growth and profitability will likely be limited,
which would have a material adverse effect on our business. </I></P>
<P align=justify>We will need to establish relationships with leading scientists
and research institutions. We believe that such relationships are pivotal to
establishing products using our technologies as a standard of care for various
indications. Additionally, although in discussion, there is no assurance that
our current research partners will continue to work with us or that we will be
able to attract additional research partners. If we are not able to establish
scientific relationships to assist in our research and development, we may not
be able to successfully develop our potential drug compounds. If this happens,
our business will be adversely affected. </P>
<P align=justify><I>We may not be able to develop market or generate sales of
our products to the extent anticipated. Our business may fail and investors
could lose all of their investment in our company. </I></P>
<P align=justify>Assuming that we are successful in developing our potential
drug compounds and receiving regulatory clearances to market our products, our
ability to successfully penetrate the market and generate sales of those
products may be limited by a number of factors, including the following:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>If our competitors receive regulatory approvals for and begin marketing
  similar products in the United States, the European Union, Japan and other
  territories before we do, greater awareness of their products as compared to
  ours will cause our competitive position to suffer; </P>
  <LI>
  <P>Information from our competitors or the academic community indicating that
  current products or new products are more effective than our future products
  could be, if and when they are generated, impede our market penetration or
  decrease our future market share; and, </P>
  <LI>
  <P>The price for our future products, as well as pricing decisions by our
  competitors, may have an effect on our revenues. </P></LI></UL>
<P align=justify>If this happens, our business will be adversely affected. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_23></A>
<P align=center>19</P>
<P align=justify><I>None of our potential drug compounds may reach the
commercial market for a number of reasons and our business may fail. </I></P>
<P align=justify>Successful research and development of pharmaceutical products
is high risk. Most products and development candidates fail to reach the market.
Our success depends on the discovery of new drug compounds that we can
commercialize. It is possible that our potential drug compounds may never reach
the market for a number of reasons. They may be found ineffective or may cause
harmful side-effects during non-clinical testing or clinical trials or fail to
receive necessary regulatory approvals. We may find that certain potential drug
compounds cannot be manufactured at a commercial scale and, therefore, they may
not be economical to produce. Our potential drug compounds could also fail to
achieve market acceptance or be precluded from commercialization by proprietary
rights of third parties. Furthermore, we do not expect our potential drug
compounds to be commercially available for a number of years, if at all. If none
of our potential drug compounds reach the commercial market, our business will
likely fail and investors will lose all of their investment in our company. If
this happens, our business will be adversely affected. </P>
<P align=justify><I>If our competitors succeed in developing products and
technologies that are more effective than our own, or if scientific developments
change our understanding of the potential scope and utility of our potential
drug compounds, then our technologies and future potential drug compounds may be
rendered undesirable or obsolete. </I></P>
<P align=justify>We face significant competition from industry participants that
are pursuing technologies similar to those that we are pursuing and are
developing pharmaceutical products that are competitive with our potential drug
compounds. Nearly all of our industry competitors have greater capital
resources, larger overall research and development staffs and facilities, and a
longer history in drug discovery and development, obtaining regulatory approval
and pharmaceutical product manufacturing and marketing than we do. With these
additional resources, our competitors may be able to respond to the rapid and
significant technological changes in the biotechnology and pharmaceutical
industries faster than we can. Our future success will depend in large part on
our ability to maintain a competitive position with respect to these
technologies. Rapid technological development, as well as new scientific
developments, may result in our potential drug compounds becoming obsolete
before we can recover any of the expenses incurred to develop them. For example,
changes in our understanding of the appropriate population of patients who
should be treated with a targeted therapy like we are developing may limit the
drug&#146;s market potential if it is subsequently demonstrated that only certain
subsets of patients should be treated with the targeted therapy. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_24></A>
<P align=center>20</P>
<P align=justify><I>Our reliance on third parties, such as university
laboratories, contract manufacturing organizations and contract or clinical
research organizations, may result in delays in completing, or a failure to
complete, non-clinical testing or clinical trials if they fail to perform under
our agreements with them. </I></P>
<P align=justify>In the course of product development, we may engage university
laboratories, other biotechnology companies or contract or clinical
manufacturing organizations to manufacture drug material for us to be used in
non-clinical and clinical testing and contract research organizations to conduct
and manage non-clinical and clinical studies. If we engage these organizations
to help us with our non-clinical and clinical programs, many important aspects
of this process have been and will be out of our direct control. If any of these
organizations we may engage in the future fail to perform their obligations
under our agreements with them or fail to perform non-clinical testing and/or
clinical trials in a satisfactory manner, we may face delays in completing our
clinical trials, as well as commercialization of any of our potential drug
compounds. Furthermore, any loss or delay in obtaining contracts with such
entities may also delay the completion of our clinical trials, regulatory
filings and the potential market approval of our potential drug compounds.</P>
<P align=justify><I>If we fail to compete successfully with respect to
acquisitions, joint venture and other collaboration opportunities, we may be
limited in our ability to research and develop our potential drug
compounds.</I></P>
<P align=justify>Our competitors compete with us to attract established
biotechnology and pharmaceutical companies or organizations for acquisitions,
joint ventures, licensing arrangements or other collaborations. Collaborations
include contracting with academic research institutions for the performance of
specific scientific testing. If our competitors successfully enter into
partnering arrangements or license agreements with academic research
institutions, we will then be precluded from pursuing those specific
opportunities. Since each of these opportunities is unique, we may not be able
to find a substitute. Other companies have already begun many drug development
programs, which may target diseases that we are also targeting, and have already
entered into partnering and licensing arrangements with academic research
institutions, reducing the pool of available opportunities.</P>
<P align=justify>Universities and public and private research institutions also
compete with us. While these organizations primarily have educational or basic
research objectives, they may develop proprietary technology and acquire patents
that we may need for the development of our potential drug compounds. We will
attempt to license this proprietary technology, if available. These licenses may
not be available to us on acceptable terms, if at all. If we are unable to
compete successfully with respect to acquisitions, joint venture and other
collaboration opportunities, we may be limited in our ability to develop new
products.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_25></A>
<P align=center>21</P>
<P align=justify><I>The use of any of our potential drug compounds in clinical
trials may expose us to liability claims, which may cost us a significant
amounts of money to defend against or pay out, causing our business to suffer.
</I></P>
<P align=justify>The nature of our business exposes us to potential liability
risks inherent in the testing, manufacturing and marketing of our potential drug
compounds. We currently do not have any potential drug compounds in clinical
trials, however, when any of our potential drug compounds enter into clinical
trials or become marketed products they could potentially harm people or
allegedly harm people and we may be subject to costly and damaging product
liability claims. Some of the patients who participate in clinical trials are
already critically ill when they enter a trial. The waivers we obtain may not be
enforceable and may not protect us from liability or the costs of product
liability litigation. Although we intend to obtain product liability insurance
that we believe is adequate, we are subject to the risk that our insurance will
not be sufficient to cover claims. The insurance costs along with the defense or
payment of liabilities above the amount of coverage could cost us significant
amounts of money, causing our business to suffer. </P>
<P align=justify><I>The patent positions of biopharmaceutical products are
complex and uncertain and we may not be able to protect our patented or other
intellectual property. If we cannot protect this property, we may be prevented
from using it or our competitors may use it and our business could suffer
significant harm. Also, the time and money we spend on acquiring and enforcing
patents and other intellectual property will reduce the time and money we have
available for our research and development, possibly resulting in a slow down or
cessation of our research and development. </I></P>
<P align=justify>We own patents related to certain of our potential drug
compounds. However, these patents do not ensure the protection of our
intellectual property for a number of reasons, including the following:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify>Competitors may interfere with our patent process in a
      variety of ways. Competitors may claim that they invented the claimed
      invention prior to us. Competitors may also claim that we are infringing
      on their patents and therefore cannot practice our technology as claimed
      under our patents and patent applications. Competitors may also contest
      our patents and patent application, if issued, by showing the patent
      examiner that the invention was not original, was not novel or was
      obvious. In litigation, a competitor could claim that our patents and
      patent application are not valid for a number of reasons. If a court
      agrees, we would lose that patents or patent application. As a company, we
      have no meaningful experience with competitors interfering with our
      patents or patent applications.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify>Because of the time, money and effort involved in
      obtaining and enforcing patents, our management may spend less time and
      resources on developing potential drug compounds than they otherwise
      would, which could increase our operating expenses and delay product
      programs.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_26></A>
<P align=center>22</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD colSpan=2>
      <P align=justify>Receipt of a patent may not provide much practical
      protection. If we receive a patent with a narrow scope, then it will be
      easier for competitors to design products that do not infringe on our
      patent.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">4. </TD>
    <TD colSpan=2>
      <P align=justify>In addition, competitors also seek patent protection for
      their inventions. Due to the number of patents in our field, we cannot be
      certain that we do not infringe on existing patents or that we will not
      infringe on patents granted in the future. If a patent holder believes our
      potential drug compound infringes on their patent, the patent holder may
      sue us even if we have received patent protection for our technology. If
      someone else claims we infringe on their patent, we would face a number of
      issues which could cause a slow down or cessation of our research and
      development, including the following:</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>Defending a lawsuit takes significant time and can be
      very expensive.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>If the court decides that our potential drug compound
      infringes on the competitor&#146;s patent, we may have to pay substantial
      damages for past infringement.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>The court may prohibit us from selling or licensing the
      potential drug compound unless the patent holder licenses the patent to
      us. The patent holder is not required to grant us a license. If a license
      is available, we may have to pay substantial royalties or grant cross
      licenses to our patents.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(d) </TD>
    <TD>
      <P align=justify>Redesigning our potential drug compounds so that they do
      not infringe on other patents may not be possible or could require
      substantial funds and time.</P></TD></TR></TABLE>
<P align=justify>It is also unclear whether our trade secrets are adequately
protected. While we use reasonable efforts to protect our trade secrets, our
employees or consultants may unintentionally or willfully disclose our
information to competitors. Enforcing a claim that someone else illegally
obtained and is using our trade secrets, like patent litigation, is expensive
and time consuming, and the outcome is unpredictable. In addition, courts
outside the United States are sometimes less willing to protect trade secrets.
Our competitors may independently develop equivalent knowledge, methods and
know-how.</P>
<P align=justify>We may also support and collaborate in research conducted by
government organizations, hospitals, universities or other educational
institutions. These research partners may be unwilling to grant us any exclusive
rights to technology or products derived from these collaborations prior to
entering into the relationship. </P>
<P align=justify>If we do not obtain required licenses or rights, we could
encounter delays in our product development efforts while we attempt to design
around other patents or even be prohibited from developing, manufacturing or
selling potential drug compounds requiring these licenses. There is also a risk
that disputes may arise as to the rights to technology or potential drug
compounds developed in collaboration with other parties. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_27></A>
<P align=center>23</P>
<P align=justify><I>We will incur increased costs as a result of recently
enacted and proposed changes in laws and regulations and we cannot predict the
impact of any future changes in law.</I></P>
<P align=justify>We face burdens relating to the recent trend toward stricter
corporate governance and financial reporting standards. Legislations or
regulations such as Section 404 of the <I>Sarbanes-Oxley Act of 2002</I> follow
the trend of imposing stricter corporate governance and financial reporting
standards have led to an increase in our costs of compliance including increases
in consulting, auditing and legal fees. Any new rules could make it more
difficult or more costly for us to obtain certain types of insurance, including
directors&#146; and officers&#146; liability insurance, and we may be forced to accept
reduced policy limits and coverage or incur substantially higher costs to obtain
the same or similar coverage. The impact of these events could also make it more
difficult for us to attract and retain qualified persons to serve on our board
of directors, our board committees or as executive officers. A failure to comply
with these new laws and regulations may impact market perception of our
financial condition and could materially harm our business. Additionally, it is
unclear what additional laws or regulations may develop, and we cannot predict
the ultimate impact of any future changes in law. </P>
<P align=justify><B><I>Risks Related to our Common Stock </I></B></P>
<P align=justify><I>A decline in the price of our common stock could affect our
ability to raise further working capital and adversely impact our operations and
would severely dilute existing or future investors if we were to raise funds at
lower prices.</I></P>
<P align=justify>A prolonged decline in the price of our common stock could
result in a reduction in the liquidity of our common stock and a reduction in
our ability to raise capital. Because our operations have been financed through
the sale of equity securities, a decline in the price of our common stock could
be especially detrimental to our liquidity and our continued operations. Any
reduction in our ability to raise equity capital in the future would force us to
reallocate funds from other planned uses and would have a significant negative
effect on our business plans and operations, including our ability to develop
new products and continue our current operations. If the stock price declines,
there can be no assurance that we can raise additional capital or generate funds
from operations sufficient to meet our obligations. We believe the following
factors could cause the market price of our common stock to continue to
fluctuate widely and could cause our common stock to trade at a price below the
price at which you purchase your shares of common stock:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>actual or anticipated variations in our quarterly operating results; </P>
  <LI>
  <P>announcements of new services, products, acquisitions or strategic
  relationships by us or our competitors; </P>
  <LI>
  <P>changes in accounting treatments or principles; </P>
  <LI>
  <P>changes in earnings estimates by securities analysts and in analyst
  recommendations; and </P>
  <LI>
  <P>general political, economic, regulatory and market conditions. </P></LI></UL>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_28></A>
<P align=center>24</P>
<P align=justify>The market price for our common stock may also be affected by
our ability to meet or exceed expectations of analysts or investors. Any failure
to meet these expectations, even if minor, could materially adversely affect the
market price of our common stock.</P>
<P align=justify><I>If we issue additional shares of common stock in the future,
it will result in the dilution of our existing stockholders.</I></P>
<P align=justify>Our articles of incorporation authorize the issuance of
150,000,000 shares of common stock. Our board of directors has the authority to
issue additional shares of common stock up to the authorized capital stated in
the articles of incorporation. Our board of directors may choose to issue some
or all of such shares of common stock to acquire one or more businesses or to
provide additional financing in the future. The issuance of any such shares of
common stock will result in a reduction of the book value or market price of the
outstanding shares of our common stock. If we do issue any such additional
shares of common stock, such issuance also will cause a reduction in the
proportionate ownership and voting power of all other stockholders. Further, any
such issuance may result in a change of control of our corporation.</P>
<P align=justify><I>Trading on the OTC Bulletin Board may be volatile and
sporadic, which could depress the market price of our common stock and make it
difficult for our stockholders to resell their shares. </I></P>
<P align=justify>There is currently a limited market for our common stock. Our
common stock is quoted on the OTC Bulletin Board service of the Financial
Industry Regulatory Authority. Trading in stock quoted on the OTC Bulletin Board
is often thin and characterized by wide fluctuations in trading prices, due to
many factors that may have little to do with our operations or business
prospects. This volatility could depress the market price of our common stock
for reasons unrelated to operating performance. Moreover, the OTC Bulletin Board
is not a stock exchange, and trading of securities on the OTC Bulletin Board is
often more sporadic than the trading of securities listed on a stock exchange
like NASDAQ. There is no assurance that a sufficient market will develop in the
stock, in which case it could be difficult for our stockholders to resell their
stock. </P>
<P align=justify><I>Our stock is classed as a &#147;penny stock&#148;. Trading of our
stock may be restricted by the Securities and Exchange Commission&#146;s penny stock
regulations which may limit a stockholder&#146;s ability to buy and sell our
stock.</I></P>
<P align=justify>Our stock is a penny stock. The Securities and Exchange Commission
  has adopted Rule 15g-9 which generally defines &#147;penny stock&#148; to be
  any equity security that has a market price (as defined) less than $5.00 per
  share or an exercise price of less than $5.00 per share, subject to certain
  exceptions. Our securities are covered by the penny stock rules, which impose
  additional sales practice requirements on broker-dealers who sell to persons
  other than established customers and &#147;accredited investors&#148;. The term
  &#147;accredited investor&#148; refers generally to institutions with assets
  in excess of $5,000,000 or individuals with a net worth in excess of $1,000,000
  or annual income exceeding $200,000 or $300,000 jointly with their spouse. The
  penny stock rules require a broker-dealer, prior to a transaction in a penny
  stock not otherwise exempt from the rules, to deliver a standardized risk disclosure
  document in a form prepared by the Securities and Exchange Commission which
  provides information about penny stocks and the nature and level of risks in
  the penny stock market. The broker-dealer also must provide the customer with
  current bid and offer quotations for the penny stock, the compensation of the
  broker-dealer and its salesperson in the transaction and monthly account statements
  showing the market value of each penny stock held in the customer&#146;s account. The bid and offer quotations, and the broker-dealer and salesperson
  compensation information, must be given to the customer orally or in writing
  prior to effecting the transaction and must be given to the customer in writing
  before or with the customer&#146;s confirmation. In addition, the penny stock
  rules require that prior to a transaction in a penny stock not otherwise exempt
  from these rules; the broker-dealer must make a special written determination
  that the penny stock is a suitable investment for the purchaser and receive
  the purchaser&#146;s written agreement to the transaction. These disclosure
  requirements may have the effect of reducing the level of trading activity in
  the secondary market for the stock that is subject to these penny stock rules.
  Consequently, these penny stock rules may affect the ability of broker-dealers
  to trade our securities. We believe that the penny stock rules discourage investor
  interest in and limit the marketability of our common stock. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_29></A>
<P align=center>25</P>
<P align=justify><I>The Financial Industry Regulatory Authority sales practice
requirements may also limit a stockholder&#146;s ability to buy and sell our stock.
</I></P>
<P align=justify>In addition to the &#147;penny stock&#148; rules described above, the
Financial Industry Regulatory Authority or FINRA has adopted rules that require
that in recommending an investment to a customer, a broker-dealer must have
reasonable grounds for believing that the investment is suitable for that
customer. Prior to recommending speculative low-priced securities to their
non-institutional customers, broker-dealers must make reasonable efforts to
obtain information about the customer&#146;s financial status, tax status, investment
objectives and other information. Under interpretations of these rules, FINRA
believes that there is a high probability that speculative low-priced securities
will not be suitable for at least some customers. The FINRA requirements make it
more difficult for broker-dealers to recommend that their customers buy our
common stock, which may limit your ability to buy and sell our stock and have an
adverse effect on the market for shares of our common stock. </P>
<P align=justify><B>ITEM 1B. UNRESOLVED STAFF COMMENTS</B></P>
<P align=justify>Not Applicable. </P>
<P align=justify><B>ITEM 2. PROPERTIES</B></P>
<P align=justify>We currently contract with Eurogenet Labs SA, a private Greek
company with a research laboratory located at 27 Marathonos Ave., 15351 Athens,
Greece for our research activities. This facility comprises approximately 10,000
square feet. This facility is leased on a month to month basis for $125,000 per
month and which amount is included in research and development expenses in our
financial statements. </P>
<P align=justify>We also sublease office facilities in the United States located
at 50 Harrison Street, Suite 315A, Hoboken, NJ 07030. This office facility is
approximately 1,000 square feet in size and has been leased for an initial one
year period commencing on September 15, 2010 at the rate of $2,500 per month.
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_30></A>
<P align=center>26</P>
<P align=justify><B>ITEM 3. LEGAL PROCEEDINGS</B></P>
<P align=justify>We know of no material, existing or pending legal proceedings
to which we are a party or of which any of our properties is the subject. In
addition, we do not know of any such proceedings contemplated by any
governmental authorities. We know of no proceedings in which any of our
directors, officers or affiliates, or any registered or beneficial stockholder
is a party adverse to our company or has a material interest adverse to our
company.</P>
<P align=justify><B>ITEM 4. (REMOVED AND RESERVED)</B></P>
<P align=center><B>PART II</B></P>
<P align=justify><B>ITEM 5. MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</B></P>
<P align=justify><B><I>Market information </I></B></P>
<P align=justify>Our common stock is quoted on the OTC Bulletin Board under the
symbol &#147;AVXL.OB&#148;. </P>
<P align=justify>The following table shows the quarterly range of high and low
bid information for our common stock over the fiscal quarters for the last two
fiscal years as quoted on the OTC Bulletin Board. We obtained the following high
and low bid information from the OTC Bulletin Board. These over-the-counter
market quotations reflect inter-dealer prices without retail mark-up, mark-down
or commission, and may not represent actual transactions. Investors should not
rely on historical prices of our common stock as an indication of its future
price performance. On December 20, 2010, the closing price of our common stock
as reported by the OTC Bulletin Board was $3.64 per share.</P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="60%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><B>Quarter
      Ended</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center><B>High</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center><B>Low</B> </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>September 30, 2010
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$4.15 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$3.00 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>June 30, 2010 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$3.609 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$2.30 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>March 31, 2010 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$3.299 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$1.94 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>December 31, 2009
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$2.83 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$1.80 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>September 30, 2009
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$3.05 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$2.00 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>June 30, 2009 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$2.84 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$1.50 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>March 31, 2009 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$2.78 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$1.15 </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>December 31, 2008
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$2.80 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="33%"
      align=center>$1.35 </TD></TR></TABLE></DIV>
<P align=justify><B><I>Transfer Agent</I></B></P>
<P align=justify>Shares of our common stock are issued in registered form. The
Nevada Agency and Trust Company, 50 West Liberty Street, Reno, Nevada
(Telephone: (775) 322-0626; Facsimile: (775) 322-5623) is the registrar and
transfer agent for shares of our common stock. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_31></A>
<P align=center>27</P>
<P align=justify><B><I>Holders of Common Stock</I></B></P>
<P align=justify>As of December 20, 2010, there were 95 holders of record of our
common stock. As of such date, 25,127,226 shares of our common stock were issued
and outstanding.</P>
<P align=justify><B><I>Dividends</I></B></P>
<P align=justify>We have not paid any cash dividends on our common stock and
have no present intention of paying any dividends on the shares of our common
stock. Our current policy is to retain earnings, if any, for use in our
operations and in the development of our business. Our future dividend policy
will be determined from time to time by our board of directors. </P>
<P align=justify><B><I>Securities Authorized for Issuance under Equity
Compensation Plans or Individual Compensation Arrangements</I></B></P>
<P align=justify>The following table summarizes certain information regarding
our equity compensation plan or individual compensation arrangements as at
September 30, 2010: </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1px solid" colSpan=4
      align=center>&nbsp;<B>Equity Compensation Plan Information</B>&nbsp;
</TD></TR>
  <TR vAlign=top>
    <TD align=center><BR><BR><BR><BR><BR><BR><B>Plan Category</B> </TD>
    <TD width="25%" align=center><BR><B>Number of securities</B> <BR><B>to be
      issued upon</B> <BR><B>exercise of outstanding</B> <BR><B>options,
      warrants and</B> <BR><B>rights</B> <BR><B>(a)</B> </TD>
    <TD width="25%" align=center><BR><BR><B>Weighted-average</B>
      <BR><B>exercise price of</B> <BR><B>outstanding options,</B>
      <BR><B>warrants and rights</B> <BR><B>(b)</B> </TD>
    <TD width="25%" align=center><B>Number of securities</B> <BR><B>remaining
      available</B> <BR><B>for future issuance</B> <BR><B>under equity</B>
      <BR><B>compensation plans</B> <BR><B>(excluding securities</B>
      <BR><B>reflected in column (a)</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Equity compensation <BR>plans approved by <BR>security
      holders </TD>
    <TD width="25%" align=right>2,375,000 <BR><BR></TD>
    <TD width="25%" align=right>3.42 <BR><BR></TD>
    <TD width="25%" align=right>625,000 <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left>Equity compensation <BR>plans not approved by <BR>security
      holders </TD>
    <TD width="25%" align=right>400,000 <BR><BR></TD>
    <TD width="25%" align=right>2.50 <BR><BR></TD>
    <TD width="25%" align=right>0 <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Total</B> </TD>
    <TD width="25%" align=right><B>2,775,000</B> </TD>
    <TD width="25%" align=right>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<B>3.37</B> </TD>
    <TD width="25%" align=right><B>625,000</B> </TD></TR></TABLE></DIV>
<P align=justify><I>Stock Option Plan </I></P>
<P align=justify>On April 17, 2007, our directors adopted the 2007 Stock Option
Plan. On May 25, 2007, our stockholders ratified and approved the 2007 Stock
Option Plan at the annual meeting of stockholders. As of September 30, 2010,
2,775,000 options have been granted to employees, directors, consultants and officers of our
company. </P>
<P align=justify>The purpose of the 2007 Stock Option Plan is to retain the
services of valued key employees and consultants of our company and such other
persons as will be select in accordance with the 2007 Stock Option Plan, and to
encourage such persons to acquire a greater proprietary interest in our company,
thereby strengthening their incentive to achieve the objectives of the
shareholders of our company, and to serve as an aid and inducement in the hiring
of new employees and to provide an equity incentive to consultants. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_32></A>
<P align=center>28</P>
<P align=justify>The exercise price of shares subject to any option must be at
least 100% of the fair market value of the shares on the date of grant. The
maximum term of any stock option is 10 years from the date the option is
granted.</P>
<P align=justify><B><I>Recent Sales of Unregistered Securities</I></B></P>
<P align=justify>Since the beginning of the fourth quarter of our fiscal year
ended September 30, 2010, we have not sold any equity securities that were not
registered under the Securities Act of 1933 that were not previously reported in
a quarterly report on Form 10-Q or in a current report on Form 8-K.</P>
<P align=justify><B><I>Purchases of Equity Securities by Our Company and
Affiliated Purchasers</I></B></P>
<P align=justify>None.</P>
<P align=justify><B>ITEM 6 SELECTED FINANCIAL DATA</B></P>
<P align=justify>Not applicable. </P>
<P align=justify><B>ITEM 7 MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATION</B></P>
<P align=justify>The following discussion should be read in conjunction with our
  audited consolidated financial statements and notes thereto for the fiscal year
  ended September 30, 2010, included elsewhere in this Report. The following Management&#146;s
  Discussion and Analysis of Financial Condition and Results of Operations contains
  &#147;forward-looking statements&#148;. Forward-looking statements are generally
  written in the future tense and/or are preceded by words such as &#147;may,&#148;
  &#147;should,&#148; &#147;forecast,&#148; &#147;could,&#148; &#147;expect,&#148;
  &#147;suggest,&#148; &#147;believe,&#148; &#147;anticipate,&#148; &#147;intend,&#148;
  &#147;plan,&#148; or other similar words. The forward-looking statements contained
  in this Report involve a number of risks and uncertainties, many of which are
  outside of our control. Factors that could cause actual results to differ materially
  from projected results include, but are not limited to, those discussed in &#147;Risk
  Factors&#148; elsewhere in this Report. Readers are expressly advised to review
  and consider those Risk Factors, which include risks associated with (1) our
  ability to successfully conduct clinical and preclinical trials for our product
  candidates, (2) our ability to obtain required regulatory approvals to develop
  and market our product candidates, (3) our ability to raise additional capital
  on favorable terms, (4) our ability to execute our development plan on time
  and on budget, (5) our ability to obtain commercial partners, (6) our ability,
  whether alone or with commercial partners, to successfully commercialize any
  of our product candidates that may be approved for sale, and (7) our ability
  to identify and obtain additional product candidates. Although we believe that
  the assumptions underlying the forward-looking statements contained in this
  Report are reasonable, any of the assumptions could be inaccurate, and therefore
  there can be no assurance that such statements will be accurate. In light of
  the significant uncertainties inherent in the forward-looking statements included
  herein, the inclusion of such information should not be regarded as a representation
  by us or any other person that the results or conditions described in such statements
  or our objectives and plans will be achieved. Furthermore, past performance
  in operations and share price is not necessarily indicative of future performance.
  Except as required by applicable laws including the securities laws of the United
  States and Canada, we disclaim any intention or obligation to update or revise
  any forward-looking statements, whether as a result of new information, future
  events or otherwise. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_33></A>
<P align=center>29</P>
<P align=justify><B><I>Our Business </I></B></P>
<P align=justify>We are a biopharmaceutical company engaged in the discovery and
development of novel drug targets to treat serious diseases for which there are
urgent unmet medical needs. The ANAVEX portfolio involves new sigma receptor
compounds (ligands) in the preclinical stage that target neurodegenerative
diseases and cancer. Our lead drug candidate ANAVEX 2-73, targeting Alzheimer&#146;s
disease (AD), is expected to enter first Human Clinical Trials (HCT) in the
first quarter of 2011. Scale-up manufacturing and preclinical development of
ANAVEX 2-73 has been completed. Genesis BioPharma Group LLC and ABX-CRO Advanced
Pharmaceutical Services have been contracted to carry out our phase I and IIa
clinical trials. We plan to commence preclinical work on other CNS compounds in
2011 provided sufficient capital is available. Additionally, we intend to
further develop compounds in earlier preclinical phases, which target diseases
like depression, epilepsy, neuropathic pain and various types of cancer and
continue to develop and expand our Sigmaceptor<SUP>tm </SUP>platform.</P>
<P align=justify>The SEC defines critical accounting policies as those that are,
in management's view, important to the portrayal of our financial condition and
results of operations and require management's judgment. The discussion and
analysis of the financial condition and results of operations is based on the
audited consolidated financial statements, which have been prepared in
accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). The
preparation of these financial statements requires us to make estimates and
judgments that affect the reported amounts of assets, liabilities, revenue and
expenses. Management bases its estimates on experience and on various
assumptions that it believes are reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets
and liabilities that are not readily apparent from other sources. Actual results
may differ from those estimates. Our critical accounting policies include:</P>
<P align=justify><I>Research and Development Expenses</I></P>
<P align=justify>Research and developments costs are expensed as incurred. These
expenses are comprised of the costs of our proprietary research and development
efforts, including salaries, facilities costs, overhead costs and other related
expenses as well as costs incurred in connection with third-party collaboration
efforts. Milestone payments made by us to third parties are expensed when the
specific milestone has been achieved.</P>
<P align=justify>In addition, we incur expenses in respect of the acquisition of
intellectual property relating to patents and trademarks. The probability of
success and length of time to developing commercial applications of the drugs
subject to the acquired patents and trademarks is difficult to determine and
numerous risks and uncertainties exist with respect to the timely completion of
the development projects. There is no assurance the acquired patents and
trademarks will ever be successfully commercialized. Due to these risks and
uncertainties, we expense the acquisition of patents and trademarks. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_34></A>
<P align=center>30</P>
<P align=justify><I>Stock-based Compensation</I></P>
<P align=justify>We account for all stock-based payments and awards under the
fair value based method.</P>
<P align=justify>Stock-based payments to non-employees are measured at the fair
value of the consideration received, or the fair value of the equity instruments
issued, or liabilities incurred, whichever is more reliably measurable. The fair
value of stock-based payments to non-employees is periodically re-measured until
the counterparty performance is complete, and any change therein is recognized
over the vesting period of the award and in the same manner as if we had paid
cash instead of paying with or using equity based instruments. Compensation
costs for stock-based payments with graded vesting are recognized on a
straight-line basis. The cost of the stock-based payments to non-employees that
are fully vested and non-forfeitable as at the grant date is measured and
recognized at that date, unless there is a contractual term for services in
which case such compensation would be amortized over the contractual term. </P>
<P align=justify>We account for the granting of share purchase options to
employees using the fair value method whereby all awards to employees will be
recorded at fair value on the date of the grant. The fair value of all share
purchase options are expensed over their vesting period with a corresponding
increase to additional paid-in capital.</P>
<P align=justify>We use the Black-Scholes option valuation model to calculate
the fair value of share purchase options at the date of the grant. Option
pricing models require the input of highly subjective assumptions, including the
expected price volatility. Changes in these assumptions can materially affect
the fair value estimates.</P>
<P align=justify><I>Derivative Liabilities</I></P>
<P align=justify>Our convertible promissory notes include embedded conversion
options which, prior to their amendments, were required to be accounted for as
separate derivative liabilities. These liabilities were required to be measured
at fair value. These instruments were adjusted to reflect fair value at each
period end. Any increase or decrease in the fair value was recorded in results
of operations as change in fair value of derivative liabilities. In determining
the appropriate fair value, we used the Black-Scholes pricing model.</P>
<P align=justify>The debt discount arising from bifurcating the derivative
liability from the host debt instrument was accreted to income during the
period.</P>
<P align=justify><B><I>Recent Accounting Pronouncements</I></B></P>
<P align=justify>In October 2009, the FASB issued ASU No. 2009-13, &#147;<I>Multiple-Deliverable
  Revenue Arrangements</I>,&#148; or ASU 2009-13, which amends existing revenue
  recognition accounting pronouncements that are currently within the scope of
  ASC 605. This guidance eliminates the requirement to establish the fair value
  of undelivered products and services and instead provides for separate revenue
  recognition based upon management&#146;s estimate of the selling price for an
  undelivered item when there is no other means to determine the fair value of
  that undelivered item. ASU 2009-13 is effective prospectively for revenue arrangements
  entered into or materially modified in fiscal years beginning on or after June
  15, 2010. The adoption of this guidance did not have a material impact on our
  consolidated financial statements. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_35></A>
<P align=center>31</P>
<P align=justify>In January 2010, the FASB issued Accounting Standards Update
  2010-06, <I>Fair Value Measurements and Disclosures (Topic 820): Improving Disclosures
  about Fair Value Measurements</I>. The ASU amends Subtopic 820-10 with new disclosure
  requirements and clarification of existing disclosure requirements. New disclosures
  required include the amount of significant transfers in and out of levels 1
  and 2 fair value measurements and the reasons for the transfers. In addition,
  the reconciliation for level 3 activity will be required on a gross rather than
  net basis. The ASU provides additional guidance related to the level of disaggregation
  in determining classes of assets and liabilities and disclosures about inputs
  and valuation techniques. The amendments are effective for annual or interim
  reporting periods beginning after December 15, 2009, except for the requirement
  to provide the reconciliation for level 3 activities on a gross basis, which
  will be effective for fiscal years beginning after December 15, 2010. We are
  currently assessing the impact of ASU 2010-6 and do not expect the adoption
  of this guidance to have a material impact on our consolidated financial statements.</P>
<P align=justify><B><I>Results of Operations</I></B></P>
<P align=justify><I>Revenue</I></P>
<P align=justify>We have not earned any revenues since our inception on January
23, 2004. We are still in the development stage and do not anticipate earning
any revenues until we can establish an alliance with targeted companies to
market or distribute the results of our research projects. </P>
<P align=justify><I>Expenses</I></P>
<P align=justify>Our expenses for the fiscal year ended September 30, 2010 and
2009 were as follows:</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_36></A>
<P align=center>32</P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="80%">

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="27%" colSpan=4 align=center nowrap><B>Year Ended September 30,</B> </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=center nowrap><B>2010</B> </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="12%" align=center nowrap><B>2009</B> </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Accounting and audit fees </TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>&nbsp;151,010 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>&nbsp;89,702 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Amortization and depreciation </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>910 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>410 </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Bank charges and interest </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>6,867 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>5,670 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Consulting fees </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>2,082,888 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>2,110,866 </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Investor relations </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>186,221 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>139,983 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Legal fees </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>173,369 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>94,791 </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Management fees </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>- </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>- </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Office and miscellaneous </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>39,722 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>11,374 </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Registration and filing fees </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>27,675 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>16,721 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Rent and administration </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>12,810 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>- </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Research and development </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>2,728,836 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>2,139,794 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Travel </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>236,268 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>128,836 </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Website design and maintenance </TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>1,692 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff width="12%" align=right>1,455 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Total expenses</B> </TD>
    <TD  width="1%" align=left>$</TD>
    <TD width="12%" align=right>&nbsp;5,648,268 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>$</TD>
    <TD width="12%" align=right>&nbsp;4,739,602 </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR></TABLE></DIV>
<P align=justify><U>Year ended September 30, 2010 and 2009</U></P>
<P align=justify>Expenses for the fiscal year ended September 30, 2010 increased
by $908,666 over the same period in 2009. Accounting and audit fees have
increased by $61,308 from $89,702 for the fiscal year ended September 30, 2009
to $151,010 for the fiscal year ended September 30, 2010 primarily as a result
of our company having to address complex accounting matters resulting from our
various agreements, thereby requiring increased attention by our external
auditors. Consulting fees have decreased by $27,978 from $2,110,866 for the
fiscal year ended September 30, 2009 to $2,082,888 for the fiscal year ended
September 30, 2010 as a result of lower stock-based compensation charges.
Investor relations expenses have increased by $46,238 from $139,983 for the
fiscal year ended September 30, 2009 to $186,221 for the fiscal year ended
September 30, 2010 as a result of increased fundraising and corporate awareness
activities. Legal fees have increased by $78,578 from $94,791 for the fiscal
year ended September 30, 2009 to $173,369 for the fiscal year ended September
30, 2010 primarily related to increased private placement activities and
drafting and review of agreements related to clinical trials and other
activities during the fiscal year ended September 30, 2010. Office and
administration expenses have increased by $28,348 from $11,374 for the fiscal
year ended September 30, 2009 to $39,722 for the fiscal year ended September 30,
2010 as a result of maintaining office operations in North America. Registration
and filing fees have increased by $10,954 from $16,721 for the fiscal year ended
September 30, 2009 to $27,675 for the fiscal year ended September 30, 2010 as a
result of increased financing activities related to share issuances. Rent and
administration fees have increased by $12,810 from $Nil for the fiscal year
ended September 30, 2009 to $12,810 for the fiscal year ended September 30, 2010
as a result of office lease expenses in North America. Research and development
expenses have increased by $589,042 from $2,139,794 for the fiscal year ended
September 30, 2009 to $2,728,836 for the fiscal year ended September 30, 2010 as
a result of increased preclinical and clinical activities relating to
preparation for clinical trials for Anavex 2-73. Travel expenses have increased
by $107,432 from $128,836 for the fiscal year ended September 30, 2009 to
$236,268 for the fiscal year ended September 30, 2010 as a result of increased
travel related to clinical trial and fundraising and corporate awareness
activities.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_37></A>
<P align=center>33</P>
<P align=justify><B><I>Liquidity and Capital Resources</I></B></P>
<P align=justify><I>Working Capital </I></P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="90%">

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=center nowrap><B>September 30, 2010</B> </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="11%" align=center nowrap><B>September 30, 2009</B> </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Cash </TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="11%" align=right>264,669 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="11%" align=right>350,994 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Current Assets </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>325,758 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="11%" align=right>406,952 </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>Current Liabilities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>3,290,071 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="11%"
    align=right>4,098,466 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Working Capital (Deficit) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="11%"
      align=right>(2,964,313</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>)&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="11%"
      align=right>(3,691,514</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>) </TD></TR></TABLE>
</DIV>
<P align=justify>As of September 30, 2010, we had $264,669 in cash, a decrease
of $86,325 from September 30, 2009. The principal components of this decrease in
cash relate to the cash used in operating activities of $4,593,587, offset by
the cash provided by financing activities of $4,510,573, including proceeds from
the issuance of common shares of $3,095,573 and proceeds from the issuance of
promissory notes of $1,415,000. As of September 30, 2010, we had a working
capital deficit of $2,964,313, a decrease in deficit of $727,201 from September
30, 2009. The principal component of this decrease in working capital deficit
was the decrease in accounts payable and accrued liabilities of $794,177. </P>
<P align=justify>We anticipate that we will require up to $10 million for the 12
months ending September 30, 2011 in order to implement our plan of operation of
researching and developing our patents, the related compounds and further
intellectual property we may acquire or develop. The majority of our capital
resource requirement is needed to enter ANAVEX 2-73 into clinical trials. If we
are not able to secure additional financing, we will not be able to implement
and fund these trials.</P>
<P align=justify><I>Going Concern</I></P>
<P align=justify>At September 30, 2010, we had an accumulated deficit of
$21,896,074 since our inception and incurred a net loss of $8,783,037 for the
fiscal year ended September 30, 2010. We expect to incur further losses in the
development of our business, all of which casts substantial doubt about our
ability to continue as a going concern. Our ability to continue as a going
concern is dependent upon our ability to generate future profitable operations
and/or to obtain the necessary financing to meet our obligations and repay our
liabilities arising from normal business operations when they come due. Our
independent auditors included an explanatory paragraph regarding substantial
doubt about our ability to continue as a going concern in their report on our
annual financial statements for the fiscal year ended September 30, 2010.</P>
<P align=justify><I>Future Financing</I></P>
<P align=justify>We will require additional financing to fund our planned
operations, including researching and developing our patents, the related
compounds and any further intellectual property that we may acquire and entering
some of our current compounds into clinical trials. We currently do not have
committed sources of additional financing and may not be able to obtain
additional financing, particularly, if the volatile conditions in the stock and
financial markets, and more particularly the market for early development stage
biotechnology research and development company stocks persist. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_38></A>
<P align=center>34</P>
<P align=justify>There can be no assurance that additional financing will be
available to us when needed or, if available, that it can be obtained on
commercially reasonable terms. If we are not able to obtain the additional
financing on a timely basis, if and when it is needed, we will be forced to
delay or scale down some or all of our research and development activities or
perhaps even cease the operation of our business. </P>
<P align=justify>Since inception we have funded our operations primarily through
equity and debt financings and we expect that we will continue to fund our
operations through other equity and debt financings. If we are able to raise
additional financing by issuing equity securities, our existing stockholders&#146;
ownership will be diluted. Obtaining commercial loans, assuming those loans
would be available, will increase our liabilities and future cash commitments.
</P>
<P align=justify>There is no assurance that we will be able to maintain
operations at a level sufficient for an investor to obtain a return on his, her,
or its investment in our common stock. Further, we may continue to be
unprofitable. </P>
<P align=justify><B><I>Off-Balance Sheet Arrangements</I></B></P>
<P align=justify>We have no off-balance sheet arrangements that have or are
reasonably likely to have a current or future effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources that is material to our
stockholders. </P>
<P align=justify><B>ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISK </B></P>
<P align=justify>Not Applicable </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_39></A>
<P align=center>35</P>
<P align=justify><B>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</B></P>
<P align=justify>&nbsp;</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-1></A>
<P align=center><B>ANAVEX LIFE SCIENCES CORP.</B></P>
<P align=center>(A Development Stage Company)</P>
<P align=center>CONSOLIDATED FINANCIAL STATEMENTS</P>
<P align=center>September 30, 2010 and 2009</P>
<P align=center>(<U>Stated in US Dollars</U>)</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-2></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left  rowSpan=4><img src="bdo.jpg" alt="" width="104" height="40"></TD>
    <TD align=left width="33%"><FONT color=#786860>Tel: 604 688
      5421 </FONT> </TD>
    <TD align=left width="33%"><FONT color=#786860>BDO Canada LLP</FONT> </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left width="33%"><FONT color=#786860>Fax: 604 688
      5132</FONT> </TD>
    <TD align=left width="33%"><FONT color=#786860>600 Cathedral Place</FONT> </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left width="33%"><B><FONT color=#786860>www.bdo.ca</FONT></B> </TD>
    <TD align=left width="33%"><FONT color=#786860>925 West Georgia
      Street</FONT> </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left width="33%">&nbsp;</TD>
    <TD align=left width="33%"><FONT color=#786860>Vancouver BC V6C 3L2
      Canada</FONT> </TD>
  </TR>
</TABLE>
<P align=center><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P align=justify>To the Directors and Stockholders, <BR>
  Anavex Life Sciences
  Corp.<BR>
  (a Development Stage Company)</P>
<P align=justify>We have audited the accompanying consolidated balance sheets of
  Anavex Life Sciences Corp. (the &#147;Company&#148;) as of September 30, 2010 and 2009,
  and the related consolidated statements of operations, cash flows and changes in
  capital deficit for the years then ended and for the period from January 23,
  2004 (date of inception) to September 30, 2010. These financial statements are
  the responsibility of the Company&#146;s management. Our responsibility is to express
  an opinion on these financial statements based on our audits.</P>
<P align=justify>We conducted our audits in accordance with the standards of the
  Public Company Accounting Oversight Board (United States). Those standards
  require that we plan and perform the audit to obtain reasonable assurance about
  whether the financial statements are free of material misstatement. The Company
  is not required to have, nor were we engaged to perform, an audit of its
  internal control over financial reporting. Our audit included consideration of
  internal control over financial reporting as a basis for designing audit
  procedures that are appropriate in the circumstances, but not for the purpose of
  expressing an opinion on the effectiveness of the Company&#146;s internal control
  over financial reporting. Accordingly, we express no such opinion. An audit also
  includes examining, on a test basis, evidence supporting the amounts and
  disclosures in the financial statements. An audit also includes assessing the
  accounting principles used and significant estimates made by management, as well
  as evaluating the overall presentation of the financial statements. We believe
  that our audits provide a reasonable basis for our opinion.</P>
<P align=justify>In our opinion, the consolidated financial statements referred
  to above present fairly, in all material respects, the financial position of
  Anavex Life Sciences Corp. at September 30, 2010 and 2009, and the results of its
  operations and its cash flows for the years then ended and for the period from
  January 23, 2004 (date of inception) to September 30, 2010, in conformity with
  accounting principles generally accepted in the United States.</P>
<P align=justify>The accompanying financial statements have been prepared
  assuming that the Company will continue as a going concern. As discussed in Note
  1 to the financial statements, the Company had an accumulated deficit of
  $21,896,074 at September 30, 2010 (2009: $12,562,233) and incurred a net loss of
  $8,783,037 (2009: $5,499,419) for the year then ended. These conditions raise
  substantial doubt about the Company&#146;s ability to continue as a going concern.
  Management&#146;s plans in regard to these matters are also described in Note 1. The
  financial statements do not include any adjustments that might result from the
  outcome of this uncertainty.</P>
<P align=justify>As discussed in Note 4 to the consolidated financial
  statements, effective October 1, 2009, the Company changed its method of
  accounting for the embedded conversion features in its promissory notes with the
  adoption of new guidance on determining whether an instrument is indexed to an
  entity&#146;s own stock. </P>
<P align=justify>/s/ BDO Canada LLP</P>
<P align=justify>Chartered Accountants</P>
<P align=justify>Vancouver, Canada <BR>
  December 17, 2010</P>
<P align=justify><FONT color=#786860>BDO Canada LLP, a Canadian limited
  liability partnership, is a member of BDO International Limited, a UK company
  limited by guarantee, and forms part of the international BDO network of
  independent member firms.</FONT></P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-3></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=center><B>ANAVEX LIFE SCIENCES CORP.</B> </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>CONSOLIDATED BALANCE SHEETS </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(<U>Stated in US Dollars</U>) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;
      &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<B><U>ASSETS</U></B> </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" nowrap><U>2010</U> </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" nowrap><U>2009</U> </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Current </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Cash </TD>
    <TD  width="1%" align=left valign="bottom">$</TD>
    <TD width="12%" align=right valign="bottom">&nbsp;264,669 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">$</TD>
    <TD width="12%" align=right valign="bottom">&nbsp;350,994 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Deferred financing charge    </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>55,777 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;VAT receivable </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">37,820 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Prepaid expenses </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">23,269 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">181 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>325,758 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>406,952 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Equipment &#150; Note 3 </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">4,091 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">1,691 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;329,849 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;408,643 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center valign="bottom" bgColor=#e6efff><B><U>LIABILITIES</U></B>&nbsp;&nbsp; </TD>
    <TD  width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="12%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="12%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Current </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Accounts payable and accrued liabilities    </TD>
    <TD  width="1%" align=left valign="bottom">$</TD>
    <TD width="12%" align=right valign="bottom">&nbsp;797,763 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">$</TD>
    <TD width="12%" align=right valign="bottom">&nbsp;1,591,940 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Current portion of promissory
      notes payable &#150; Note 6 </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">2,492,308 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">2,506,526 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>3,290,071 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>4,098,466 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Promissory notes payable &#150; Note 6 </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">168,000 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">3,290,071 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">4,266,466 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center valign="bottom" bgColor=#e6efff><B><U>CAPITAL DEFICIT</U></B>&nbsp;&nbsp;    </TD>
    <TD  width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="12%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="12%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock &#150; Note 7 </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;&nbsp;&nbsp;&nbsp; Authorized: <BR>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      150,000,000 common shares, par value $0.001 per share </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=left valign="bottom"><BR></TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=left valign="bottom"><BR></TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;&nbsp;&nbsp;&nbsp; Issued and outstanding:
      <BR>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      23,516,952 common shares (2009: 20,746,761) </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff><BR>
      23,517 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff><BR>
      20,747 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Shares to be issued </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">300,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Additional paid-in capital </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>18,912,335 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>8,383,663 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Deficit accumulated during the development stage </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(21,896,074</TD>
    <TD  width="2%"
    align=left valign="bottom">) </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(12,562,233</TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(2,960,222</TD>
    <TD  width="2%"
    align=left valign="bottom">) </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(3,857,823</TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;329,849 </TD>
    <TD  width="2%"
    align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;408,643 </TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
  </TR>
</TABLE>
<P align=justify>Nature of Operations and Ability to Continue as a Going Concern
  &#150; Note 1 <BR>
  Commitments &#150; Note 10</P>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-4></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=bottom>
    <TD align=center><B>ANAVEX LIFE SCIENCES CORP.</B> </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
    </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>for the years ended September 30, 2010 and 2009 and </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>for the period from January 23, 2004 (Date of Inception)
      to September 30, 2010 </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(<U>Stated in US Dollars</U>) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">January 23, </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">2004 (Date of </TD>
    <TD  width="2%" align=center valign="bottom"></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" colSpan=4 align=center valign="bottom">Years Ended </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" nowrap>Inception) to </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" colSpan=4 align=center valign="bottom" nowrap>September 30, </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" nowrap>September 30, </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom"><U>2010</U> </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom"><U>2009</U> </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom"><U>2010</U> </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Expenses </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Accounting and audit fees </TD>
    <TD  width="1%" align=left valign="bottom">$</TD>
    <TD width="10%" align=right valign="bottom">&nbsp;151,010 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">$</TD>
    <TD width="10%" align=right valign="bottom">&nbsp;89,702 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">$</TD>
    <TD width="10%" align=right valign="bottom">&nbsp;364,128 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Amortization and depreciation    </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>910 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>410 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>1,540 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Bank charges and interest </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">6,867 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">5,670 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">27,643 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Consulting fees &#150;
      Notes 8 and 10(b) </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>2,082,888 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>2,110,866 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>7,830,890 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Investor relations </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">186,221 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">139,983 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">589,764 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Legal fees </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>173,369 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>94,791 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>386,489 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Management fees </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">14,625 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Office and miscellaneous    </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>39,722 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>11,374 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>108,469 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Registration and filing fees </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">27,675 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">16,721 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">68,726 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Rent and administration    </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>12,810 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>161,560 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Research and development </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">2,728,836 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">2,139,794 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">7,307,810 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Travel </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>236,268 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>128,836 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>492,059 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Website design and maintenance </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">1,692    </TD>
    <TD  width="2%"
    align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">1,455    </TD>
    <TD  width="2%"
    align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">28,417 </TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Loss before other income (expenses) </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">(5,648,268</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">(4,739,602</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">(17,382,120</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Other income (expenses) </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Interest </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">(284,959</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">(52,191</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">(397,434</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Accretion of debt discount
      &#150; Note 6 </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>(1,836,997</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>(170,164</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>(2,007,161</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Change in fair value of derivative liability
      &#150; Note 5 </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">(630,774</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">(630,774</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Loss on settlement of accounts
      payable &#150; Note 7 </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>(444,000</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>(444,000</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Loss on extinguishment of debt &#150; Note
      6 </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">(487,469</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">(487,469</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Foreign exchange gain (loss)    </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">61,961 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(49,993</TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">3,688 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Net loss for the period </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;(8,783,037</TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;(5,499,419</TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;(21,345,270</TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">) </TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Basic and diluted loss per share </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;(0.41</TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;(0.27</TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Weighted average number of shares outstanding    </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">21,440,558 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">20,203,795 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%"
  align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-5></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=bottom>
    <TD align=center><B>ANAVEX LIFE SCIENCES CORP.</B> </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>CONSOLIDATED STATEMENTS OF CASH FLOWS </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>for the years ended September 30, 2010 and 2009 and </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>for the period from January 23, 2004 (Date of Inception)
      to September 30, 2010 </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(<U>Stated in US Dollars</U>) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=center valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">January 23, </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=center valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">2004 (Date of </TD>
    <TD  width="2%" align=center valign="bottom"></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" colSpan=4 align=center valign="bottom" nowrap>Years ended </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">Inception) to </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" colSpan=4 align=center valign="bottom" nowrap>September 30, </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" nowrap>September 30, </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=center valign="bottom" nowrap><U>2010</U> </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" nowrap><U>2009</U> </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom"><U>2010</U> </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="23%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>Cash Flows used in Operating Activities </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD width="23%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
  </TR>
  <TR vAlign=top bgcolor="#E6EFFF">
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Net loss for the period </TD>
    <TD  width="1%" align=left valign="bottom">$</TD>
    <TD width="23%" align=right valign="bottom">&nbsp;(8,783,037</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
    <TD  width="1%" align=left valign="bottom">$</TD>
    <TD width="10%" align=right valign="bottom">&nbsp;(5,499,419</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
    <TD  width="1%" align=left valign="bottom">$</TD>
    <TD width="10%" align=right valign="bottom">&nbsp;(21,345,270</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp; &nbsp; &nbsp;Adjustments to reconcile
      net loss to net cash used in operations: </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD width="23%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
  </TR>
  <TR vAlign=top bgcolor="#E6EFFF">
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Amortization
      and depreciation </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=right valign="bottom">910 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">410 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">1,540 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Accretion
      of debt discount </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD width="23%" align=right valign="bottom" bgColor=#FFFFFF>1,836,997 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#FFFFFF>170,164 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#FFFFFF>2,007,161 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
  </TR>
  <TR vAlign=top bgcolor="#E6EFFF">
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Stock-based
      compensation </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=right valign="bottom">770,055 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">812,336 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">3,267,177 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Amortization
      of deferred financing charge </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD width="23%" align=right valign="bottom" bgColor=#FFFFFF>55,777 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#FFFFFF>55,777 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
  </TR>
  <TR vAlign=top bgcolor="#E6EFFF">
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Change in fair
      value of derivative liability </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=right valign="bottom">630,774 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">630,774 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD
      align=left valign="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consulting
      expense recorded in exchange for shares to be issued <br>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;      &#150; Note 8 </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">236,337 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">236,337 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Common
      shares issued for consulting expenses </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>70,760 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>390,510 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Promissory
      note issued for severance &#150; Notes 6 and 7 </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">71,500 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Common
      shares issued for severance </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>340,600 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD
      align=left valign="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common
      shares issued for research and development expenses </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">800,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Management
      fees contributed </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>14,625 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Loss on settlement
      of accounts payable </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=right valign="bottom">444,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">444,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Loss
      on extinguishment of debt </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>487,469 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>487,469 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Rent contributed    </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">3,750 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Changes in non-cash working
      capital balances related to operations: </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD
      align=left valign="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VAT
      receivable </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=right valign="bottom">(37,820</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">(37,820</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
  </TR>
  <TR vAlign=top>
    <TD
      align=left valign="bottom" bgColor=#e6efff>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid
      expenses </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" align=right valign="bottom" bgColor=#e6efff>(23,088</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>(181</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>(23,269</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;&nbsp;Accounts payable and
      accrued liabilities </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="23%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">511,844 </TD>
    <TD  width="2%"
    align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">927,469 </TD>
    <TD  width="2%"
    align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">2,362,203 </TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Net cash used in operating activities </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="23%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(4,593,588</TD>
    <TD  width="2%"
    align=left valign="bottom">) </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(2,794,655</TD>
    <TD  width="2%"
    align=left valign="bottom">) </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(10,292,936</TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Cash Flows provided by Financing Activities </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=left valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=left valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=left valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Issuance of common shares    </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" align=right valign="bottom" bgColor=#e6efff>3,095,573 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>1,638,031 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>6,229,071 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Share Subscriptions received </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">300,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Proceeds from promissory
      notes </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" align=right valign="bottom" bgColor=#e6efff>1,415,000 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>1,202,500 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>4,067,500 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Repayment of promissory note </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom">(100,000</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Due to related parties    </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>33,665 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Shareholder advances </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="23%" align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD  width="2%"
    align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD  width="2%"
    align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">333,000 </TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Net cash provided by financing activities </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="23%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">4,510,573 </TD>
    <TD  width="2%"
    align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">3,140,531 </TD>
    <TD  width="2%"
    align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">10,563,236 </TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Cash Flows used in Investing Activities </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="23%" align=left valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=left valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=left valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Acquisition of equipment    </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="23%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(3,310</TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(1,239</TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(5,631</TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="23%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Net cash used in investing activities </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="23%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(3,310</TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(1,239</TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(5,631</TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="23%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Increase (decrease) in cash during the period    </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="23%" align=right valign="bottom" bgColor=#e6efff>(86,325</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>344,637 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=right valign="bottom" bgColor=#e6efff>264,669 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="23%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Cash, beginning of period </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="23%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">350,994 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">6,357 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="23%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Cash, end of period </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="23%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;264,669 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;350,994 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="10%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;264,669 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
  </TR>
</TABLE>
<P align=justify>Supplemental Cash Flow Information &#150; Note 11</P>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-6></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=bottom>
    <TD align=center><B>ANAVEX LIFE SCIENCES CORP.</B> </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIT </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>for the period January 23, 2004 (Date of Inception) to September
      30, 2010 </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(<U>Stated in US Dollars</U>) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD colSpan=10 align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">Deficit </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD colSpan=10
    align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Common Stock </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom" nowrap>Accumulated </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom" nowrap>Additional </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">Common </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">During the </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">Paid-in </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom" nowrap>Shares to be </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom" nowrap>Development </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%"
      align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Shares </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Par Value    </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%"
      align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Issued </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Stage    </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Total    </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for cash on January 23,
      2004 - at $0.0033 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>12,000,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;12,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;28,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;40,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp;Net loss from January 23, 2004 to September 30,
      2004 </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(14,395</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">) </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(14,395</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, September 30, 2004 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>12,000,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>12,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>28,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>(14,395</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>25,605 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp;Capital stock issued for cash on December 31,
      2004 - at $0.0033 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">7,200,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">7,200 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">16,800 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">24,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp;Management fees contributed </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>13,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>13,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp;Rent contributed </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">3,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">3,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp;Net loss for the year </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(91,625</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(91,625</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, September 30, 2005 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>19,200,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>19,200 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>60,800 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>(106,020</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>(26,020</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp;Management fees contributed </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">1,625 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">1,625 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp;Rent contributed </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>750 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>750 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp;Debt forgiven by directors </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">33,666 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">33,666 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp;Net loss for the year </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(25,532</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(25,532</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, September 30, 2006 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>19,200,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>19,200 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>96,841 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>(131,552</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>(15,511</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;&nbsp; Capital stock issued for research and development
      services on <BR>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; September 24, 2007 - at $3.60
    </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">222,222 </TD>
    <TD align=left valign="bottom"><BR></TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">222 </TD>
    <TD align=left valign="bottom"><BR></TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">799,778 </TD>
    <TD align=left valign="bottom"><BR></TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom"><BR></TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom"><BR></TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">800,000 </TD>
    <TD align=left valign="bottom"><BR></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;&nbsp; Capital stock issued for settlement
      of loan payable on September <BR>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25, 2007 - at $3.60 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>92,500 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff><BR></TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>93 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff><BR></TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>332,907 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff><BR></TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff><BR></TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff><BR></TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>333,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff><BR></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp;Net loss for the year </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(1,579,993</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">) </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(1,579,993</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Balance, September 30, 2007 &#150; carried forward </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">19,514,722 </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;19,515 </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;1,229,526 </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;- </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;(1,711,545</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">) </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;(462,504</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">) </TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-7></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=bottom>
    <TD align=center><B>ANAVEX LIFE SCIENCES CORP.</B> </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIT </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>for the period January 23, 2004 (Date of Inception) to September
      30, 2010 </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(<U>Stated in US Dollars</U>) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">Deficit </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD colSpan=10
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Common Stock </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom" nowrap>Accumulated </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom" nowrap>Additional </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom">Common </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom">During the </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">Paid-in </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom" nowrap>Shares to be </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom" nowrap>Development </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Shares </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=center valign="bottom" nowrap style="BORDER-BOTTOM: #000000 1px solid">Par Value    </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Issued </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Stage    </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Total    </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, September 30, 2007 &#150; brought
      forward </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>19,514,722 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;19,515 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;1,229,526 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;(1,711,545</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;(462,504</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp;Capital stock issued for cash on December 10,
      2007 - at $3.50 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">150,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">150 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">524,850 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">525,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp;Capital stock issued for consulting
      services on December 18, 2007 &nbsp;&#150; at $3.86 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>50,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>50 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>192,950 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>193,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp; &nbsp;Capital stock issued in settlement
      of debt on December 18, 2007 -       &nbsp;&nbsp;at $4.50 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>10,000 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>10 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>44,990 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>45,000 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp;Stock-based compensation for shares
      issued at a discount </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>65,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>65,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp;Capital stock issued for severance on May 15,
      2008 - at $5.24 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">65,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">65 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">340,535 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">340,600 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp;Common shares to be issued for
      consulting services </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>252,599 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>252,599 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; &nbsp;Capital stock issued for consulting services on
      August 19, 2008 - &nbsp;at
      $5.07 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">25,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">25 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">126,725 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">(126,750</TD>
    <TD align=left valign="bottom">) </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top bgcolor="#E6EFFF">
    <TD align=left valign="bottom">&nbsp; &nbsp;Capital stock issued for cash on August 19, 2008
      - at $4.25 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">142,698 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">142 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">606,325 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">606,467 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp; &nbsp;Stock based compensation </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>1,493,937 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>1,493,937 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
  </TR>
  <TR vAlign=top bgcolor="#E6EFFF">
    <TD align=left valign="bottom">&nbsp; &nbsp;Net loss for the year </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(5,351,269</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">) </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(5,351,269</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp; </TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp; </TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp; </TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp; </TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp; </TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp; </TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp; </TD>
    <TD valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
  </TR>
  <TR vAlign=top bgcolor="#E6EFFF">
    <TD align=left valign="bottom">Balance, September 30, 2008 </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">19,957,420 </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;19,957 </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;4,624,838 </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;125,849 </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;(7,062,814</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">) </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;(2,292,170</TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">) </TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-8></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=bottom>
    <TD align=center><B>ANAVEX LIFE SCIENCES CORP.</B> </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>STATEMENT OF CHANGES IN CAPITAL DEFICIT </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>for the period January 23, 2004 (Date of Inception) to September
      30, 2010 </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(Stated in US Dollars) </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(<U>Unaudited</U>) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>Deficit </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" colSpan=10
    align=center>Common Stock </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>Accumulated </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>Additional </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>Common </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>During the </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">Paid-in </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">Shares to </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">Development </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Shares </TD>
    <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Par Value    </TD>
    <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
    <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Be Issued    </TD>
    <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Stage    </TD>
    <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Total    </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, September 30, 2008 &#150; brought
      forward </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>19,957,420 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;19,957 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;4,624,838 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;125,849 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;(7,062,814</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>(2,292,170</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Stock-based compensation &#150; Note 10 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">812,336 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">812,336 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for consulting services
      on November 20, 2008 - $2.63 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>25,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>25 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>65,725 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>(65,750</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Capital stock issued for consulting services on February 20,
      2009 - $2.50 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">25,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">25 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">62,475 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">(62,500</TD>
    <TD align=left valign="bottom">) </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for cash on March 6, 2009
      - at $2.25 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>89,148 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>89 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>200,494 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>200,583 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Capital stock issued for consulting services on March 20, 2009
      - at $2.00 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">2,500 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">3 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">4,997 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">5,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for cash on March 20,
      2009 - at $2.25 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>10,800 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>11 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>24,289 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>24,300 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Capital stock issued for cash on June 11, 2009 - at $2.25 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">36,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">36 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">80,964 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">81,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for services on June 11,
      2009 - at $2.25 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>29,227 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>29 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>65,731 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>65,760 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Capital stock issued for cash on June 19, 2009 - at $2.25 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">495,556 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">496 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">1,114,504 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">1,115,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for finders&#146; fees
      on June 26, 2009 &#150; at $2.51 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>22,222 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>22 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>55,755 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>55,777 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Shares to be issued for consulting services -Note 8 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">236,337 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">236,337 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for cash on August 19,
      2009 &#150; at $2.25 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>128,888 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>129 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>289,869 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>289,998 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Less: Finders fees </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=right valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">(72,850</TD>
    <TD align=left valign="bottom">) </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">(72,850</TD>
    <TD align=left valign="bottom">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Beneficial conversion features on convertible
      debt issuances - Note 4 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>333,056 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>333,056 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Extinguishment of debt - Note 6 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">487,469 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">487,469 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Cancellation of common shares &#150; Note 8    </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>(75,000</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>(75</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>234,011 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>(233,936</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Share subscriptions received </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">300,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">300,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Net loss for the year </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(5,499,419</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(5,499,419</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, September 30, 2009 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">20,746,761 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;20,747 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;8,383,663 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;300,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;(12,562,233</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;(3,857,823</TD>
    <TD align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">) </TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-9></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=bottom>
    <TD align=center><B>ANAVEX LIFE SCIENCES CORP.</B> </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>CONSOLIDATED STATEMENT OF SHAREHOLDERS&#146; DEFICIT </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>for the period January 23, 2004 (Date of Inception) to September
      30, 2010 </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(Stated in US Dollars) </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(<U>Unaudited</U>) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>Deficit </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" colSpan=10
    align=center>Common Stock </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>Accumulated </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>Additional </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>Common </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>During the </TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp;</TD>
    <TD align=center>&nbsp; </TD>
    <TD align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">Paid-in </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">Shares to </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">Development </TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD align=center valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Shares </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Par Value    </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Be Issued    </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Stage    </TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="9%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Total    </TD>
    <TD
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, September 30, 2009 &#150; brought
      forward </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>20,746,761 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;20,747 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;8,383,663 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;300,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;(12,562,233</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>&nbsp;(3,857,823</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Cumulative effect of accounting changes &#150; Note 4 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">(333,056</TD>
    <TD align=left valign="bottom">) </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">(550,804</TD>
    <TD align=left valign="bottom">) </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">(883,860</TD>
    <TD align=left valign="bottom">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for cash on October 2,
      2009 &#150; at $2.25 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>266,666 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>267 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>599,733 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>(300,000</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>300,000 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Capital stock issued in settlement of promissory note on February
      2, 2010 &#150; at $2.02 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">49,505 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">49 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">99,951 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">100,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for cash on April 9, 2010
      - at $2.60 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>92,499 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>93 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>240,405 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>240,498 </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Capital stock issued in settlement of debt on April 30, 2010
      - at $2.85 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">9,825 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">9 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">27,991 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">28,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Finders&#146; fees paid in cash </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>(24,050</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#e6efff>(24,050</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>Capital stock issued for cash on June 29, 2010
      - at $2.50 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>941,000 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>941 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>2,351,559 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>2,352,500 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
  </TR>
  <TR vAlign=top bgcolor="#E6EFFF">
    <TD align=left valign="bottom">Finders&#146; fees paid in cash </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">(206,500</TD>
    <TD align=left valign="bottom">) </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">(206,500</TD>
    <TD align=left valign="bottom">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>Capital stock issued in settlement of debt
      on July 5, 2010 &#150; at $2.50 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>400,000 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>400 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>999,600 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>1,000,000 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
  </TR>
  <TR vAlign=top bgcolor="#E6EFFF">
    <TD align=left valign="bottom">Capital stock issued for cash on September 3, 2010 &#150; at
      $2.75 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">163,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">163 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">448,087 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">448,250 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>Capital stock issued for finders&#146; fees
      on September 3, 2010 &#150; at $2.75 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>9,000 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>9 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>(9</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>) </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
  </TR>
  <TR vAlign=top bgcolor="#E6EFFF">
    <TD align=left valign="bottom">Finders&#146; fees paid in cash </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">(15,125</TD>
    <TD align=left valign="bottom">) </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">(15,125</TD>
    <TD align=left valign="bottom">) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>Shares issued on conversion of promissory note
      on September 30, 2010 &#150; at $2.25 &#150; Note 6 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>328,058 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>328 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>737,802 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>738,130 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
  </TR>
  <TR vAlign=top bgcolor="#E6EFFF">
    <TD align=left valign="bottom">Shares issued on conversion of promissory note on September
      30, 2010 &#150; at $2.35 &#150; Note 6 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">510,638 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">511 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">1,199,489 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">1,200,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>Reclassification of derivative liability on
      modification of note terms </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>3,144,520 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>3,144,520 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
  </TR>
  <TR vAlign=top bgcolor="#E6EFFF">
    <TD align=left valign="bottom">Settlement of accounts payable &#150; Note 7 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">444,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">444,000 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>Stock-based compensation &#150; Note 10 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>770,055 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
    <TD align=right valign="bottom" bgColor=#FFFFFF>770,055 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF>&nbsp;</TD>
  </TR>
  <TR vAlign=top bgcolor="#E6EFFF">
    <TD align=left valign="bottom">Equity component of convertible interest bearing promissory
      note &#150; Note 6 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">44,220 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">- </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD align=right valign="bottom">44,220 </TD>
    <TD align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>Net loss for the year </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">(8,783,037</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">) </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">(8,783,037</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR bgcolor="#E6EFFF">
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#FFFFFF>Balance, September 30, 2010 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD
    align=right valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">23,516,952 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
    align=right valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">&nbsp;23,517 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
    align=right valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">&nbsp;18,912,335 </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
    align=right valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">&nbsp;- </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
    align=right valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">&nbsp;(21,896,074</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">) </TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD
    align=right valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">&nbsp;(2,960,222</TD>
    <TD align=left valign="bottom" bgColor=#FFFFFF style="BORDER-BOTTOM: #000000 3px double">) </TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-10></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=bottom>
    <TD align=center><B>ANAVEX LIFE SCIENCES CORP.</B> </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=bottom>
    <TD align=center>(<U>Stated in US Dollars</U>) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 1 </TD>
    <TD width="90%" align=left><U>Nature of Operations and Ability to Continue
      as a Going Concern</U> </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The Company is in the development stage
  and has not yet realized any revenues from its planned operations. The Company
  is seeking to develop and market proprietary drug targets for the treatment
  of cancer and diseases of the central nervous system.</P>
<P style="MARGIN-LEFT: 10%" align=justify>These financial statements have been
  prepared in accordance with generally accepted accounting principles in the
  United States of America on a going concern basis, which assumes that the Company
  will continue to realize its assets and discharge its obligations and commitments
  in the normal course of operations. Realization values may be substantially
  different from carrying values as shown and these financial statements do not
  give effect to adjustments that would be necessary to the carrying values and
  classification of assets and liabilities should the Company be unable to continue
  as a going concern. At September 30, 2010, the Company had not yet achieved
  profitable operations, had an accumulated deficit of $21,896,074 (2009 - $12,562,233)
  since its inception and incurred a net loss of $8,783,037 (2009 - $ 5,499,419)
  for the year then ended and expects to incur further losses in the development
  of its business, all of which casts substantial doubt about the Company&#146;s
  ability to continue as a going concern. The Company&#146;s ability to continue
  as a going concern is dependent upon its ability to generate future profitable
  operations and/or to obtain the necessary financing to meet its obligations
  and repay its liabilities arising from normal business operations when they
  come due. Management has no formal plan in place to address this concern but
  considers obtaining additional funds by equity financing and/or from issuing
  promissory notes. Management expects the Company&#146;s cash requirement over
  the twelve-month period ended September 30, 2011 to be approximately $10,000,000.
  While the Company is expending its best efforts to achieve the above plans,
  there is no assurance that any such activity will generate funds for operations.</P>
<P style="MARGIN-LEFT: 10%" align=justify>The Company was incorporated in the
  State of Nevada, United States of America on January 23, 2004 as Thrifty Printing
  Inc. On January 25, 2007, the Company changed its business from developing online
  photofinishing services to its current business and changed its name to Anavex
  Life Sciences Corp.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 2 </TD>
    <TD width="90%" align=left><U>Significant Accounting Policies</U> </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The preparation of financial statements
  in accordance with United States generally accepted accounting principles requires
  management to make estimates and assumptions that affect the reported amounts
  of assets and liabilities at the date of the financial statements and the reported
  amounts of revenue and expenses in the reporting period. The Company regularly
  evaluates estimates and assumptions related to deferred income tax asset valuations,
  asset impairment, conversion features embedded in convertible notes payable,
  derivative valuations, stock based compensation and loss contingencies. The
  Company bases its estimates and assumptions on current facts, historical experience
  and various other factors that it believes to be reasonable under the circumstances,
  the results of which form the basis for making judgments about the carrying
  values of assets and liabilities and the accrual of costs and expenses that
  are not readily apparent from other sources. The actual results experienced
  by the Company may differ materially and adversely from the Company&#146;s estimates.
  To the extent there are material differences between the estimates and the actual
  results, future results of operations will be affected.</P>
<P style="MARGIN-LEFT: 10%" align=justify>The financial statements have, in management&#146;s
  opinion, been properly prepared within the framework of the significant accounting
  policies summarized below:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD> <P align=justify><U>Principles of Consolidation</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>These consolidated financial statements include the
        accounts of Anavex Life Sciences Corp. and its wholly- owned subsidiary,
        Anavex Life Sciences (France) SA, a company incorporated under the laws
        of France. All inter-company transactions and balances have been eliminated.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-11></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 2 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 2 </TD>
    <TD width="90%" align=left><U>Significant Accounting Policies </U>&#150; (cont&#146;d)
    </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD> <P align=justify><U>Development Stage Company</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>The Company is devoting substantially all of its present
        efforts to establish a new business and none of its planned principal
        operations have commenced. All losses accumulated since inception has
        been considered as part of the Company&#146;s development stage activities.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD> <P align=justify><U>Equipment</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>Equipment is recorded at cost and is depreciated at
        33% per annum on the straight-line basis.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD> <P align=justify><U>Impairment of Long-Lived Assets</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>The Company reviews the recoverability of its long-lived
        assets whenever events or changes in circumstances indicate that the carrying
        amount of such assets may not be recoverable. The estimated future cash
        flows are based upon, among other things, assumptions about future operating
        performance, and may differ from actual cash flows. Long-lived assets
        evaluated for impairment are grouped with other assets to the lowest level
        for which identifiable cash flows are largely independent of the cash
        flows of other groups of assets and liabilities. If the sum of the projected
        undiscounted cash flows (excluding interest) is less than the carrying
        value of the assets, the assets will be written down to the estimated
        fair value in the period in which the determination is made.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">e) </TD>
    <TD> <P align=justify><U>Financial Instruments</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>The carrying value of the Company&#146;s financial instruments,
        consisting of cash and accounts payable and accrued liabilities approximate
        their fair value due to the short-term maturity of such instruments. Based
        on borrowing rates currently available to the Company for similar terms
        and based on the short term duration of the debt instruments, the carrying
        value of the promissory notes payable approximate their fair value. Unless
        otherwise noted, it is management&#146;s opinion that the Company is not
        exposed to significant interest, currency or credit risks arising from
        these financial instruments.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">f) </TD>
    <TD> <P align=justify><U>Foreign Currency Translation</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>The functional currency of the Company is the US dollar.
        Monetary items denominated in a foreign currency are translated into US
        dollars at exchange rates prevailing at the balance sheet date and non-monetary
        items are translated at exchange rates prevailing when the assets were
        acquired or obligations incurred. Foreign currency denominated expense
        items are translated at exchange rates prevailing at the transaction date.
        Unrealized gains or losses arising from the translations are credited
        or charged to income in the period in which they occur.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">g) </TD>
    <TD> <P align=justify><U>Research and Development Expenses</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>Research and developments costs are expensed as incurred.
        These expenses are comprised of the costs of the Company&#146;s proprietary
        research and development efforts, including salaries, facilities costs,
        overhead costs and other related expenses as well as costs incurred in
        connection with third-party collaboration efforts. Milestone payments
        made by the Company to third parties are expensed when the specific milestone
        has been achieved.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>In addition, the Company incurs expenses in respect
        of the acquisition of intellectual property relating to patents and trademarks.
        The probability of success and length of time to developing commercial
        applications of the drugs subject to the acquired patents and trademarks
        is difficult to determine and numerous risks and uncertainties exist with
        respect to the timely completion of the development projects. There is
        no assurance the acquired patents and trademarks will ever be successfully
        commercialized. Due to these risks and uncertainties, the acquisition
        of patents and trademarks does not meet the definition of an asset and
        thus are expensed as incurred.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-12></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 3 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 2 </TD>
    <TD width="90%" align=left><U>Significant Accounting Policies </U>&#150; (cont&#146;d)
    </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">h) </TD>
    <TD> <P align=justify><U>Income Taxes</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>The Company has adopted the asset and liability method
        of accounting for income taxes. Under the asset and liability method,
        deferred tax assets and liabilities are recognized for the future tax
        consequences attributable to temporary differences between the financial
        statements carrying amounts of existing assets and liabilities and their
        respective tax bases. Deferred tax assets and liabilities are measured
        using enacted tax rates expected to apply to taxable income in the years
        in which those temporary differences are expected to be recovered or settled.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>The Company has adopted the provisions of FASB ASC 740
        "Income Taxes" regarding accounting for uncertainty in income taxes. The
        Company initially recognizes tax positions in the financial statements
        when it is more likely than not the position will be sustained upon examination
        by the tax authorities. Such tax positions are initially and subsequently
        measured as the largest amount of tax benefit that is greater than 50%
        likely of being realized upon ultimate settlement with the tax authority
        assuming full knowledge of the position and all relevant facts. Application
        requires numerous estimates based on available information. The Company
        considers many factors when evaluating and estimating our tax positions
        and tax benefits, and our recognized tax positions and tax benefits may
        not accurately anticipate actual outcomes. As additional information is
        obtained, there may be a need to periodically adjust the recognized tax
        positions and tax benefits. These periodic adjustments may have a material
        impact on the consolidated statements of operations.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">i) </TD>
    <TD> <P align=justify><U>Basic and Diluted Loss per Share</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>The basic loss per common share is computed by dividing
        net loss available to common stockholders by the weighted average number
        of common shares outstanding. Diluted loss per common share is computed
        similar to basic loss per common share except that the denominator is
        increased to include the number of additional common shares that would
        have been outstanding if the potential common shares had been issued and
        if the additional common shares were dilutive. For the year ended September
        30, 2010, loss per share excludes 5,594,362 (September 30, 2009 &#150;
        5,247,548) potentially dilutive common shares (related to convertible
        notes payable and outstanding options and warrants) as their effect was
        anti-dilutive.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">j) </TD>
    <TD> <P align=justify><U>Stock-based Compensation</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>The Company accounts for all stock-based payments and
        awards under the fair value based method.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>Stock-based payments to non-employees are measured at
        the fair value of the consideration received, or the fair value of the
        equity instruments issued, or liabilities incurred, whichever is more
        reliably measurable. The fair value of stock-based payments to non-employees
        is periodically re-measured until the counterparty performance is complete,
        and any change therein is recognized over the vesting period of the award
        and in the same manner as if the Company had paid cash instead of paying
        with or using equity based instruments. Compensation costs for stock-based
        payments with graded vesting are recognized on a straight-line basis.
        The cost of the stock-based payments to non-employees that are fully vested
        and non-forfeitable as at the grant date is measured and recognized at
        that date, unless there is a contractual term for services in which case
        such compensation would be amortized over the contractual term.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>The Company accounts for the granting of share purchase
        options to employees using the fair value method whereby all awards to
        employees will be recorded at fair value on the date of the grant. The
        fair value of all share purchase options are expensed over their vesting
        period with a corresponding increase to additional paid-in capital.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>The Company uses the Black-Scholes option valuation
        model to calculate the fair value of share purchase options at the date
        of the grant. Option pricing models require the input of highly subjective
        assumptions, including the expected price volatility. Changes in these
        assumptions can materially affect the fair value estimates.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-13></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 4 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 2 </TD>
    <TD width="90%" align=left><U>Significant Accounting Policies </U>&#150; (cont&#146;d)
    </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">k) </TD>
    <TD> <P align=justify><U>Website Costs</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>Direct costs incurred during the application stage of
        development of the Company&#146;s website are capitalized and amortized
        over the estimated useful life. Fees incurred for web site hosting are
        expensed over the period of the benefit. Costs of operating a web site
        are expensed as incurred.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">l) </TD>
    <TD> <P align=justify><U>Comprehensive Income (Loss)</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>Comprehensive income (loss) represents the net change
        in stockholders&#146; equity during a period from sources other than transactions
        with stockholders. The Company has not recorded any components of comprehensive
        income (loss) for the years ended September 30, 2010 and 2009 and, as
        at September 30, 2010, the Company does not have a balance recorded in
        respect of accumulated comprehensive income (loss).</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">m) </TD>
    <TD> <P align=justify><U>Comparative Figures</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>Certain of the comparative figures have been reclassified
        to conform with the presentation in the current year.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">n) </TD>
    <TD> <P align=justify><U>Recent Accounting Pronouncements</U></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>In October 2009, the FASB issued ASU No. 2009-13, &#147;<I>Multiple-Deliverable
        Revenue Arrangements</I>,&#148; or ASU 2009-13, which amends existing
        revenue recognition accounting pronouncements that are currently within
        the scope of ASC 605. This guidance eliminates the requirement to establish
        the fair value of undelivered products and services and instead provides
        for separate revenue recognition based upon management&#146;s estimate
        of the selling price for an undelivered item when there is no other means
        to determine the fair value of that undelivered item. ASU 2009-13 is effective
        prospectively for revenue arrangements entered into or materially modified
        in fiscal years beginning on or after June 15, 2010. The adoption of this
        guidance did not have a material impact on the Company&#146;s consolidated
        financial statements.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>In January 2010, the FASB issued Accounting Standards
        Update 2010-06, <I>Fair Value Measurements and Disclosures (Topic 820):
        Improving Disclosures about Fair Value Measurements</I>. The ASU amends
        Subtopic 820-10 with new disclosure requirements and clarification of
        existing disclosure requirements. New disclosures required include the
        amount of significant transfers in and out of levels 1 and 2 fair value
        measurements and the reasons for the transfers. In addition, the reconciliation
        for level 3 activity will be required on a gross rather than net basis.
        The ASU provides additional guidance related to the level of disaggregation
        in determining classes of assets and liabilities and disclosures about
        inputs and valuation techniques. The amendments are effective for annual
        or interim reporting periods beginning after December 15, 2009, except
        for the requirement to provide the reconciliation for level 3 activities
        on a gross basis, which will be effective for fiscal years beginning after
        December 15, 2010. The Company is currently assessing the impact of ASU
        2010-6 and does not expect the adoption of this guidance to have a material
        impact on its consolidated financial statements.</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 3 </TD>
    <TD width="90%" align=left><U>Equipment</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="36%" colSpan=7
    align=center>September 30, 2010 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="10%" align=center>Accumulated </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="10%" align=center><U>Cost</U> </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="10%" align=center><U>Depreciation</U> </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="10%" align=center><U>Net</U> </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Computer equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="10%"
    align=right>&nbsp;5,631 </TD>
    <TD bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="10%"
    align=right>&nbsp;1,540 </TD>
    <TD bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="10%"
    align=right>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4,091 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="36%" colSpan=7
    align=center>September 30, 2009 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid"  width="2%"
    align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="10%" align=center>Accumulated </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="10%" align=center>&nbsp; </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="10%" align=center><U>Cost</U> </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="10%" align=center><U>Depreciation</U> </TD>
    <TD  width="2%" align=center>&nbsp;</TD>
    <TD  width="1%" align=center>&nbsp;</TD>
    <TD width="10%" align=center><U>Net</U> </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp; </TD>
    <TD  width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Computer equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="10%"
    align=right>&nbsp;2,321 </TD>
    <TD bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="10%"
    align=right>&nbsp;630 </TD>
    <TD bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="1%" align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="10%"
    align=right>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,691 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff
    width="2%" align=left>&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-14></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 5 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 4 </TD>
    <TD width="90%" align=left><U>Adoption of New Accounting Policy</U> </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>In June 2008, the Financial Accounting
  Standards Board (&#147;FASB&#148;) issued ASC 815-40-15, <I>&#147;Determining
  Whether an Instrument (or Embedded Feature) is Indexed to an Entity&#146;s Own
  Stock&#148;</I>. This guidance requires entities to evaluate whether an equity-linked
  financial instrument (or embedded feature) is indexed to its own stock by assessing
  the instrument&#146;s contingent exercise provisions and settlement provisions.
  Instruments not indexed to their own stock fail to meet the scope exception
  of ASC 815-10-15-74(a), and should be classified as a liability and marked-to-market.
  ASC 815-40-15 was effective for fiscal years beginning after December 15, 2008
  and thus, upon its adoption on October 1, 2009, was applied to the Company&#146;s
  outstanding promissory notes.</P>
<P style="MARGIN-LEFT: 10%" align=justify>The Company&#146;s outstanding promissory
  notes, as described in Note 6, included embedded conversion options that, prior
  to the adoption of this accounting policy, were not accounted for as derivative
  liabilities. Effective October 1, 2009, these conversion options met the criteria
  of a derivative instrument liability because the terms of the promissory notes
  require that the conversion price be adjusted in certain circumstances that
  do not meet the &#147;fixed-for-fixed&#148; criteria in ASC 815-40-15-5. As
  a result, the Company is now required to separately account for the embedded
  conversion option as a derivative instrument liability, carried at fair value
  and marked-to-market each period, with changes in the fair value each period
  charged or credited to income. The discount resulting from separating the embedded
  conversion feature is accreted via a charge to income using the effective yield
  method over the term of the debt. </P>
<P style="MARGIN-LEFT: 10%" align=justify>The transition provisions of ASC 815-40-15
  require cumulative effect adjustments as of October 1, 2009 to reflect the amounts
  that would have been recognized if derivative fair value accounting had been
  applied from the original issuance date of an equity-linked financial instrument
  through the implementation date of the revised guidance. Thus, the Company calculated
  the value of the derivative liabilities associated with the embedded conversion
  features as at the date of their issuances, recorded the accretion expense applicable
  to the debt discount arising upon the bifurcation of the derivative liabilities
  and recorded the change in the fair value of the derivative liabilities from
  the date of the issuance of the promissory notes up to October 1, 2009. Additionally,
  in conjunction with the foregoing, the previously calculated amounts in respect
  of the beneficial conversion features and the accretion expense on the beneficial
  conversion debt discounts were reversed.</P>
<P style="MARGIN-LEFT: 10%" align=justify>The cumulative effect of this change
  in accounting principle of $883,860 has been recognized as an increase of the
  opening balance of the accumulated deficit of $550,804 and a decrease in the
  opening balance of additional paid-in capital of $333,056 as of October 1, 2009,
  with corresponding adjustments at October 1, 2009 to decrease the carrying value
  of the Convertible Debentures by $1,629,886 and the recognition of a derivative
  liability of $2,513,746. </P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 5 </TD>
    <TD width="90%" align=left><U>Derivative Liabilities</U> </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>Derivative liabilities, consisting of
  the embedded conversion features in the Company&#146;s convertible promissory
  notes, are accounted for as separate liabilities measured at their respective
  fair values, as follows:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Balance, October 1, 2009 &#150; Note 4 </TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>&nbsp;2,513,746 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Change in fair value for the year ended September 30, 2010
    </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>630,774 </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Reclassification of derivative liability to
      additional paid-in capital on amendment to terms of the promissory notes
      payable &#150; Note 6 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="1%" align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff width="12%"
    align=right>(3,144,520</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#e6efff
    width="2%" align=left>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Balance, September 30, 2010 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double"  width="1%"
    align=left>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" width="12%"
      align=right>&nbsp;- </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double"  width="2%"
    align=left>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The fair value of the convertible promissory
  notes embedded call options have been determined using the Black-Scholes option
  pricing model using the following weighted average assumptions:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD width="56%" align=left>&nbsp; </TD>
    <TD width="17%" align=center nowrap><U>September 30, 2010</U> </TD>
    <TD width="17%" align=center nowrap><U>October 31, 2009</U> </TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="17%">&nbsp; </TD>
    <TD width="17%">&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Risk-free interest rate </TD>
    <TD bgColor=#e6efff width="17%" align=center>0.42% </TD>
    <TD bgColor=#e6efff width="17%" align=center>0.97% </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Expected life of derivative liability </TD>
    <TD width="17%" align=center>2 years </TD>
    <TD width="17%" align=center>2.24 years </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Annualized volatility </TD>
    <TD bgColor=#e6efff width="17%" align=center>68.51% </TD>
    <TD bgColor=#e6efff width="17%" align=center>71.78% </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Dividend rate </TD>
    <TD width="17%" align=center>0.00% </TD>
    <TD width="17%" align=center>0.00% </TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-15></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 6 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 6 </TD>
    <TD width="90%" align=left><U>Promissory Notes Payable</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="10%" valign="bottom"  >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" nowrap>September 30, </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" nowrap>September 30, </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom"><U>2010</U> </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom"><U>2009</U> </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Convertible non-interest bearing promissory
      notes payable </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>&nbsp;1,919,418 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>&nbsp;1,919,418 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD align=left valign="bottom">Convertible interest bearing promissory notes payable </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">668,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Interest bearing promissory notes payable </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>572,890 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>150,000 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD align=left valign="bottom">Non-interest bearing promissory notes payable </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">100,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Less: beneficial conversion
      features </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>(333,056</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Less: fair value of derivative liabilities
      on date of issuance </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">(2,489,422</TD>
    <TD  width="2%" align=left valign="bottom">) </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp;Less: equity component
      of convertible note </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>(44,220</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp;Add: accumulated accretion </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">2,533,642 </TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">170,164 </TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>2,492,308 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>2,674,526 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD align=left valign="bottom">Less: current portion </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(2,492,308</TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">) </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(2,506,526</TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" valign="bottom" >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">$</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;- </TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">$</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;168,000 </TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify><I><U>Convertible non-interest bearing
  promissory notes</U></I></P>
<P style="MARGIN-LEFT: 10%" align=justify>The convertible non-interest bearing
  promissory notes are due on demand and are convertible into units at $2.25 per
  unit with respect to $100,000 and at $2.50 per unit with respect to $1,819,418.
  Each unit will be comprised of one common share and one common share purchase
  warrant exercisable at $3.00 per share for a period of two years from the conversion
  date. </P>
<P style="MARGIN-LEFT: 10%" align=justify>The embedded conversion features included
  in these promissory notes were recorded as separate derivative liability along
  with a corresponding debt discount and were determined to have a cumulative
  fair value of $1,698,631 at their respective issuance dates. During the twelve
  months ended September 30, 2010, the Company recorded accretion expense of $1,202,816
  in respect of the debt discount on these notes.</P>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2010, the Company and the respective note-holders agreed to amend the notes
  by removing certain dilutive issuance clauses with the result that, as at September
  30, 2010, the embedded conversion features were no longer required to be recorded
  as a separate derivative liability. In accordance with the guidance of ASC 815-15-50-3,
  &#147;<I>Embedded Conversion Option that Is No Longer Bifurcated&#148;, </I>the
  Company re-measured the fair value of the derivative liability associated with
  the embedded conversion features in these notes on the date the notes were amended
  and determined it to be $3,144,520 which was then reclassified from liabilities
  to additional paid-in capital.</P>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2009, the promissory note of $1,669,418 was issued in exchange for a promissory
  note of the same amount that had matured as a result of the Company renegotiating
  this debt. The Company recorded the transaction as a debt extinguishment with
  a loss on extinguishment of $487,469 recorded as a result of recognizing the
  new promissory note as its fair value of $2,156,887. The premium of the fair
  value of the note over its principal balance in the amount of $487,469 was recorded
  as additional paid-in capital.</P>
<P style="MARGIN-LEFT: 10%" align=justify><I><U>Convertible interest bearing promissory
  notes</U></I></P>
<P style="MARGIN-LEFT: 10%" align=justify>The convertible interest bearing promissory
  notes included an amount of $500,000 that was to mature on June 3, 2014 and
  notes totaling $168,000 that were to mature on June 19, 2011. All of these notes
  earned interest at 8% per annum. All of the promissory notes were convertible
  into units at $2.25 per unit. Each unit was to be comprised of one common share
  and one common share purchase warrant exercisable at $3.00 per share for a period
  of two years from the conversion date for the $500,000 note and one common share
  and one-half of one common share purchase warrant exercisable at $3.50 per share
  for a period of two years from the conversion date for the notes totaling $168,000.
  The embedded conversion features included in these promissory notes, recorded
  as a separate derivative liability along with a corresponding debt discount,
  were determined to have a cumulative fair value of $790,791 at their respective
  issuance dates. These notes and accrued interest thereon totaling $738,130 were
  converted to units during the year ended September 30, 2010 through the issuance
  of 328,058 common shares and 328,058 common share purchase warrants. During
  the twelve months ended September 30, 2010, the Company recorded accretion expense
  of $589,961 on the discounts of these notes including accretion of the remaining
  balance of the unamortized debt discount on the date the notes were converted.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-16></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 7 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 6 </TD>
    <TD width="90%" align=left><U>Promissory Notes Payable &#150; (cont&#146;d)</U>
    </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify><I><U>Convertible interest bearing promissory
  notes &#150; (cont&#146;d)</U></I></P>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2009, the Company issued 22,222 common shares at $2.51 per share as a finder&#146;s
  fee on the $500,000 promissory note and recorded as a deferred financing charge
  of $55,777. This amount was being amortized to income over the term of the promissory
  note. Upon of the conversion of this promissory note, the balance of the unamortized
  deferred financing charge was charged to income resulting in a total amortization
  of deferred financing charge of $55,777 for the year ended September 30, 2010.</P>
<P style="MARGIN-LEFT: 10%" align=justify>During the twelve months ended September
  30, 2010, the Company issued a convertible promissory note in the amount of
  $1,000,000. This note paid interest at 20% per annum and was to mature on February
  22, 2012. The Company could prepay any portion of the note and accrued interest
  thereon after it had been outstanding for a period of 12 months. The Company
  was required to pay at least $200,000 in respect of interest on this promissory
  note representing the interest that would have been payable had the note been
  outstanding for 12 months irrespective of when the note was repaid or converted.
  Additionally, at any time after six months from the date of its issuance, the
  holder of the note could convert the outstanding loan into common shares of
  the Company at a rate of one common share for each $2.35 of the loan balance
  outstanding. This promissory note permitted the Company, upon receiving a notice
  of conversion from the lender, to settle the conversion in cash. Therefore,
  in accordance with ASC 470-20, the Company selected the income method to determine
  the fair value of the liability component of the note with the residual value
  allocated to the equity component. The result was that an amount of $44,220
  was determined to be the value of the equity component credited to additional
  paid-in capital. The debt discount arising from the bifurcation of the debt
  and equity components of the note was being accreted on an effective yield basis
  over the life of the note. On September 30, 2010, this promissory note and accrued
  interest thereon totaling $1,200,000 was converted to 510,638 common shares.
  During the twelve months ended September 30, 2010, the Company recorded accretion
  expense of $44,220 on the discount of this note including accretion of the remaining
  balance of the unamortized debt discount on the date the note was converted.</P>
<P style="MARGIN-LEFT: 10%" align=justify><I><U>Interest bearing promissory notes</U></I></P>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2009, the Company issued a promissory note in the amount of $150,000 bearing
  interest at 8% and which matured on December 31, 2009. On January 1, 2010, the
  Company exchanged this note with a new note bearing interest at 8%, having a
  principal balance of $157,890 representing principal and accrued interest on
  the promissory note that had matured and having a maturity date of December
  31, 2010.</P>
<P style="MARGIN-LEFT: 10%" align=justify>During the twelve months ended September
  30, 2010, the Company issued additional 8% interest bearing notes totaling $415,000
  which mature on December 5, 2010 as to $50,000, December 22, 2010 as to $100,000,
  February 17, 2011 as to $65,000 and May 4, 2011 as to $200,000. </P>
<P style="MARGIN-LEFT: 10%" align=justify><I><U>Non-interest bearing promissory
  note</U></I><I> </I></P>
<P style="MARGIN-LEFT: 10%" align=justify>Pursuant to a termination agreement
  the Company has issued one non-interest bearing promissory note to a former
  officer of the Company, in the amount of $200,000. The Company repaid $100,000
  and, as of September 30, 2009, the Company was in default of the payment terms
  for the remaining $100,000 balance owing. On February 2, 2010 the Company issued
  49,505 common shares of the Company, at their fair value of $2.02 per share
  pursuant to an agreement with the former officer to settle the outstanding amount
  owed. </P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 7 </TD>
    <TD width="90%" align=left><U>Capital Stock</U> </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>On May 24, 2006, the board of directors
  approved a six (6) for one (1) forward split of the authorized issued and outstanding
  common stock. The Company&#146;s authorized capital increased from 25,000,000
  shares of common stock to 150,000,000 shares of common stock.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On September 24, 2007, the Company issued
  222,222 common shares common shares at $3.60 per share for a total of $800,000
  for research and development expenses. The common shares were recorded based
  upon the quoted market price of the Company&#146;s common stock on the agreement
  date.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On September 25, 2007, the Company settled
  a loan payable in the amount of $333,000 by issuing 92,500 common shares at
  $3.60 per share, being the quoted market price of the Company&#146;s common
  stock on the settlement date.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-17></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 8 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 7 </TD>
    <TD width="90%" align=left><U>Capital Stock &#150; (cont&#146;d)</U> </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>On December 10, 2007, the Company issued
  150,000 units at $3.50 per unit for proceeds of $525,000. Each unit consisted
  of one common share and one common share purchase warrant entitling the holder
  to purchase an additional common share at $5.00 per share until December 10,
  2009. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On December 18, 2007, the Company issued
  10,000 shares at $4.50 per share for a total of $45,000 pursuant to an agreement
  to settle a debt and issued 50,000 shares at $3.86 per share for a total of
  $193,000 pursuant to a consulting agreement. The Company recorded compensation
  expense of $65,000 in respect of these issuances based on the excess of the
  fair value of these shares over the balances at which they were recorded by
  the Company.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On May 15, 2008, the Company issued
  65,000 common shares at $5.24 per share for a total of $340,600 to its former
  CEO in accordance with the terms of a severance agreement upon the termination
  of his services. The common shares were recorded based upon the quoted market
  price of the Company&#146;s common stock on the agreement date.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On August 19, 2008, the Company issued
  25,000 common shares at $5.07 per share for a total of $ 126,750 to a director
  of the Company pursuant to an agreement to provide consulting services. The
  common shares were recorded based upon the quoted market price of the Company&#146;s
  common stock on the agreement date.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On August 19, 2008, the Company issued
  142,698 units at $4.25 per unit for proceeds of $606,467 pursuant to private
  placement agreements. Each unit consisted of one common share and one common
  share purchase warrant entitling the holder to purchase an additional common
  share at $5.00 per share until August 19, 2009. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On November 20, 2008, the Company issued
  25,000 common shares at $2.63 per share for a total of $65,750 to a director
  of the Company pursuant to an agreement to provide consulting services. The
  common shares were recorded based upon the quoted market price of the Company&#146;s
  common stock on the issuance date. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On February 20, 2009, the Company issued
  25,000 common shares at $2.50 per share for a total of $62,500 to a director
  of the Company pursuant to an agreement to provide consulting services. The
  common shares were recorded based upon the quoted market price of the Company&#146;s
  common stock on the issuance date.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On March 6, 2009, the Company issued
  89,148 units at $2.25 per unit for proceeds of $200,583 pursuant to private
  placement agreements. Each unit consisted of one common share and one common
  share purchase warrant entitling the holder to purchase an additional common
  share at $4.00 per share until March 6, 2010.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On March 20, 2009, the Company issued
  10,800 units at $2.25 per unit for proceeds of $24,300 pursuant to private placement
  agreements. Each unit consisted of one common share and one common share purchase
  warrant entitling the holder to purchase an additional common share at $4.00
  per share until March 20, 2010.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On March 20, 2009, the Company issued
  2,500 common shares at $2.00 per share for a total of $5,000 to a public relations
  consultant pursuant to an agreement to provide consulting services. The common
  shares were recorded based upon the quoted market price of the Company&#146;s
  common stock on the issuance date.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On May 14, 2009, the Company entered
  into a revised consulting agreement with a director whereby the consultant returned
  75,000 common shares to the Company for cancellation. The return of shares was
  recorded in the same amount at which they were originally issued. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On June 11, 2009 the Company issued
  36,000 units at $2.25 per unit for proceeds of $81,000 pursuant to private placement
  agreements. Each unit consisted of one common share and one common share purchase
  warrant entitling the holder to purchase an additional common share at $4.00
  per share until June 11, 2010. The Company paid finders&#146; fees in the amount
  of $8,100 in relation to this private placement.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On June 11, 2009 the Company issued
  29,227 common shares at $2.25 per share for service rendered by consultants.
  The common shares were recorded based upon the fair value of the Company&#146;s
  common stock on the issuance date of the shares.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On June 19, 2009, the Company issued
  495,556 units at $2.25 per Unit for total proceeds of $1,115,000 pursuant to
  private placement agreements. Each unit consisted on one common share and one
  and one-half of a common share purchase warrant entitling the holder to purchase
  additional common shares at $2.25 per share until June 19, 2011.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On June 26, 2009, the Company issued
  22,222 common shares at $2.51 per share for finder&#146;s fees related to the
  issuance of a $500,000 note payable. The common shares were recorded based upon
  the quoted market price of the Company&#146;s common stock on the issue date.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-18></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 9 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 7 </TD>
    <TD width="90%" align=left><U>Capital Stock &#150; (cont&#146;d)</U> </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>On August 19, 2009, the Company issued
  128,888 units at $2.25 per Unit for total proceeds of $289,998. Of these placements,
  40,000 Units consisted of one common share and one share purchase warrant entitling
  the holder to purchase an additional common share at $4.00 per share until July
  9, 2010 and 88,888 Units consisted on one common share and one and one-eighth
  share purchase warrant entitling the holder to purchase an additional common
  shares at $2.25 per share until August 4, 2011. The Company paid finders&#146;
  fees totalling $19,000 in respect of these private placements.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On October 2, 2009 the Company issued
  266,666 units at $2.25 per unit for proceeds of $600,000 pursuant to private
  placement agreement. Each unit consisted of one common share and one and one-eighth
  common share purchase warrant entitling the holder to purchase an additional
  common share at $2.25 per share until October 2, 2011. The Company had received
  $300,000 of this amount in the year ended September 30, 2010.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On February 2, 2010 the Company issued
  49,505 common shares of the Company, at their fair value of $2.02 per share
  pursuant to an agreement with a former officer to settle an outstanding amount
  owed.</P>
<P style="MARGIN-LEFT: 10%" align=justify> On April 9, 2010, the Company issued 92,499 units at $2.60 per unit for
  proceeds of $240,498 pursuant to private placement agreement. Each unit consisted
  of one common share and one-half common share purchase warrant entitling the
  holder to purchase an additional common share at $3.50 per share until April
  9, 2011.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On April 30, 2010, the Company issued
  9,825 common shares of the Company, at $2.85 per share as consideration for
  terminating a consulting agreement and for services rendered under the agreement.
  The common shares were recorded based upon the quoted market price of the Company&#146;s
  common stock on the date of the termination of the agreement.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On June 29, 2010, the Company issued
  941,000 units at $2.50 per unit for total proceeds of $2,352,500 pursuant to
  private placement agreements. Each unit consisted on one common share and one-half
  of a common share purchase warrant entitling the holder to purchase additional
  common shares at $3.50 per share until December 29, 2011.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On July 5, 2010, the Company issued
  400,000 units in settlement of $1,000,000 owing to a creditor. Each unit consisted
  of one common share and one-half common share purchase warrant entitling the
  holder to purchase an additional common share at 3.50 per share until January
  5, 2012. The fair value of the units issued was determined to be $1,444,000
  on the date they were issued and thus the Company recorded a loss on settlement
  of accounts payable of $444,000 with a corresponding credit to additional paid-in
  capital of the same amount on date of issuance. The fair value of the shares
  included in the units was determined with reference to their quoted market price
  and the value of the warrants was determined using the Black-Scholes model with
  the following assumptions: exercise price - $3.50, stock price - $3.15, expected
  volatility &#150; 68.45%, expected life &#150; 1.5 years, dividend yield &#150;
  0.00% .</P>
<P style="MARGIN-LEFT: 10%" align=justify>On September 3, 2010, the Company issued
  163,000 units at $2.75 per unit for proceeds of $448,250 pursuant to private
  placement agreement. Each unit consisted of one common share and one-half common
  share purchase warrant entitling the holder to purchase an additional common
  share at $3.75 per share until March 3, 2012.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On September 3, 2010, the Company issued
  9,000 units at $2.75 per unit for finder&#146;s fees related to the private
  placement of the same date. Each unit consisted of one common share and one-half
  common share purchase warrant entitling the holder to purchase an additional
  common share at $3.75 per share until March 3, 2012.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On September 30, 2010, the Company issued
  510,638 common shares at $2.35 per share pursuant to the terms of a convertible
  note payable.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On September 30, 2010, the Company issued
  82,310 units at $2.25 per unit pursuant to the terms of convertible notes payable.
  Each unit consisted of one common share and one-half common share purchase warrant
  entitling the holder to purchase an additional common share at $3.50 per share
  until September 30, 2012.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On September 30, 2010, the Company issued
  245,748 units at $2.25 per unit pursuant to the terms of convertible notes payable.
  Each unit consisted of one common share and one common share purchase warrant
  entitling the holder to purchase an additional common share at $3.00 per share
  until September 30, 2012.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-19></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 10 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 8 </TD>
    <TD width="90%" align=left><U>Related Party Transactions</U> </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The following amounts have been donated
  to the Company by the directors:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD width="48%" align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD colSpan=4 align=center valign="bottom">&nbsp;</TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="11%" align=center valign="bottom">January 23, </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD colSpan=4 align=center valign="bottom">&nbsp;</TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="11%" align=center valign="bottom" nowrap>2004 (Date of </TD>
    <TD  width="2%" align=center valign="bottom"></TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD colSpan=4 align=center valign="bottom">Years ended </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="11%" align=center valign="bottom" nowrap>Inception) to </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD colSpan=4 align=center valign="bottom" nowrap>September 30, </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="11%" align=center valign="bottom" nowrap>September 30, </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="11%" align=center valign="bottom"><U>2010</U> </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="11%" align=center valign="bottom"><U>2009</U> </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="11%" align=center valign="bottom"><U>2010</U> </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="11%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="11%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="11%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Management fees </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD width="11%" align=right valign="bottom" bgColor=#e6efff>&nbsp;&nbsp;&nbsp;&nbsp;-</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD width="11%" align=right valign="bottom" bgColor=#e6efff>&nbsp;- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD width="11%" align=right valign="bottom" bgColor=#e6efff>&nbsp;14,625 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom">Rent </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="11%" align=right valign="bottom">-</TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="11%" align=right valign="bottom">- </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="11%" align=right valign="bottom">3,750 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Debt forgiven by directors </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="11%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="11%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="11%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">33,666 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="11%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="11%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="11%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">$</TD>
    <TD width="11%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;&nbsp;- </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">$</TD>
    <TD width="11%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">- </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">$</TD>
    <TD width="11%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;52,041 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2010, the Company was charged consulting fees totaling $725,310 (2009: $486,690)
  by directors, officers and a significant shareholder of the Company.</P>
<P style="MARGIN-LEFT: 10%" align=justify>As at September 30, 2010, included in
  accounts payable and accrued liabilities is $9,521 (2009: $57,464) owing to
  directors and officers of the Company.</P>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2008, the Company terminated the services of its CEO and agreed to a severance
  package consisting of the issuance of 65,000 common shares at $5.24 per share
  totaling $340,600. The common shares were valued using the quoted market price
  of the Company&#146;s common stock on the agreement date. In addition, the Company
  issued a promissory note payable to the former CEO in the amount of $200,000
  of which $128,500 was applied to unpaid consulting fees and the remaining $71,500
  was charged as severance pay in the current year. As at September 30, 2009,
  the Company had paid an amount of $100,000 on account of the promissory note.
  The remaining $100,000 was settled for shares during 2010 &#150; Note 6.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On May 20, 2008, the Company executed
  an agreement with a director of the Company to provide consulting services for
  consideration consisting of 200,000 common shares to be issued every quarter
  at the rate of 25,000 per quarter commencing August 20, 2008 and by granting
  400,000 share purchase options which vest at the rate of 100,000 per quarter
  commencing August 20, 2008. On May 14, 2009, the agreement was amended whereby
  the director was granted 400,000 share purchase options in exchange for rescinding
  the portion of the agreement that called for compensation of 200,000 common
  shares. Consequently, as a result of this amendment, the director returned 75,000
  common shares to the Company for cancellation that had previously been issued.</P>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2009, the Company calculated compensation expense associated with this agreement
  as follows:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD> <P align=justify>At September 30, 2008, the value of the shares to be
        issued under this agreement was $125,849. During the year ended September
        30, 2009, as a result of re-measuring the remaining shares to be issued,
        the Company recognized a compensation expense of $236,337 up to the date
        of the agreement being amended and the director returning the previously
        issued common shares to the Company for cancellation. As a result of the
        agreement being amended, there are no remaining common shares to be issued.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD> <P align=justify>In accordance with the agreement being amended on May
        14, 2009, the director was granted 400,000 additional share purchase options
        having a fair value of $272,000. As a result, the Company recorded an
        incremental share-based compensation charge of $38,064 in respect of these
        options after giving effect to the director receiving these options in
        exchange for surrendering the right to receive common shares, having a
        fair value of $233,936 as at the date of the amendment for future consulting
        services to be performed. Additionally, as at September 30, 2009, the
        remaining unvested options granted to the director upon the amendment
        of the agreement were re-measured resulting in the Company recognizing
        $167,812 included in consulting fees.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD> <P align=justify>During the year ended September 30, 2010, the remaining
        unvested options pertaining to the original agreement were periodically
        re-measured up to their measurement date which resulted in the Company
        recognizing $64,268 included in consulting fees in the consolidated financial
        statements for the year ended September 30, 2010. (2009: $238,063).</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-20></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 11 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 9 </TD>
    <TD width="90%" align=left><U>Income Taxes</U> </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The tax effects of the temporary differences
  that give rise to the Company's estimated deferred tax assets and liabilities
  are as follows:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" nowrap><U>2010</U> </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" nowrap><U>2009</U> </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom"><U>(34.00%</U></TD>
    <TD  width="2%" align=left valign="bottom"><U>)</U> </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom"><U>(34.00%</U></TD>
    <TD  width="2%" align=left valign="bottom"><U>)</U> </TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Net operating loss carryforwards </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>&nbsp;3,849,000 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>&nbsp;2,134,000 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom">Research and development tax credits </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">331,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">196,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Foreign exchange </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>17,000 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>27,000 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom">Intangible asset costs </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">35,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">38,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Other </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>- </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>18,000 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom">Valuation allowance for deferred tax assets </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(4,232,000</TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">) </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(2,413,000</TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">) </TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom">Net deferred tax assets </TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;- </TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="12%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;- </TD>
    <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The provision for income taxes differ
  from the amount established using the statutory income tax rate as follows:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" nowrap><U>2010</U> </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" nowrap><U>2009</U> </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">&nbsp; </TD>
    <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Income benefit at statutory rate </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>&nbsp;(2,986,000</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>$</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>&nbsp;(1,870,000</TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom">Stock-based compensation </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">263,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">277,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Foreign income taxed at foreign statutory rate    </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>4,000 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>4,000 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom">Debt extinguishment </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">150,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">166,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Debt accretion </TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>625,000 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=right valign="bottom" bgColor=#e6efff>58,000 </TD>
    <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom">Other permanent differences </TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">125,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=right valign="bottom">26,000 </TD>
    <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Change in valuation allowance </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">1,819,000 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">1,339,000 </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
    <TD  width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" valign="bottom">&nbsp; </TD>
    <TD  width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Deferred income tax recovery </TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;- </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD
    width="1%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">$</TD>
    <TD width="12%"
    align=right valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;- </TD>
    <TD
    width="2%" align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>As of September 30, 2010, the Company
  had net operating loss carry-forwards of approximately $11,340,000 available
  to offset future taxable income. The carry-forwards will begin expiring in 2027
  unless utilized in earlier years. The Company is in arrears in filing its income
  tax returns in the United States for years prior to 2008 and the Company has
  not filed any income tax returns in France as they are not yet due.</P>
<P style="MARGIN-LEFT: 10%" align=justify>The Company evaluates its valuation
  allowance requirements based on projected future operations. When circumstances
  change and this causes a change in management&#146;s judgment about the recoverability
  of deferred tax assets, the impact of the change on the valuation allowance
  is reflected in current income. As management of the Company does not currently
  believe that it is more likely than not that the Company will receive the benefit
  of this asset, a valuation allowance equal to the deferred tax asset has been
  established at both September 30, 2010 and September 30, 2009.</P>
<P style="MARGIN-LEFT: 10%" align=justify>Uncertain Tax Positions</P>
<P style="MARGIN-LEFT: 10%" align=justify>The Company files income tax returns
  in the U.S. federal jurisdiction, various state and foreign jurisdictions. The
  Company&#146;s tax returns are subject to tax examinations by U.S. federal and
  state tax authorities, or examinations by foreign tax authorities until respective
  statute of limitation. It is subject to tax examinations by tax authorities
  for all taxation years commencing on or after 2004.</P>
<P style="MARGIN-LEFT: 10%" align=justify>Provision has not been made for U.S.
  or additional foreign taxes on undistributed earnings of foreign subsidiaries.
  Such earnings have been and will continue to be reinvested but could become
  subject to additional tax if they were remitted as dividends, or were loaned
  to the Company affiliate. It is not practicable to determine the amount of additional
  tax, if any, that might be payable on the undistributed foreign earnings. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-21></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 12 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Note 10 </TD>
    <TD width="90%" align=left><U>Commitments</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD> <P align=justify><U>Share Purchase Warrants</U></P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>A summary of the Company&#146;s share purchase warrants
        outstanding is presented below:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">&nbsp; </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" nowrap>Weighted </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">&nbsp; </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">Average </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" nowrap>Number of </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">Exercise </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom"><U>Shares</U> </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom"><U>Price</U> </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD width="1%" align="center" valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">&nbsp; </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">&nbsp; </TD>
    <TD width="2%" align="center" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, September 30, 2008 </TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" bgColor=#e6efff>292,698 </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;5.00 </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">Expired </TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">(142,698)</TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">$&nbsp;5.00 </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Granted </TD>
    <TD width="1%"
    align=center valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
    align=center valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">833,448 </TD>
    <TD width="2%"
    align=center valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;2.62 </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">Balance, September 30, 2009 </TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">983,448 </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">$&nbsp;2.93 </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Expired </TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" bgColor=#e6efff>(325,948) </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;4.46 </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">Issued </TD>
    <TD width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">1,389,651 </TD>
    <TD width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">$&nbsp;3.16 </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, September 30, 2010 </TD>
    <TD width="1%"
    align=center valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="12%"
    align=center valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">2,047,151 </TD>
    <TD width="2%"
    align=center valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;2.87 </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>At September 30, 2010, the Company has
  2,047,151 currently exercisable share purchase warrants outstanding as follows:</P>
<DIV align=right>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="85%">
    <TR vAlign=top>
      <TD align=center valign="bottom"><U>Number</U> </TD>
      <TD width="33%" align=center valign="bottom"><U>Exercise Price</U> </TD>
      <TD width="33%" align=right valign="bottom"><U>Expiry Date</U> </TD>
    </TR>
    <TR>
      <TD align="center" valign="bottom">&nbsp; </TD>
      <TD width="33%" valign="bottom">&nbsp; </TD>
      <TD width="33%" valign="bottom">&nbsp; </TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom" bgColor=#e6efff>46,249 </TD>
      <TD width="33%" align=center valign="bottom" bgColor=#e6efff>$ 3.50 </TD>
      <TD width="33%" align=right valign="bottom" bgColor=#e6efff>April 9, 2011 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom">557,501 </TD>
      <TD width="33%" align=center valign="bottom">$ 2.25 </TD>
      <TD width="33%" align=right valign="bottom">June 19, 2011 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom" bgColor=#e6efff>99,999 </TD>
      <TD width="33%" align=center valign="bottom" bgColor=#e6efff>$ 2.25 </TD>
      <TD width="33%" align=right valign="bottom" bgColor=#e6efff>August 4, 2011 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom">41,155 </TD>
      <TD width="33%" align=center valign="bottom">$ 3.50 </TD>
      <TD width="33%" align=right valign="bottom">September 30, 2011 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom" bgColor=#e6efff>299,999 </TD>
      <TD width="33%" align=center valign="bottom" bgColor=#e6efff>$ 2.25 </TD>
      <TD width="33%" align=right valign="bottom" bgColor=#e6efff>October 2, 2011 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom">470,500 </TD>
      <TD width="33%" align=center valign="bottom">$ 3.50 </TD>
      <TD width="33%" align=right valign="bottom">December 29, 2011 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom" bgColor=#e6efff>200,000 </TD>
      <TD width="33%" align=center valign="bottom" bgColor=#e6efff>$ 3.50 </TD>
      <TD width="33%" align=right valign="bottom" bgColor=#e6efff>January 5, 2012 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom">86,000 </TD>
      <TD width="33%" align=center valign="bottom">$ 3.75 </TD>
      <TD width="33%" align=right valign="bottom">March 3, 2012 </TD>
    </TR>
    <TR vAlign=top>
      <TD
      align=center valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">245,748 </TD>
      <TD width="33%" align=center valign="bottom" bgColor=#e6efff>$ 3.00 </TD>
      <TD width="33%" align=right valign="bottom" bgColor=#e6efff>September 30, 2012 </TD>
    </TR>
    <TR>
      <TD align="center" valign="bottom">&nbsp; </TD>
      <TD width="33%" valign="bottom">&nbsp; </TD>
      <TD width="33%" valign="bottom">&nbsp; </TD>
    </TR>
    <TR vAlign=top>
      <TD
      align=center valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">2,047,151 </TD>
      <TD width="33%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
      <TD width="33%" align=left valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    </TR>
  </TABLE>
</DIV>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD> <P align=justify><U>Stock&#150;based Compensation Plan</U></P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>In April, 2007, the Company adopted a stock option plan
        which provides for the granting of stock options to selected directors,
        officers, employees or consultants in an aggregate amount of up to 3,000,000
        common shares of the Company and, in any case, the number of shares to
        be issued to any one individual pursuant to the exercise of options shall
        not exceed 10% of the issued and outstanding share capital. The granting
        of stock options, exercise prices and terms are determined by the Company's
        Board of Directors. If no vesting schedule is specified by the Board of
        Directors on the grant of options, then the options shall vest over a
        4-year period with 25% the granted vesting each year commencing 1 year
        from the grant date. For stockholders who have greater than 10% of the
        outstanding common shares of the Company and who have granted options,
        the exercise price of their options shall not be less than 110% of the
        fair of the stock on grant date. Otherwise, options granted shall have
        an exercise price equal to their fair value on grant date.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-22></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 13 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Note 10 </TD>
    <TD width="90%" align=left><U>Commitments &#150; (cont&#146;d)</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD> <P align=justify><U>Stock&#150;based Compensation Plan &#150; (cont&#146;d)</U></P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>A summary of the status of company&#146;s outstanding
        stock purchase options for the year ended September 30, 2010 is presented
        below:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">&nbsp; </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" nowrap>Weighted </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">&nbsp; </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">Average </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" nowrap>Number of </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" nowrap>Exercise </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom"><U>Shares</U> </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom"><U>Price</U> </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD width="1%" valign="bottom">&nbsp;</TD>
    <TD width="12%" align="center" valign="bottom">&nbsp; </TD>
    <TD width="2%" align="center" valign="bottom">&nbsp;</TD>
    <TD width="1%" align="center" valign="bottom">&nbsp;</TD>
    <TD width="12%" align="center" valign="bottom">&nbsp; </TD>
    <TD width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Outstanding at September 30, 2008 </TD>
    <TD width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" bgColor=#e6efff>1,420,000 </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;4.44 </TD>
    <TD width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">Granted </TD>
    <TD width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">1,775,000 </TD>
    <TD width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">$&nbsp;2.51 </TD>
    <TD width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align="center" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align="center" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">Outstanding at September 30, 2009 </TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">3,195,000 </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom">$&nbsp;3.37 </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Cancelled </TD>
    <TD width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" bgColor=#e6efff>(820,000) </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;2.50 </TD>
    <TD width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">Granted </TD>
    <TD width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">400,000 </TD>
    <TD width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="12%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">$&nbsp;3.48 </TD>
    <TD width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align="center" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align="center" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">Outstanding at September 30, 2010 </TD>
    <TD width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="12%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">2,775,000 </TD>
    <TD width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="12%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$&nbsp;3.29 </TD>
    <TD width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align="center" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align="center" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">Exercisable at September 30, 2010 </TD>
    <TD width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="12%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">1,613,333 </TD>
    <TD width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$3.52    </TD>
    <TD width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align="center" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="12%" align="center" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">Exercisable at September 30, 2009 </TD>
    <TD width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="12%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">1,330,000 </TD>
    <TD width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="12%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$4.38    </TD>
    <TD width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>At September 30, 2010, the following
  stock options were outstanding:</P>
<DIV align=right>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=0 cellSpacing=0 cellPadding=0 width="85%">
    <TR vAlign=top>
      <TD colSpan=3 align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Number
        of Shares </TD>
      <TD  width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">&nbsp; </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">&nbsp; </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" nowrap>Aggregate </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" nowrap>Remaining </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">&nbsp; </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">&nbsp; </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">&nbsp; </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">Intrinsic </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">contractual </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom">Total </TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" nowrap>Number </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" nowrap>Exercise </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" nowrap>Expiry Date </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">Value </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">life (yrs) </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="13%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Vested </TD>
      <TD  width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="13%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Price </TD>
      <TD  width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="13%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
      <TD  width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="13%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
      <TD  width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD  width="1%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="13%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp; </TD>
      <TD  width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    </TR>
    <TR>
      <TD align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">&nbsp; </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">&nbsp; </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">&nbsp; </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">&nbsp; </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">&nbsp; </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom" bgColor=#e6efff>400,000 <SUP>(1)</SUP> </TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" bgColor=#e6efff>400,000 </TD>
      <TD  width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;5.25 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>May 20, 2011 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>$</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>&nbsp;- </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>0.64 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom">50,000 <SUP>(2)</SUP> </TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">50,000 </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">$&nbsp;3.75 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">November 1, 2012 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">14,500 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">2.09 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom" bgColor=#e6efff>100,000 <SUP>(3)</SUP> </TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" bgColor=#e6efff>- </TD>
      <TD  width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;3.86 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>December 1, 2012 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>18,000 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>2.17 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom">150,000 <SUP>(4)</SUP> </TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">150,000 </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">$&nbsp;3.10 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">December 3, 2012 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">141,000 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">2.18 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom" bgColor=#e6efff>450,000 <SUP>(5)</SUP> </TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" bgColor=#e6efff>450,000 </TD>
      <TD  width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;3.10 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>June 3, 2013 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>423,000 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>2.68 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom">50,000 <SUP>(6)</SUP> </TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">50,000 </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">$&nbsp;2.75 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">January 14, 2014 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">64,500 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">3.29 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom" bgColor=#e6efff>5,000 <SUP>(7)</SUP> </TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" bgColor=#e6efff>5,000 </TD>
      <TD  width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;2.50 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>March 2, 2014 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>7,700 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>3.42 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom">400,000 <SUP>(8)</SUP> </TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">400,000 </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">$&nbsp;2.50 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">May 12, 2012 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">616,000 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">1.62 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom" bgColor=#e6efff>500,000 <SUP>(9)</SUP> </TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" bgColor=#e6efff>- </TD>
      <TD  width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;2.50 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>June 11, 2014 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>770,000 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>3.05 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom">200,000 <SUP>(10)</SUP> </TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">100,000 </TD>
      <TD  width="2%" align=center valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">$&nbsp;3.50 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">June 29, 2015 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">108,000 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">4.75 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom" bgColor=#e6efff>200,000 <SUP>(11)</SUP> </TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" bgColor=#e6efff>8,333 </TD>
      <TD  width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;3.45 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>September 1, 2015 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>118,000 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align=right valign="bottom" bgColor=#e6efff>4.92 </TD>
      <TD  width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">270,000 <SUP>(12)</SUP>      </TD>
      <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">- </TD>
      <TD  width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">$&nbsp;3.00 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">February 8, 2017 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="13%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">280,800 </TD>
      <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=right valign="bottom">6.36 </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    </TR>
    <TR>
      <TD align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align="center" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
      <TD  width="2%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" align="center" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
      <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
      <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
      <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD  width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
      <TD width="13%" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
      <TD  width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">2,775,000 </TD>
      <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
      <TD width="13%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">1,613,333 </TD>
      <TD  width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
      <TD  width="1%" align=center valign="bottom">&nbsp;</TD>
      <TD width="13%" align=center valign="bottom">&nbsp; </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=left valign="bottom">&nbsp; </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
      <TD  width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">$</TD>
      <TD width="13%"
      align=right valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;2,561,500 </TD>
      <TD  width="2%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
      <TD  width="1%" align=left valign="bottom">&nbsp;</TD>
      <TD width="13%" align=left valign="bottom">&nbsp; </TD>
      <TD  width="2%" align=left valign="bottom">&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 15%" align=justify>The aggregate intrinsic value is calculated
  as the difference between the exercise price of the underlying awards and the
  quoted market price of the Company&#146;s stock for the options that were in-the-money
  at September 30, 2010.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="15%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(1)</SUP> </TD>
    <TD> <P align=justify>As at September 30, 2010 and 2009, these options had
        fully vested. The Company did not recognize any stock-based compensation
        for these options in the year ended September 30, 2010 (2009: $40,020)</P></TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(2)</SUP> </TD>
    <TD> <P align=justify>As at September 30, 2010 and 2009, these options had
        fully vested. The Company did not recognize any stock-based compensation
        for these options in the year ended September 30, 2010 (2009: $nil)</P></TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(3)</SUP> </TD>
    <TD> <P align=justify>As at September 30, 2010, these options have not vested.
        The options vest upon the Company listing its shares on the American Stock
        Exchange or any other nationally recognized stock exchange by December
        1, 2012 or in the event of a change of control and a listing on a nationally
        recognized stock exchange is not required. No stock-based compensation
        has been recorded in the financial statements as the performance condition
        has not yet been met.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<A name=page_F-23></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 14 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Note 10 </TD>
    <TD width="90%" align=left><U>Commitments &#150; (cont&#146;d) </U></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>b) </TD>
    <TD width="85%" align=left><U>Stock&#150;based Compensation Plan &#150; (cont&#146;d)
      </U></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="15%" ></TD>
    <TD align=left><SUP>(4) </SUP></TD>
    <TD width="80%" align=left> <P align=justify>As at September 30, 2010 and
        2009, these options had fully vested. As a result of re-pricing these
        options, the Company recognized stock-based compensation of $31,035 during
        the year ended September 30, 2010 (2009: recognized stock based compensation
        of $12,956) </P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="80%"> <P align=justify></P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%"></TD>
    <TD align=left><SUP>(5) </SUP></TD>
    <TD width="80%" align=left> <P align=justify>As at September 30, 2010 and 2009,
        these options had fully vested. As a result of re-pricing these options,
        the Company recognized stock-based compensation of $196,425 during the
        year ended September 30, 2010 (2009: recognized stock based compensation
        of $341,354). </P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="80%"> <P align=justify></P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%"></TD>
    <TD align=left><SUP>(6) </SUP></TD>
    <TD width="80%" align=left> <P align=justify>These options were granted during
        the year ended September 30, 2009 and have fully vested as at September
        30, 2010. The Company has recognized stock-based compensation in the amount
        of $9,910 for these options for the year ended September 30, 2010 (2009:
        $56,509) </P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="80%"> <P align=justify></P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%"></TD>
    <TD align=left><SUP>(7) </SUP></TD>
    <TD width="80%" align=left> <P align=justify>As at September 30, 2010 and
        2009, these options had fully vested. The Company did not recognize any
        stock-based compensation for these options in the year ended September
        30, 2010 (2009: $6,000) </P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="80%"> <P align=justify></P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%"></TD>
    <TD align=left><SUP>(8) </SUP></TD>
    <TD width="80%" align=left> <P align=justify>As at September 30, 2010 and
        2009, these options had fully vested. The Company recognized stock-based
        compensation of $64,268 for these options in the year ended September
        30, 2010 (2009: $238,063) </P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="80%"> <P align=justify></P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%"></TD>
    <TD align=left><SUP>(9) </SUP></TD>
    <TD width="80%" align=left> <P align=justify>As at September 30, 2010 and
        2009 none of these options have vested. The options  vest as to 100,000 per compound entered into Phase II trial. The fair value of these options
        was calculated to be $740,000, which the Company has not yet recognized
        in the financial statements as the performance conditions have not yet
    been met. </P>
    </TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="80%"> <P align=justify></P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%"></TD>
    <TD align=left><SUP>(10) </SUP></TD>
    <TD width="80%" align=left> <P align=justify>These options were granted during
        the year ended September 30, 2010 and, as at September 30, 2010, 100,000
        of these options have vested. The remaining options vest on December 29,
        2010. The fair value of these options on the grant date was calculated
        to be $500,000 of which the Company has recognized stock-based compensation
        in the amount of $375,000 for the year ended September 30, 2010. </P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="80%"> <P align=justify></P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%"></TD>
    <TD align=left><SUP>(11) </SUP></TD>
    <TD width="80%" align=left> <P align=justify><SUP></SUP>These options were
        granted during the year ended September 30, 2010 and as at September 30,
        2010, 8,333 of these options have vested and the remaining options vest
        8,333 monthly until August 2012 and 8,341 vest in September 2012. The
        Company has recognized stock-based compensation in the amount of $20,917
        for the year ended September 30, 2010. </P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="80%"> <P align=justify></P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%"></TD>
    <TD align=left><SUP>(12 ) </SUP></TD>
    <TD width="80%" align=left> <P align=justify>As at September 30, 2010 and
        2009, these options have not vested. The options vest upon one or more
        compounds: entering Phase 2 Trial &#150; 90,000 options; entering Phase
        3 Trial &#150; 90,000 options; and receiving FDA approval &#150; 90,000
        options. No stock-based compensation has been recorded in the financial
        statements as none of the performance conditions have yet been met. </P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="80%"> <P align=justify></P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%"></TD>
    <TD align=left><SUP>(13) </SUP></TD>
    <TD width="80%" align=left> <P align=justify>The Company cancelled 700,000
        share purchase options on which it had recorded stock-based compensation
        of $72,500 during the year ended September 30, 2010 (2009: $117,434) </P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>The fair value of stock options granted
  has been determined using the Black-Scholes option pricing model using the following
  weighted average assumptions applied to stock options granted during the years:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD width="15%" align=center><U>2010 </U></TD>
    <TD width="15%" align=center><U>2009 </U></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD>&nbsp; </TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="15%">&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Risk-free interest rate </TD>
    <TD bgColor=#e6efff width="15%" align=right>0.79% - 2.20% </TD>
    <TD bgColor=#e6efff width="15%" align=right>1.16% - 2.71% </TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left>Expected life of options </TD>
    <TD width="15%" align=right>5 years </TD>
    <TD width="15%" align=right>1.75 - 5 years </TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Annualized volatility </TD>
    <TD bgColor=#e6efff width="15%" align=right>88.54% - 95.45% </TD>
    <TD bgColor=#e6efff width="15%" align=right>73.61% </TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left>Dividend rate </TD>
    <TD width="15%" align=right>0.00% </TD>
    <TD width="15%" align=right>0.00% </TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-24></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 15 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Note 10 </TD>
    <TD width="90%" align=left><U>Commitments &#150; (cont&#146;d)</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD> <P align=justify><U>Stock&#150;based Compensation Plan &#150; (cont&#146;d)</U></P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>At September 30, 2010, the following summarizes the
        unvested stock options:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">&nbsp; </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" nowrap>Weighted </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" nowrap>Weighted </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">&nbsp; </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" nowrap>Average </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">Average </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">Number of </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">Exercise </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" nowrap>Grant-date </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; </TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom"><U>Shares</U> </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom"><U>Price</U> </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom"><U>Fair value</U> </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" align="center" valign="bottom">&nbsp; </TD>
    <TD width="2%" align="center" valign="bottom">&nbsp;</TD>
    <TD width="1%" align="center" valign="bottom">&nbsp;</TD>
    <TD width="10%" align="center" valign="bottom">&nbsp; </TD>
    <TD width="2%" align="center" valign="bottom">&nbsp;</TD>
    <TD width="1%" align="center" valign="bottom">&nbsp;</TD>
    <TD width="10%" align="center" valign="bottom">&nbsp; </TD>
    <TD width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Unvested options at September 30, 2008 </TD>
    <TD width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" bgColor=#e6efff>970,000 </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;4.31 </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;2.42 </TD>
    <TD width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp; &nbsp;Granted </TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">1,775,000 </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">$&nbsp;2.51 </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">$&nbsp;3.08 </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp;Vested </TD>
    <TD width="1%"
    align=left valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
    align=center valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">(880,000) </TD>
    <TD width="2%"
    align=center valign="bottom" bgColor=#e6efff style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;4.20 </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;3.48 </TD>
    <TD width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD valign="bottom">&nbsp; </TD>
    <TD width="1%" valign="bottom">&nbsp;</TD>
    <TD width="10%" align="center" valign="bottom">&nbsp; </TD>
    <TD width="2%" align="center" valign="bottom">&nbsp;</TD>
    <TD width="1%" align="center" valign="bottom">&nbsp;</TD>
    <TD width="10%" align="center" valign="bottom">&nbsp; </TD>
    <TD width="2%" align="center" valign="bottom">&nbsp;</TD>
    <TD width="1%" align="center" valign="bottom">&nbsp;</TD>
    <TD width="10%" align="center" valign="bottom">&nbsp; </TD>
    <TD width="2%" valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>Unvested options at September 30, 2009 </TD>
    <TD width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" bgColor=#e6efff>1,865,000 </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;4.31 </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;1.55 </TD>
    <TD width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp; &nbsp;Cancelled </TD>
    <TD width="1%" align=left valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">(820,000)</TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">$&nbsp;2.50 </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">$&nbsp;1.57 </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom" bgColor=#e6efff>&nbsp; &nbsp; &nbsp; &nbsp;Granted </TD>
    <TD width="1%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" bgColor=#e6efff>400,000 </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;3.48 </TD>
    <TD width="2%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align=center valign="bottom" bgColor=#e6efff>$&nbsp;2.51 </TD>
    <TD width="2%" align=left valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">&nbsp; &nbsp; &nbsp; &nbsp;Vested </TD>
    <TD width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="10%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">(283,333)</TD>
    <TD width="2%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">$&nbsp;2.90 </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">$&nbsp;1.82 </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="1%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align="center" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align="center" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="1%" align="center" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
    <TD width="10%" align="center" valign="bottom" bgColor=#e6efff>&nbsp; </TD>
    <TD width="2%" valign="bottom" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left valign="bottom">Unvested options at September 30, 2010 </TD>
    <TD width="1%"
    align=left valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="10%"
      align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">1,161,667 </TD>
    <TD width="2%"
    align=center valign="bottom" style="BORDER-BOTTOM: #000000 3px double">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">$&nbsp;2.98 </TD>
    <TD width="2%" align=center valign="bottom">&nbsp;</TD>
    <TD width="1%" align=center valign="bottom">&nbsp;</TD>
    <TD width="10%" align=center valign="bottom">$&nbsp;1.80 </TD>
    <TD width="2%" align=left valign="bottom">&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>As at September 30, 2010, there was
  a total of $606,083 of unrecognized compensation cost associated with unvested
  share-based compensation awards that will become vested exclusive of achieving
  any performance milestones that is expected to be recognized as follows: $376,000
  in the year ended September 30, 2011 and $230,083 in the year ended September
  30, 2012. There has been no stock-based compensation recognized in the financial
  statements for the year ended September 30, 2010 for options that will vest
  upon the achievement of performance milestones because the Company has determined
  that satisfaction of the performance milestones was not probable. Compensation
  relating to stock options exercisable upon achieving performance milestones
  will be recognized in the period the milestones are achieved.</P>
<P style="MARGIN-LEFT: 15%" align=justify>Stock-based compensation amounts, including
  those relating to shares issued for services during the year ended September
  30, 2009 (Note 6), are classified in the Company&#146;s Statement of Operations
  as follows:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&nbsp; </TD>
    <TD width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=center><U>2010</U> </TD>
    <TD width="2%" align=center>&nbsp;</TD>
    <TD width="1%" align=center>&nbsp;</TD>
    <TD width="12%" align=center><U>2009</U> </TD>
    <TD width="2%" align=left>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD bgColor=#e6efff align=left>Consulting fees </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="1%"
    align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="12%"
    align=center>$&nbsp;770,055 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="2%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="1%"
    align=center>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="12%"
    align=center>$&nbsp;1,119,433 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" bgColor=#e6efff width="2%"
    align=left>&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD> <P align=justify><U>Patent and Collaboration Agreement</U></P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD> <P align=justify>On February 1, 2007, the Company signed a contract with
        an officer of the Company to acquire property for the development of a
        new drug compound including three patents and one patent application.
        Pursuant to the agreement, the Company agreed to the following:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%">i) </TD>
    <TD> <P align=justify>Invest a minimum of $200,000 every fiscal year into
        scientific research and;</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">ii) </TD>
    <TD> <P align=justify>Hire the director as a consultant to carry out the Company&#146;s
        Research and Development program at $US6,000 per month and;</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">iii) </TD>
    <TD> <P align=justify>Pay to the director 6% of the net income earned from
        the exploitation of the patent and patent application; and</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">iv) </TD>
    <TD> <P align=justify>Disburse a one-time payment to the director an amount
        of $72,000 before December 31, 2007 as consideration for the transfer
        of the patents and the patent application. (paid)</P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>Effective January 1, 2008, the monthly
  salary paid to the director was increased to 7,000 Euros.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-25></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 16 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Note 10 </TD>
    <TD width="90%" align=left><U>Commitments &#150; (cont&#146;d)</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD colSpan=2> <P align=justify><U>CFO Consulting Agreement</U></P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD colSpan=2> <P align=justify>On September 1, 2010, we appointed a Chief
        Financial Officer (&#147;CFO&#148;) pursuant to a consulting agreement
        effective September 1, 2010. The terms of the CFO consulting agreement
        are as follows:</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(i) </TD>
    <TD> <P align=justify>Pay a consulting fee at the rate of $100,000 per annum;</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(ii) </TD>
    <TD> <P align=justify>Pay an annual incentive bonus of not less than 50% of
        the annual consulting fee, subject to achieving defined milestones;</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(iii) </TD>
    <TD> <P align=justify>Grant 200,000 stock options exercisable at $3.45 per
        option until September 1, 2015, vesting 8,333 options per month over the
        first 24 months of the option period;</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD vAlign=top width="5%">(iv) </TD>
    <TD> <P align=justify>reimburse any reasonable business expenses incurred
        in performing duties and promoting the business of our company.</P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>The agreement is for a period of two
  years and either party may terminate the agreement by providing the other party
  with 60 days written notice. In the event of a termination by the Company without
  Just Cause as that term is defined in the Contractor Agreement, the Company
  shall make certain payments and the options granted shall continue to vest for
  a period of not less than six months.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Note 11 </TD>
    <TD width="90%" align=left><U>Supplemental Cash Flow Information</U> </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>Investing and financing activities that
  do not have a direct impact on current cash flows are excluded from the statements
  of cash flows. </P>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2010:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD> <P align=justify>The Company issued 49,505 common shares at $2.20 per
        share in settlement of a promissory note to a former officer of the Company
        for a total of $100,000</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD> <P align=justify>The Company issued 9,825 common shares at $2.85 per
        share for a total of $28,000 as consideration for amounts owing in respect
        of consulting services which was included in accounts payable as at September
        30, 2009</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD> <P align=justify>The Company issued 400,000 units at $2.50 per unit for
        a total of $1,000,000 as consideration for amounts owing for services
        rendered in prior years. Each unit consisted of one common share and one-half
        common share purchase warrant entitling the holder to purchase an additional
        common share at 3.50 per share until January 5, 2012. The fair value of
        the units issued was determined to be $1,444,000 on the date they were
        issued and thus the Company recorded a loss on settlement of accounts
        payable of $444,000 with a corresponding credit to additional paid-in
        capital of the same amount on date of issuance.</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD> <P align=justify>The Company issued 9,000 common shares at $2.75 per
        share for a total of $24,750 as consideration for finders&#146; fees associated
        with a private placement</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">e) </TD>
    <TD> <P align=justify>The Company issued 328,058 common shares at $2.25 per
        share upon conversion of promissory notes in the amount of $738,130, including
        accrued interest of $70,130, and</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">f) </TD>
    <TD> <P align=justify>The Company issued 510,638 common shares at $2.35 per
        share upon settlement of a promissory note in the amount of $1, 200,000
        including accrued interest of $200,000.</P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>During the year ended September 30,
  2009:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD> <P align=justify>The Company issued 25,000 shares at $2.63 per share,
        25,000 common shares at $2.50 per share, for a total of $128,250 pursuant
        to the consulting agreement with a director to issue common shares in
        exchange for consulting services. Subsequent to their issuance, pursuant
        to an amendment of the agreement to compensate the director, these shares
        were returned to treasury for cancellation &#150; Notes 4 and 6.</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD> <P align=justify>The Company issued 2,500 common shares at $2.50 per
        share, 29,227 at $2.25 per share for a total of $70,760 as consideration
        for consulting services.</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD> <P align=justify>As a result of re-measuring remaining shares to be issued
        pursuant to a consulting agreement, the Company recorded compensation
        expense of $236,337 as consideration for consulting services; and</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD> <P align=justify>The Company issued 22,222 common shares at $2.51 per
        share for a total of $55,777 pursuant to a deferred financing charge on
        an issuance of a convertible promissory note.</P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>There were no amounts paid in 2010 and
  2009 in respect of interest or income taxes.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_F-26></A><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(A Development Stage Company) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Notes to the Consolidated Financial Statements </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>September 30, 2010 and 2009 </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>(<U>Stated in US Dollars</U>) &#150; Page 17 </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">
  <TR vAlign=top>
    <TD align=left >Note 12 </TD>
    <TD width="90%" align=left><U>Subsequent Events</U> </TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>Subsequent to September 30, 2010, the
  Company:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD> <P align=justify>issued 853,075 units to the note holders to settle convertible
        notes outstanding in the amount of $1,919,419. Each unit consists of one
        share of our common stock and one share purchase warrant. Each whole share
        purchase warrant entitles the holder to purchase one share of our common
        stock at a purchase price of US $3.00 per share for a period of 24 months.
        A portion of the Convertible Notes had originally been convertible to
        units at $2.50 per unit.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD> <P align=justify>issued 145,063 shares of common stock to the note holders
        to settle non-convertible, interest-bearing notes having a principal balance
        of $372,890 and accrued interest of $26,033 for total settlement of $398,923.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD> <P align=justify>issued 181,818 shares of our common stock to one creditor
        in settlement of $500,000 debt.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD> <P align=justify>issued 393,845 units at a purchase price of $2.75 per
        unit for gross proceeds of $1,083,075. Each unit consisted of one share
        of common stock and one-half of one share purchase warrant. Each whole
        share purchase warrant entitles the holder to purchase one share of common
        stock at a purchase price of US$4.50 per share for a period of 18 months.
        A finder&#146;s fee of 3,636 common shares was paid.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">e) </TD>
    <TD> <P align=justify>issued 29,851 units at a purchase price of $3.35 per
        unit for gross proceeds of $100,000. Each unit consists of one share of
        our common stock and one-half of one share purchase warrant. Each whole
        share purchase warrant entitles the holder to purchase one share of our
        common stock at a purchase price of $4.50 per share for a period of 24
        months. The Company paid a finders&#146; fee of 10% of the gross proceeds
        to eligible finders.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">f) </TD>
    <TD> <P align=justify>issued 2,985 units pursuant to a shares for services
        agreement. Each unit consists of one common share and one-half share purchase
        warrant. Each whole warrant entitles the holder thereof to purchase an
        additional common share at a purchase price of $4.50 per share for a period
        of 24 months from the date of issuance.</P></TD>
  </TR>
</TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=-->
<A name=page_40></A>
<P align=center>36</P>
<P align=justify><B>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL MATTERS</B></P>
<P align=justify>None</P>
<P align=justify><B>ITEM 9A(T). CONTROLS AND PROCEDURES</B></P>
<P align=justify><B><I>Disclosure Controls and Procedures </I></B></P>
<P align=justify>As required by Rule 13a-15 under the Securities Exchange Act of
1934, our management, with the participation of our principal executive officer
and our principal financial officer, evaluated our disclosure controls and
procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934)
as of the end of the period covered by this annual report. </P>
<P align=justify>Disclosure controls and procedures are controls and other
procedures that are designed to ensure that information required to be disclosed
in our reports filed or submitted under the Securities Exchange Act of 1934 is
recorded, processed, summarized and reported, within the time periods specified
in the Securities and Exchange Commission&#146;s rules and forms. Disclosure controls
and procedures include controls and procedures designed to ensure that
information required to be disclosed in our reports filed under the Securities
Exchange Act of 1934 is accumulated and communicated to our principal executive
officer and our principal financial officer, as appropriate, to allow timely
decisions regarding required disclosure.</P>
<P align=justify>Based on its evaluation, our management, with the participation
of our principal executive officer and our principal financial officer concluded
that as of the end of the period covered by this annual report, our disclosure
controls and procedures were not effective. The ineffectiveness of our
disclosure controls and procedures was due to material weaknesses described
below.</P>
<P align=justify><B><I>Management&#146;s Annual Report on Internal Control over
Financial Reporting</I></B></P>
<P align=justify>Management is responsible for establishing and maintaining
adequate internal control over our financial reporting, as such term is defined
in Rule 13a-15(f) under the Securities Exchange Act of 1934. Our management
evaluated, under the supervision and with the participation of our principal
executive officer and our principal financial officer, the effectiveness of our
internal control over financial reporting as of September 30, 2010.</P>
<P align=justify>Based on its evaluation under the framework in Internal
Control&#151;Integrated Framework, issued by the Committee of Sponsoring
Organizations of the Treadway Commission, our management, with the participation
of our principal executive officer and our principal financial officer concluded
that our internal control over financial reporting was not effective as of
September 30, 2010. The ineffectiveness of our internal control over financial
reporting was due to the existence of significant deficiencies constituting
material weaknesses, as described in greater detail below. A material weakness
is a control deficiency, or combination of control deficiencies, such that there
is a reasonable possibility that a material misstatement of the annual or
interim financial statements will not be prevented or detected on a timely
basis.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_41></A>
<P align=center>37</P>
<P align=justify>This annual report does not include an attestation report of
our independent registered public accounting firm regarding internal control
over financial reporting. Management&#146;s report was not subject to attestation by
our independent registered public accounting firm pursuant to temporary rules of
the Securities and Exchange Commission that permit our company to provide only
management&#146;s report in this annual report.</P>
<P align=justify><I>Material Weaknesses Identified </I></P>
<P align=justify>Based on our management&#146;s evaluation required by Rule 13a-15 of
the Securities Exchange Act of 1934, certain significant deficiencies in
internal control became evident to management that our management believes
represent material weaknesses, including: </P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(i) </TD>
    <TD>
      <P align=justify>Insufficient segregation of duties in our finance and
      accounting functions due to limited personnel. During the fiscal year
      ended September 30, 2010, we had limited staff that performed nearly all
      aspects of our financial reporting process, including, but not limited to,
      access to the underlying accounting records and systems, the ability to
      post and record journal entries and responsibility for the preparation of
      the financial statements. This creates certain incompatible duties and a
      lack of review over the financial reporting process that would likely
      result in a failure to detect errors in spreadsheets, calculations, or
      assumptions used to compile the financial statements and related
      disclosures as filed with the Securities and Exchange Commission. These
      control deficiencies could result in a material misstatement to our
      interim or annual financial statements that would not be prevented or
      detected;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(ii) </TD>
    <TD>
      <P align=justify>There has been a lack of sufficient supervision and
      review by our management;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(iii) </TD>
    <TD>
      <P align=justify>Insufficient corporate governance policies. Although we
      have a code of ethics which provides broad guidelines for corporate
      governance, our corporate governance activities and processes have not
      always formally documented. Specifically, decisions made by the board to
      be carried out by management should be documented and communicated on a
      timely basis to reduce the likelihood of any misunderstandings regarding
      key decisions affecting our operations and management; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(iv) </TD>
    <TD>
      <P align=justify>Our company&#146;s accounting staff has not had sufficient
      technical accounting knowledge relating to accounting for income taxes and
      complex US GAAP matters. Management corrected any errors prior to the
      release of our company&#146;s September 30, 2010 financial
  statements.</P></TD></TR></TABLE>
<P align=justify><I>Plan for Remediation of Material Weaknesses</I></P>
<P align=justify>We intend to take appropriate and reasonable steps to make the
necessary improvements to remediate these deficiencies. We intend to consider
the results of our remediation efforts and related testing as part of our
year-end 2011 assessment of the effectiveness of our internal control over
financial reporting.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_42></A>
<P align=center>38</P>
<P align=justify>We have implemented certain remediation measures and are in the
process of designing and implementing additional remediation measures for the
material weaknesses described in this annual report. </P>
<P align=justify>In order to correct the foregoing deficiencies, we have taken
the following remediation measures:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1) </TD>
    <TD>
      <P align=justify>We have committed to the establishment of effective
      internal controls and have recently retained the services of a new chief
      financial officer experienced in public company administration and
      internal control systems. This individual will be conducting a review of
      the internal control systems in place and will be recommending and
      implementing improvements to these processes.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2) </TD>
    <TD>
      <P align=justify>Due to our size and nature, segregation of all
      conflicting duties has not always been possible and may not be
      economically feasible. However, we are in the process of implementing new
      processes and procedures that will mitigate any material weaknesses
      identified, and we intend to ensure the timely filing of all required SEC
      filings in the future.</P></TD></TR></TABLE>
<P align=justify>We believe that the foregoing steps will remediate the
deficiencies identified above, and we intend to continue to monitor the
effectiveness of these steps and make any changes that our management deems
appropriate.</P>
<P align=justify><I>Limitations on Effectiveness of Controls</I></P>
<P align=justify>Our principal executive officer and our principal financial
officer do not expect that our disclosure controls and procedures or our
internal control over financial reporting will prevent all errors and all fraud.
A control system, no matter how well conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the control system
are met. Further, the design of a control system must reflect the fact that
there are resource constraints, and the benefits of controls must be considered
relative to their costs. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues and instances of fraud, if any, within our company have been
detected. These inherent limitations include the realities that judgments in
decision-making can be faulty, and that breakdowns can occur because of a simple
error or mistake. Additional controls can be circumvented by the individual acts
of some persons, by collusion of two or more people, or by management override
of the controls. The design of any system of controls also is based in part upon
certain assumptions about the likelihood of future events, and there can be no
assurance that any design will succeed in achieving its stated goals under all
potential future conditions; over time, controls may become inadequate because
of changes in conditions, or the degree of compliance with the policies or
procedures may deteriorate. Because of the inherent limitations in a
cost-effective control system, misstatements due to error or fraud may occur and
not be detected.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_43></A>
<P align=center>39</P>
<P align=justify><B><I>Changes in Internal Control over Financial Reporting
</I></B></P>
<P align=justify>There were no changes in our internal control over financial
reporting during the fourth quarter ended September 30, 2010 that have
materially affected, or are reasonably likely to materially affect our internal
control over financial reporting.</P>
<P align=justify><B>ITEM 9B OTHER INFORMATION</B></P>
<P align=justify>None.</P>
<P align=center><B>PART III</B></P>
<P align=justify><B>ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE</B></P>
<P align=justify><B><I>Directors and Executive Officers</I></B></P>
<P align=justify>Our directors are to be elected at our annual meeting and each
director elected is to hold office until his or her successor is elected and
qualified. Our board of directors may remove our officers at any time.</P>
<P align=justify>Our directors and executive officers, their age, positions
held, and duration of such, are as follows:</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD bgColor=#eeeeee align=center><BR><B>Name</B> </TD>
    <TD bgColor=#eeeeee width="40%" align=center ><BR><B>Position
      Held with Our Company</B> </TD>
    <TD bgColor=#eeeeee width="15%" align=center ><BR><B>Age</B>
    </TD>
    <TD bgColor=#eeeeee width="22%" align=center><B>Date First Elected</B>
      <BR><B>or Appointed</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Dr. Cameron Durrant </TD>
    <TD width="40%" align=left >Executive Chairman and Director
    </TD>
    <TD width="15%" align=center >50 </TD>
    <TD width="22%" align=center>December 17, 2007 </TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>Harvey Lalach </TD>
    <TD bgColor=#ffffff width="40%" align=left >President, Chief
      Operating Officer, Secretary and Director </TD>
    <TD bgColor=#ffffff width="15%" align=center >45 </TD>
    <TD bgColor=#ffffff width="22%" align=center>April 25, 2006 </TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>Alison Ayers </TD>
    <TD bgColor=#ffffff width="40%" align=left >Director </TD>
    <TD bgColor=#ffffff width="15%" align=center >58 </TD>
    <TD bgColor=#ffffff width="22%" align=center>May 20, 2008 </TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>David Tousley </TD>
    <TD bgColor=#ffffff width="40%" align=left >Chief Financial
      Officer and Director </TD>
    <TD bgColor=#ffffff width="15%" align=center >55 </TD>
    <TD bgColor=#ffffff width="22%" align=center>June 3, 2008
</TD></TR></TABLE></DIV>
<P align=justify><I>Business Experience </I></P>
<P align=justify>The following is a brief account of the education and business
experience of directors and executive officers during at least the past five
years, indicating their principal occupation during the period, and the name and
principal business of the organization by which they were employed. </P>
<P align=justify><U>Dr. Cameron Durrant</U></P>
<P align=justify>Dr. Durrant was most recently Worldwide Vice President,
Infectious Diseases, Global Strategic Marketing at Johnson &amp; Johnson (NYSE:
JNJ) Dr. Durrant was also President and CEO of Pediamed Pharmaceuticals, Inc..
Dr. Durrant&#146;s background also includes executive-level positions with Merck
&amp; Co. (NYSE: MRK), Glaxo Smith Kline PLC (NYSE GSK) and Pharmacia
Corporation (now part of Pfizer Inc. (NYSE: PFE).</P>
<P align=justify>Dr. Durrant has been President, Chief Executive Officer and director
  of Striker Energy Corp. (OTCBB: SKRY) since November 17, 2010 and is also the
  founder and President of PediatRx, Inc., a wholly owned subsidiary of Striker
  Energy Corp. Striker Energy Corp. is a publicly traded specialty pharmaceutical
  company that brings prescription, branded products to healthcare professionals
  for the treatment of serious medical conditions treated in the hospital, with
  an initial focus on oncology supportive care.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_44></A>
<P align=center>40</P>
<P align=justify>Dr. Durrant is a founding board member of Bexion Pharmaceuticals,
  a private oncology research and development company with therapeutics, diagnostic/imaging
  and drug delivery capabilities, and a board member of Pressure-Point, Inc, a
  private medical device company with a focus on emesis care. Dr. Durrant has
  previously served on several public and private company boards, is an advisor
  to Pilgrim Software and to Saxa Private Equity Partners.</P>
<P align=justify>Dr. Durrant was a regional winner and national finalist for
Ernst &amp; Young&#146;s Entrepreneur of the Year award in 2005. Dr. Durrant holds a
MBA from Henley Management College at Oxford and a MB and BCh (equivalent to
American MD degree) from the Welsh National School of Medicine in Cardiff,
U.K.</P>
<P align=justify>We believe Dr. Durrant is qualified to serve on our board of
directors because of his knowledge of our company&#146;s history and current
operations, which he gained from being a director of our company since December
17, 2007, in addition to his education and business experiences described
above.</P>
<P align=justify><U>Harvey Lalach</U></P>
<P align=justify>For the past 22 years Mr. Lalach has been involved in various
aspects of the securities industry. From 1986 through to 1997 he was involved in
various roles in financial institutions starting at the Vancouver Stock Exchange
and later working in securities related roles for BMO Nesbitt Burns and TD Bank
and for the past 10 years Mr. Lalach has focused on the operation and
administration of numerous start-up US and Canadian public companies serving as
both director and officer in various capacities. Most recently Mr. Lalach served
as President and CEO for Assure Energy, Inc. (OTCBB: ASUR) and Quarry Oil &amp;
Gas Corp. (TSXV: QUC). Throughout his career, Mr. Lalach has gained extensive
experience in the management and governance of listed public companies.</P>
<P align=justify>We believe Mr. Lalach is qualified to serve on our board of
directors because of his knowledge of our company&#146;s history and current
operations, which he gained from serving as our officer and director since April
25, 2006, in addition to his business experiences described above.</P>
<P align=justify><U>David Tousley</U></P>
<P align=justify>Mr. Tousley has over 25 years of senior-level experience in
biotech, specialty pharmaceuticals and full-phase pharmaceutical companies. He
has held the position of President, COO and CFO at companies including
airPharma, PediaMed Pharmaceuticals, Inc., AVAX Technologies Inc. (AVXT.OB), and
Pasteur, Merieux, Connaught, (known today as Sanofi-Pasteur SA). During his
career, Mr. Tousley has led all aspects of operations, including pharmaceutical
development, in both the private and public company environment. His
accomplishments include the raising over $100 million in debt and equity
financings and he has led key business development activities, including joint
ventures, partnerships, acquisitions and divestitures in the U.S., Europe and
Australia. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_45></A>
<P align=center>41</P>
<P align=justify>Mr. Tousley has also been Chief Financial Officer, Treasurer,
Secretary, and director of Striker Energy Corp. (OTCBB: SKRY) since November 17,
2010 and is also Secretary and Treasurer of PediatRx, Inc., a wholly owned
subsidiary of Striker Energy Corp. Striker Energy Corp. is a publicly traded
specialty pharmaceutical company that brings prescription, branded products to
healthcare professionals for the treatment of serious medical conditions treated
in the hospital, with an initial focus on oncology supportive care. Mr. Tousley currently
serves as a director of ImmunoGenetix Therapeutics, Inc, a biotech company that
is developing advanced DNA immunotherapies for HIV infection. </P>
<P align=justify>Mr. Tousley holds an MBA in accounting from Rutgers Graduate
School of Business and a B.A. in English from Rutgers College, both in New
Jersey and belongs to the New Jersey Society of Certified Public Accountants and
the American Institute of Certified Public Accountants. </P>
<P align=justify>We believe Mr. Tousley is qualified to serve on our board of
directors because of his knowledge of our company&#146;s history and current
operations, which he gained from being a director of our company since June 3,
2008, in addition to his education and business experiences described above.</P>
<P align=justify><U>Alison Ayers</U></P>
<P align=justify>Ms. Ayers is the current Worldwide Commercial Head for Oncology
for Pfizer Inc. (NYSE: PFE). She is a member of the leadership team that
develops Pfizer&#146;s oncology strategic plan and which manages the portfolio,
including asset prioritization, development planning, strategic and investment
decisions including licensing and acquisitions. </P>
<P align=justify>Previously, Ms. Ayers was Commercial Head, Infectious Disease,
Worldwide Marketing for Pfizer, responsible for strategic leadership for the
company&#146;s infectious disease portfolio. Under her leadership, Pfizer&#146;s
infectious disease portfolio exceeded $3 billion in sales in 2005, with two
compounds achieving sales growth of 20-30%. </P>
<P align=justify>Before joining Pfizer Ms. Ayers was Vice President of Portfolio
Management for Pharmacia Healthcare Ltd, where she developed and implemented
strategies to maximize earnings from the company&#146;s complex global $2.5 billion
diversified products portfolio, which is comprised of more than 600 mature,
non-promoted products. In her earlier role as Vice President, Commercial
Development, Oncology for Pharmacia, Ms. Ayers was responsible for providing
commercial leadership for the company&#146;s oncology pipeline, and held a pivotal
role in the acquisition of biotech company Sugen, which delivered Pfizer&#146;s
leading angiogenesis inhibitor, Sutent. Pharmacia was acquired by Pfizer in
2003. </P>
<P align=justify>Ms. Ayers&#146; background also includes senior positions in
business and product planning for numerous bioscience and pharmaceutical
companies, including Merck &amp; Co. (NYSE: MRK), The Health Care Group, U.S.
Bioscience, Inc. (Amex: UBS), Bristol-Myers Squibb Co. (NYSE: BMY) and Lederle
Laboratories. She holds a Master of Science with distinction in biopharmacy and
a Diploma in Business Studies, both from the University of London, UK, as well
as a Bachelor of Science with honors in physiology and biochemistry from the
University of Southampton, UK. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_46></A>
<P align=center>42</P>
<P align=justify>We believe Ms. Ayers is qualified to serve on our board of
directors because of her knowledge of our company&#146;s history and current
operations, which she gained from being a director of our company since May 20,
2008, in addition to her education and business experiences described above.</P>
<P align=justify><B><I>Certain Significant Employees</I></B></P>
<P align=justify>Our significant employees, their age, positions held, and
duration of such and a brief description of the background and business
experience for the past five years are as follows: </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee
      align=left><B>Name</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="40%"
    align=left ><B>Position Held with Our Company</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="20%"
    align=center><B>Age</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="20%"
    align=left><B>Date First Appointed</B> </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Alexandre
      Vamvakides </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="40%" align=left
    >Chief Scientific Officer </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="20%" align=center>71
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="20%"
      align=left>January 27, 2007 </TD></TR></TABLE></DIV>
<P align=justify><I>Business Experience </I></P>
<P align=justify>The following is a brief account of the education and business
experience of certain significant employees during at least the past five years,
indicating their principal occupation during the period, and the name and
principal business of the organization by which they were employed. </P>
<P align=justify><U>Alexandre Vamvakides</U></P>
<P align=justify>Dr. Vamvakides has spent 30 years in research focusing on the
therapeutic/pharmacological areas of nootropes, anti-neurodegenerative
(anti-Alzheimer), antiepileptic, antidepressive, and prototype molecules. During
his career, Dr. Vamvakides has been published over 80 times in highly respected
Medical/Scientific journals. In the past 30 years, Dr. Vamvakides has pioneered
his expertise at the Institut National de la Sante et de la Recherche Medicale
(INSERM) in Paris France, at the University of Athens (Greece), Ciba-Geigy
(Basel, Switzerland) and Sanofi (Montpellier, France), and many other research
laboratories throughout Europe for the discovery and development of new concepts
in the therapeutic areas of Central Nervous System, oncology and
anti-inflammatory diseases. Dr. Vamvakides holds a M.Sc. in Chemistry from
Bordeaux University, France, a M.Sc. in Pharmacology, a M.Sc. in Biochemistry
and a Ph.D. in Molecular Pharmacology all from the University of Paris Medical
School.</P>
<P align=justify><B><I>Family Relationships </I></B></P>
<P align=justify>There are no family relationships between any director or
executive officer. </P>
<P align=justify><B><I>Involvement in Certain Legal Proceedings</I></B></P>
<P align=justify>There are no material proceedings to which any director or
executive officer or any associate of any such director or officer is a party
adverse to our company or has a material interest adverse to our company.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_47></A>
<P align=center>43</P>
<P align=justify>No director or executive officer has been involved in any of
the following events during the past ten years:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify>any bankruptcy petition filed by or against any business
      of which such person was a general partner or executive officer either at
      the time of the bankruptcy or within two years prior to that
  time;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify>any conviction in a criminal proceeding or being subject
      to a pending criminal proceeding (excluding traffic violations and other
      minor offences);</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD>
      <P align=justify>being subject to any order, judgment, or decree, not
      subsequently reversed, suspended or vacated, of any court of competent
      jurisdiction, permanently or temporarily enjoining, barring, suspending or
      otherwise limiting his involvement in any type of business, securities or
      banking activities;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">4. </TD>
    <TD>
      <P align=justify>being found by a court of competent jurisdiction (in a
      civil action), the Securities and Exchange Commission or the Commodity
      Futures Trading Commission to have violated a federal or state securities
      or commodities law, and the judgment has not been reversed, suspended, or
      vacated;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">5. </TD>
    <TD>
      <P align=justify>being the subject of, or a party to, any federal or state
      judicial or administrative order, judgment, decree, or finding, not
      subsequently reversed, suspended or vacated, relating to an alleged
      violation of: (i) any federal or state securities or commodities law or
      regulation; or (ii) any law or regulation respecting financial
      institutions or insurance companies including, but not limited to, a
      temporary or permanent injunction, order of disgorgement or restitution,
      civil money penalty or temporary or permanent cease- and- desist order, or
      removal or prohibition order; or (iii) any law or regulation prohibiting
      mail or wire fraud or fraud in connection with any business entity;
    or</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">6. </TD>
    <TD>
      <P align=justify>being the subject of, or a party to, any sanction or
      order, not subsequently reversed, suspended or vacated, of any
      self-regulatory organization (as defined in Section 3(a)(26) of the
      Securities Exchange Act of 1934), any registered entity (as defined in
      Section 1(a)(29) of the Commodity Exchange Act), or any equivalent
      exchange, association, entity or organization that has disciplinary
      authority over its members or persons associated with a
  member.</P></TD></TR></TABLE>
<P align=justify><B><I>Compliance with Section 16(a) of the Securities Exchange
Act of 1934</I></B></P>
<P align=justify>Section 16(a) of the Securities Exchange Act of 1934 requires
  our executive officers and directors and persons who own more than 10% of our
  common stock to file with the Securities and Exchange Commission initial statements
  of beneficial ownership, reports of changes in ownership and annual reports
  concerning their ownership of our common stock and other equity securities,
  on Forms 3, 4 and 5 respectively. Executive officers, directors and greater
  than 10% shareholders are required by the Securities and Exchange Commission
  regulations to furnish us with copies of all Section 16(a) reports that they
  file.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_48></A>
<P align=center>44</P>
<P align=justify>Based solely on our review of the copies of such forms received
  by us, or written representations from certain reporting persons, we believe
  that during fiscal year ended September 30, 2010, all filing requirements applicable
  to our officers, directors and greater than 10% percent beneficial owners were
  complied with the exception of the following:</P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="90%">

  <TR vAlign=top>
    <TD align=center><BR><BR>Name </TD>
    <TD width="25%" align=center><BR>Number of <BR>Late Reports </TD>
    <TD width="25%" align=center>Number of Transactions <BR>Not Reported on a
      Timely <BR>Basis </TD>
    <TD width="25%" align=center><BR>Failure to File <BR>Required Forms </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Dr. Cameron
      Durrant </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>2
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>2
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>N/A
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Harvey Lalach </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>2
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>2
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>N/A
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>Alison Ayers </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>2
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>2
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>N/A
    </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left>David Tousley </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>2
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>2
</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="25%" align=center>N/A
    </TD></TR></TABLE></DIV>
<P align=justify><B><I>Code of Ethics </I></B></P>
<P align=justify>We have adopted a code of ethics that applies to our principal
executive officer, principal financial officer, principal accounting officer or
controller, or persons performing similar functions. We undertake herewith to
provide by mail to any person without charge, upon request, a copy of such code
of ethics if we receive the request in writing by mail to Anavex Life Sciences
Corp., 315A, 50 Harrison St., Hoboken, NJ 07030 Attention: President.</P>
<P align=justify><B><I>Audit Committee and Audit Committee Financial
Expert</I></B></P>
<P align=justify>We have an audit committee, comprised of two directors, Harvey
Lalach and David Tousley. During the fiscal year ended September 30, 2010, our
audit committee held one meeting. The audit committee represents our board of
directors in discharging its responsibility relating to the accounting,
reporting and financial practices of our company, and has general responsibility
for oversight of internal controls, accounting and audit activities and legal
compliance of our company. However, the audit committee&#146;s function is one of
oversight only and does not relieve our management of its responsibilities for
preparing financial statements which accurately and fairly present our financial
results and conditions or the responsibilities of the independent registered
public accounting firm relating to the audit or review of financial statements.
</P>
<P align=justify>David Tousley is considered as an &#147;audit committee financial
expert&#148; as defined in Item 407(d)(5)(ii) of Regulation S-K, and is Chairman of
the audit committee. Due to the retention of Mr. Tousley as chief financial
officer of the company, we intend to appoint a new Chairman in the near
future.</P>
<P align=justify><B><I>Nominating and Compensation Committees </I></B></P>
<P align=justify>We do not have standing nominating or compensation committees,
or committees performing similar functions. Our board of directors believes that
it is not necessary to have a standing compensation committee at this time
because the functions of such committee are adequately performed by our board of
directors. Our board of directors has not adopted a charter for the compensation
committee.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_49></A>
<P align=center>45</P>
<P align=justify>Our board of directors also is of the view that it is
appropriate for us not to have a standing nominating committee because our board
of directors has performed and is expected to perform adequately the functions
of a nominating committee. Our board of directors has not adopted a charter for
the nominating committee. There has not been any defined policy or procedure
requirements for stockholders to submit recommendations or nomination for
directors. Our board of directors does not believe that a defined policy with
regard to the consideration of candidates recommended by stockholders is
necessary at this time because we believe that, at this stage of our
development, a specific nominating policy would be premature and of little
assistance until our business operations are at a more advanced level. There are
no specific, minimum qualifications that our board of directors believes must be
met by a candidate recommended by our board of directors. The process of
identifying and evaluating nominees for director typically begins with our board
of directors soliciting professional firms with whom we have an existing
business relationship, such as law firms, accounting firms or financial advisory
firms, for suitable candidates to serve as directors. It is followed by our
board of directors&#146; review of the candidates&#146; resumes and interview of
candidates. Based on the information gathered, our board of directors then makes
a decision on whether to recommend the candidates as nominees for director. We
do not pay any fee to any third party or parties to identify or evaluate or
assist in identifying or evaluating potential nominee.</P>
<P align=justify><B>ITEM 11. EXECUTIVE COMPENSATION</B></P>
<P align=justify><B><I>Summary Compensation</I></B></P>
<P align=justify>The particulars of compensation paid to the following
persons:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>our principal executive officers;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>each of our two most highly compensated executive
      officers who were serving as executive officers at the end of the fiscal
      year ended September 30, 2010 who had total compensation exceeding
      $100,000; and</P></TD></TR></TABLE>
<P align=justify>up to two additional individuals for whom disclosure would have
been provided under (b) but for the fact that the individual was not serving as
our executive officer at the end of the most recently completed financial year,
who we will collectively refer to as the named executive officers, for our
fiscal years ended September 30, 2010 and 2009, are set out in the following
summary compensation table: </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_50></A>
<P align=center>46</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee colSpan=10
    align=center>&nbsp;&nbsp;<B>SUMMARY COMPENSATION
      TABLE</B>&nbsp;&nbsp;&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee
      align=center><BR><BR><BR><B>Name</B> <BR><B>and Principal</B>
      <BR><B>Position</B> <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="9%"
    align=center><BR><BR><BR><BR><BR><B>Year</B> <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="9%"
    align=center><BR><BR><BR><BR><B>Salary </B><BR><B>($)</B> <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="9%"
    align=center><BR><BR><BR><BR><STRONG>Bonus </STRONG><BR><B>($)</B> <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="9%"
    align=center><BR><BR><BR><B>Stock </B><BR><STRONG>Awards</STRONG>
      <BR><B>($)</B> <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="9%"
    align=center><BR><BR><BR><STRONG>Option</STRONG> <BR><B>Awards
      </B><BR><B>($)</B> <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="9%"
    align=center><B>Non-</B> <BR><B>Equity</B> <BR><B>Incentive</B>
      <BR><B>Plan</B> <BR><STRONG>Compensa- </STRONG><BR><B>tion</B>
      <BR><B>($)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="9%"
    align=center><BR><B>Nonqualified</B> <BR><B>Deferred</B>
      <BR><B>Compensation </B><BR><STRONG>Earnings</STRONG> <BR><B>($)</B>
    <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="9%"
    align=center><BR><B>All</B> <BR><B>Other</B>
      <BR><STRONG>Compensa-</STRONG> <BR><B>tion</B> <BR><B>($)</B> <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="9%"
    align=center><BR><BR><BR><BR><B>Total</B> <BR><B>($)</B> <BR></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff
      align=left>Dr. Cameron Durrant<SUP>(1)</SUP> <BR><I>Executive Chairman
      and</I> <BR><I>Director</I> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>2010 <BR>2009 <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$200,000 <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$125,000 <BR>$536,000 <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$325,000 <BR>$536,000 <BR></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff
      align=left>Dr. Herve de Kergrohen<SUP>(2)</SUP> <BR><I>Former Chief
      Executive</I> <BR><I>Officer</I> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>2010 <BR>2009 <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$223,483 <BR>$67,452 <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>$1,183,000 <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$223,483 <BR>$1,250,452 <BR></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff
      align=left>Harvey Lalach<SUP>(3)</SUP> <BR><I>President, Chief
      Operating</I> <BR><I>Officer, Secretary and</I> <BR><I>Director and Former
      Chief</I> <BR><I>Financial Officer</I> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>2010 <BR>2009 <BR><BR><BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$150,000 <BR>$150,000 <BR><BR><BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR><BR><BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR><BR><BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$125,000 <BR>Nil <BR><BR><BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR><BR><BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR><BR><BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR><BR><BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$275,000 <BR>$150,000 <BR><BR><BR></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff
      align=left>David Tousley<SUP>(4)</SUP> <BR><I>Chief Financial Officer
      and</I> <BR><I>Director</I> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>2010 <BR>2009 <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$8,333 <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$627,000 <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$635,333 <BR>Nil <BR></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff
      align=left>Alexandre Vamvakides<SUP>(5)</SUP> <BR><I>Chief Scientific
      Officer</I> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>2010 <BR>2009 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$113,495 <BR>$215,565 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>$1,183,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$113,495 <BR>$1,398.565 </TD></TR></TABLE></DIV><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD vAlign=top width="5%">(1) </TD>
    <TD>
      <P align=justify>Dr. Cameron Durrant was appointed as our Executive
      Chairman on January 2, 2010. Prior to that date, Dr. Durrant served as an
      advisor to the company and as a director and received certain stock option
      awards for his services in that capacity. During the fiscal year ended
      September 30, 2010 Dr. Durrant was granted 50,000 stock options (2009:
      400,000)</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(2) </TD>
    <TD>
      <P align=justify>Dr. de Kergrohen was appointed as our Chief Executive
      Officer and one of our directors on June 16, 2009. Dr. de Kergrohen was
      terminated as our Chief Executive Officer and as a director on March 1,
      2010. Stock option awards reported above represent the amount of expense
      recorded in the financial statements each year. During the fiscal year
      ended September 30, 2010 Dr. de Kergrohen was not granted any stock
      options (2009: 700,000). At the time of his termination, no stock options
      had vested and all options were canceled.</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(3) </TD>
    <TD>
      <P align=justify>Mr. Lalach was appointed President, CFO and Secretary on
      April 25, 2006. During the fiscal year ended September 30, 2010 Mr. Lalach
      was granted 50,000 stock options (2009: Nil)</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(4) </TD>
    <TD>
      <P align=justify>David Tousley was appointed as our Chief Financial
      Officer on September 1, 2010. Prior to that date, Mr, Tousley served as a
      member of our board of directors. During the fiscal year ended September
      30, 2010 Mr. Tousley was granted 250,000 stock options (2009:
  Nil).</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(5) </TD>
    <TD>
  <P align=justify>Dr. Vamvakides was appointed Chief Scientific Officer on January 31, 2007. During the fiscal year ended September 30, 2009, Dr. Vamvakides was granted 500,000 stock options which options vest as to 100,000 per compound entered into Phase II trial.  No expense has been recorded to date as the performance conditions have not been met.</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(6) </TD>
    <TD>
      <P align=justify>Details of our stock-based compensation arrangements,
      including the assumptions used in calculating the fair value of our share
      based awards, are disclosed in footnote 10 to our financial
    statements.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_51></A>
<P align=center>47</P>
<P align=justify><B><I>Consulting Agreements</I></B></P>
<P align=justify><I>Alexandre Vamvakides</I></P>
<P align=justify>We have a collaboration agreement with Alexandre Vamvakides
dated February 1, 2007 to provide the services of a Chief Scientific Officer and
to acquire property for the development of a new drug compound including three
patents and one patent application. Pursuant to the agreement, we agreed to the
following:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>invest a minimum of $200,000 every fiscal year into
      scientific research;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>hire the Chief Scientific Officer as a consultant to
      carry out our research and development program at $6,000 per
  month;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>pay to the director 6% of the net income earned from the
      exploitation of the patent and patent application; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(d) </TD>
    <TD>
      <P align=justify>disburse a one-time payment to the director an amount of
      $72,000 before December 31, 2007 as consideration for the transfer of the
      patents and the patent application, which has been
paid.</P></TD></TR></TABLE>
<P align=justify>The agreement is in force until terminated by either Dr.
Vamvakides or our company. During the fiscal year ended September 30, 2008, we
agreed to increase the compensation of Dr. Vamvakides to 7,000 Euros per
month.</P>
<P align=justify>On October 19, 2009 we signed a stock option agreement with
Alexandre Vamvakides which amended the June 11, 2009 stock option agreement to
include vesting provisions. All other terms of the June 11, 2009 stock option
agreement remain unchanged. Pursuant to the stock option agreement, we granted
to Dr. Vamvakides options to purchase 500,000 shares of our common stock at an
exercise price of $2.50 per share until June 11, 2014. The options vest as to
100,000 per compound entered into Phase II trial.</P>
<P align=justify><I>Cameron Durrant</I></P>
<P align=justify>On May 20, 2008, we entered into a consulting agreement with
Cameron Durrant to provide certain management and consulting services to our
company. Consideration for his services included: </P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>the issuance of 200,000 shares of common stock to be paid
      installments of 25,000 shares every quarter;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>the issuance of 400,000 stock options exercisable at
      $5.25 per share for a period of three years, subject to vesting
      provisions; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>a payment of a finder&#146;s fee for any financing our company
      receives in the amount of 4% on the first $100,000,000 and 2% on the
      balance.</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_52></A>
<P align=center>48</P>
<P align=justify>On May 14, 2009, we signed an amended consulting agreement with
Cameron Durrant, whereby the consideration of 200,000 common shares to be paid
in installments of 25,000 common shares every quarter was replaced with a grant
of 400,000 options at an exercise price of $2.50 per share until May 12, 2014
and vest as follows:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>200,000 options upon the execution of the amended
      consulting agreement;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>50,000 options on August 14, 2009</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>50,000 options on November 14, 2009</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(d) </TD>
    <TD>
      <P align=justify>50,000 on February 14, 2010</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(e) </TD>
    <TD>
      <P align=justify>50,000 options on May 14, 2010</P></TD></TR></TABLE>
<P align=justify>Dr. Durrant received 75,000 shares of common stock pursuant to
the consulting agreement dated May 20, 2008 and subsequently returned these
75,000 shares to our company for cancellation as a result of the award
modification.</P>
<P align=justify>On January 2, 2010 we signed a second amended consulting
agreement with Dr. Durrant, whereby we retained his services as our Executive
Chairman commencing as of January 2, 2010. In consideration of Dr. Durrant&#146;s
services, we agreed to pay him a monthly fee of $25,000, which equates to
$300,000 over the course of one year. The term of this agreement is for a period
of two years commencing on January 2, 2010 and expiring on January 1, 2012. </P>
<P align=justify><I>Harvey Lalach</I></P>
<P align=justify>We have a consulting agreement dated February 1, 2007 with
Harvey Lalach to provide management services to our company for consideration of
$7,000 per month. The contract had a two year term, and has been extended for an
additional two year term expiring January 31, 2011. During the fiscal year ended
September 30, 2008, we agreed to increase the compensation of Mr. Lalach to
$12,500 per month.</P>
<P align=justify><I>David Tousley</I></P>
<P align=justify>On September 1, 2010, we entered into an independent contractor
agreement with Mr. Tousley, one of our board of directors to provide certain
services to our company. Pursuant to the agreement, Mr. Tousley agreed to
perform such duties as are regularly and customarily performed by the Chief
Financial Officer of a corporation in consideration for, among other things,
$100,000 per annum. Mr. Tousley is also eligible to receive an annual bonus of
50% of his annual fees and a stock option award at the end of each year at the
discretion of the board of directors. The term of the agreement is two years
from September 1, 2010, unless both parties agree to extend. Either party may
terminate the agreement by giving six months notice plus two months for every
year of engagement of the contractor, up to 12 months. On September 1, 2010 we
issued 200,000 stock options exercisable at $3.45 per option to Mr. Tousley. The
options expire five years from the date of grant and vest monthly over the term
of Mr. Tousley&#146;s independent contractor agreement. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_53></A>
<P align=center>49</P>
<P align=justify><B><I>Outstanding Equity Awards at Fiscal Year-End</I></B></P>
<P align=justify>The following table sets forth for each named executive officer
and director certain information concerning the outstanding equity awards as of
September 30, 2010. </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee align=left
    >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="45%"
    colSpan=5 align=center><B>Option Awards</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="36%"
    colSpan=4 align=center><B>Stock Awards</B> </TD></TR>
  <TR vAlign=top>
    <TD bgColor=#eeeeee align=center
      ><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><B>Name</B>
    </TD>
    <TD bgColor=#eeeeee width="9%"
      align=center><BR><BR><BR><BR><BR><BR><BR><BR><BR><B>Number of</B>
      <BR><B>Securities</B> <BR><B>Underlying </B><BR><B>Unexercised
      </B><BR><B>Options</B> <BR><B>Exercisable </B></TD>
    <TD bgColor=#eeeeee width="9%"
      align=center><BR><BR><BR><BR><BR><BR><BR><BR><BR><B>Number of</B>
      <BR><B>Securities</B> <BR><STRONG>Underlying
      </STRONG><BR><STRONG>Unexercised </STRONG><BR><B>Options</B>
      <BR><STRONG>Unexercisable </STRONG></TD>
    <TD bgColor=#eeeeee width="9%"
      align=center><BR><BR><BR><BR><BR><B>Equity</B> <BR><B>Incentive</B>
      <BR><B>Plan</B> <BR><B>Awards:</B> <BR><B>Number of</B>
      <BR><B>Securities</B> <BR><STRONG>Underlying</STRONG>
      <BR><STRONG>Unexercised </STRONG><BR><B>Unearned
      </B><BR><STRONG>Options</STRONG> </TD>
    <TD bgColor=#eeeeee width="9%"
      align=center><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><STRONG>Option</STRONG>
      <BR><STRONG>Exercise </STRONG><BR><B>Price</B> </TD>
    <TD bgColor=#eeeeee width="9%"
      align=center><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><B>Option</B>
      <BR><STRONG>Expiration </STRONG><BR><B>Date</B> </TD>
    <TD bgColor=#eeeeee width="9%"
      align=center><BR><BR><BR><BR><BR><BR><BR><BR><B>Number</B> <BR><B>of
      Shares</B> <BR><B>or Units </B><BR><B>of Stock</B> <BR><B>that</B>
      <BR><STRONG>Have Not </STRONG><BR><B>Vested</B> </TD>
    <TD bgColor=#eeeeee width="9%"
      align=center><BR><BR><BR><BR><BR><BR><B>Market </B><BR><B>Value
      </B><BR><B>of</B> <BR><B>Shares or</B> <BR><STRONG>Units of</STRONG>
      <BR><B>Stock</B> <BR><B>that</B> <BR><STRONG>Have Not
      </STRONG><BR><B>Vested</B> </TD>
    <TD bgColor=#eeeeee width="9%" align=center><BR><BR><B>Equity</B>
      <BR><B>Incentive</B> <BR><B>Plan</B> <BR><B>Awards :
      </B><BR><STRONG>Number of </STRONG><BR><STRONG>Unearned
      </STRONG><BR><B>Shares,</B> <BR><B>Units or</B> <BR><B>Other</B>
      <BR><B>Rights</B> <BR><B>that</B> <BR><STRONG>Have Not
      </STRONG><BR><B>Vested</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#eeeeee width="9%"
    align=center><B>Equity</B> <BR><B>Incentive</B> <BR><B>Plan</B>
      <BR><B>Awards :</B> <BR><B>Market or</B> <BR><STRONG>Payout</STRONG>
      <BR><STRONG>Value of</STRONG> <BR><STRONG>Unearned</STRONG>
      <BR><B>Shares,</B> <BR><B>Units or</B> <BR><B>Other</B> <BR><B>Rights</B>
      <BR><B>that</B> <BR><STRONG>Have Not</STRONG> <BR><B>Vested</B> </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff align=left
    >Harvey <BR>Lalach </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>150,000 <BR>25,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>25,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$5.00 <BR>$3.50 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>June 3, 2013 <BR>June 29,2015 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff align=left
    >Alison <BR>Ayers </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>150,000 <BR>25,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>25,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$5.00 <BR>$3.50 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>June 3, 2013 <BR>June 29, 2015 </TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff align=left
    >Cameron <BR>Durrant <BR><BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>400,000 <BR>400,000 <BR>150,000 <BR>25,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR>Nil <BR>25,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR>Nil <BR>Nil </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$5.25 <BR>$2.50 <BR>$3.10 <BR>$3.50</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff
    width="9%" align=right>May 20, 2011 <BR>May 12, 2012 <BR>Dec 12, 2012
      <BR>June 29, 2015 </TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR><BR><BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR><BR><BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR><BR><BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR><BR><BR></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff align=left
    >David <BR>Tousley <BR></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>150,000 <BR>25,000 <BR>8,333 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>25,000 <BR>191,667 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>Nil <BR>Nil <BR>Nil </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>$3.10 <BR>$3.50 <BR>$3.45 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff width="9%"
    align=right>June 3, 2013 <BR>June 29, 2015 <BR>Sept 1, 2015 </TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR><BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR><BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR><BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" bgColor=#ffffff align=left
    >Alexandre <BR>Vamvakides </TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>500,000 <BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>$2.50 <BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>June 11,2014 <BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil <BR></TD>
    <TD bgColor=#ffffff width="9%" align=right>Nil
<BR></TD></TR></TABLE></DIV>
<P align=justify>We have not adopted any other equity compensation plan other
than our 2007 Stock Option Plan. </P>
<P align=justify><B><I>Compensation of Directors</I></B></P>
<P align=justify>The table below shows the compensation of our directors who
were not our named executive officers for the fiscal year ended September 30,
2010: </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD bgColor=#eeeeee align=center><BR><BR><BR><BR><B>Name</B> </TD>
    <TD bgColor=#eeeeee width="11%" align=center><BR><BR><B>Fees Earned or</B>
      <BR><B>Paid in Cash</B> <BR><B>($)</B> </TD>
    <TD bgColor=#eeeeee width="11%" align=center><BR><BR><B>Stock</B>
      <BR><B>Awards</B> <BR><B>($)</B> </TD>
    <TD bgColor=#eeeeee width="11%" align=center><BR><BR><B>Option</B>
      <BR><B>Awards</B><SUP>(1)</SUP> <BR><B>($)</B> </TD>
    <TD bgColor=#eeeeee width="11%" align=center><BR><B>Non-Equity</B>
      <BR><B>Incentive Plan</B> <BR><B>Compensation</B> <BR><B>($)</B> </TD>
    <TD bgColor=#eeeeee width="11%" align=center><B>Nonqualified</B>
      <BR><B>Deferred</B> <BR><B>Compensation</B> <BR><B>Earnings</B>
      <BR><B>($)</B> </TD>
    <TD bgColor=#eeeeee width="11%" align=center><BR><BR><B>All other</B>
      <BR><B>Compensation</B> <BR><B>($)</B> </TD>
    <TD bgColor=#eeeeee width="11%" align=center><BR><BR><BR><B>Total</B>
      <BR><B>($)</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Alison <BR>Ayers </TD>
    <TD width="11%" align=right>Nil <BR></TD>
    <TD width="11%" align=right>Nil <BR></TD>
    <TD width="11%" align=right>$125,000 <BR></TD>
    <TD width="11%" align=right>Nil <BR></TD>
    <TD width="11%" align=right>Nil <BR></TD>
    <TD width="11%" align=right>Nil <BR></TD>
    <TD width="11%" align=right>$125,000 <BR></TD></TR></TABLE></DIV><BR>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD vAlign=top width="5%"><SUP>(1)</SUP> </TD>
    <TD>
      <P align=justify>Details of our stock-based compensation arrangements,
      including the assumptions used in calculating the fair value of our share
      based awards, are disclosed in footnote 10 to our financial
    statements</P></TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_54></A>
<P align=center>50</P>
<P align=justify>We reimburse our directors for expenses incurred in connection
with attending board meetings. We have not paid any director&#146;s fees or other
cash compensation for services rendered as a director since our inception to
September 30, 2010.</P>
<P align=justify>During the fiscal year ended September 30, 2010, there were no
standard or other arrangements pursuant to which any of our directors were
compensated for services provided in their capacity as directors.</P>
<P align=justify>We currently have no formal plan for compensating our directors
for their services in their capacity as directors, although we may elect to
issue stock options to such persons in the future. Directors are entitled to
reimbursement for reasonable travel and other out-of-pocket expenses incurred in
connection with attendance at meetings of our board of directors. Our board of
directors may award special remuneration to any director undertaking any special
services on our behalf other than services ordinarily required of a director.
</P>
<P align=justify><I>Retirement or Similar Benefit Plans</I></P>
<P align=justify>There are no arrangements or plans in which we provide
retirement or similar benefits for our directors or executive officers. </P>
<P align=justify><I>Resignation, Retirement, Other Termination, or Change in
Control Arrangements </I></P>
<P align=justify>We have no contract, agreement, plan or arrangement, whether
written or unwritten, that provides for payments to our directors or executive
officers at, following, or in connection with the resignation, retirement or
other termination of our directors or executive officers, or a change in control
of our company or a change in our directors&#146; or executive officers&#146;
responsibilities following a change in control with the exception of the
agreement with David Tousley, our Chief Financial Officer, whereby if the
agreement is terminated within six months following a change of control, or if
the surviving entity fails to provide a similar agreement following a change of
control, then we agreed to pay Mr. Tousley a lump sum amount equal to 150% of
the amount calculated by multiplying (i) one twelfth of the annual fees in the
amount of $100,000 times (ii) the number of months in the termination notice
period (defined as the period of six months plus two months per year of
engagement of Mr. Tousley up to a maximum of twelve months).</P>
<P align=justify><B>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS</B></P>
<P align=justify>The following table sets forth, as of December 20, 2010,
certain information with respect to the beneficial ownership of our common stock
by each stockholder known by us to be the beneficial owner of more than 5% of
our common stock, by each of our current directors and executive officers. Each
person has sole voting and investment power with respect to the shares of common
stock, except as otherwise indicated. Beneficial ownership consists of a direct
interest in the shares of common stock, except as otherwise indicated.</P>
<P align=justify><B><I>Security ownership of certain beneficial owners
</I></B></P>
<P align=justify>In the following tables, we have determined the number and percentage
  of shares beneficially owned in accordance with Rule 13d-3 of the <i>Securities
  Exchange Act of 1934</i> based on information provided to us by our controlling
  stockholder, executive officers and directors, and this information does not
  necessarily indicate beneficial ownership for any other purpose.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_55></A>
<P align=center>51</P>
<P align=justify> In determining the number of shares of our common stock beneficially
  owned by a person and the percentage ownership of that person, we include any
  shares as to which the person has sole or shared voting power or investment
  power, as well as any shares subject to warrants or options held by that person
  that are currently exercisable or exercisable within 60 days.</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD bgColor=#eeeeee align=left><BR><B>Title of class</B> </TD>
    <TD bgColor=#eeeeee width="25%" align=center><B>Name and address of</B>
      <BR>
      <B>beneficial owner</B> </TD>
    <TD bgColor=#eeeeee width="25%" align=center><B>Amount and nature of</B>
      <BR><B>beneficial ownership</B> </TD>
    <TD bgColor=#eeeeee width="25%" align=center><B>Percent of</B>
      <BR><B>class </B><B><SUP>1</SUP></B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR><BR></TD>
    <TD width="25%" align=left><B>Athanasios Skarpelos</B> <BR>2, Place du
      Port <BR>Geneva, Switzerland <BR>CH 1204 </TD>
    <TD width="25%" align=left>6,725,832 <BR><BR><BR></TD>
  <TD width="25%" align=center>26.77% <BR><BR><BR></TD></TR></TABLE></DIV>
<P align=justify><B><I>Security Ownership of Management </I></B></P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 8pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD bgColor=#eeeeee align=center><BR><B>Title of class</B> </TD>
    <TD bgColor=#eeeeee width="25%" align=center><B>Name and address of</B>
      <BR><B>beneficial owner</B> </TD>
    <TD bgColor=#eeeeee width="25%" align=center><B>Amount and nature of</B>
      <BR><B>beneficial ownership</B> </TD>
    <TD bgColor=#eeeeee width="25%" align=center><B>Percent of</B>
      <BR><B>class </B><B><SUP>1</SUP></B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Common Stock <BR><BR><BR></TD>
    <TD width="25%" align=left><B>Harvey Lalach</B> <BR>4837 Canyon Ridge
      Crescent <BR>Kelowna, British Columbia <BR>Canada </TD>
    <TD width="25%" align=right>800,000 <SUP>2</SUP> Direct <BR><BR><BR></TD>
    <TD width="25%" align=center>3.16% <BR><BR><BR></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>Common Stock <BR><BR></TD>
    <TD bgColor=#ffffff width="25%" align=left><B>Alexandre Vamvakides</B>
      <BR>3, Cite De L&#146;alma <BR>Paris, France </TD>
    <TD bgColor=#ffffff width="25%" align=right>Nil <BR><BR></TD>
    <TD bgColor=#ffffff width="25%" align=center>Nil <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>Common Stock <BR><BR></TD>
    <TD bgColor=#ffffff width="25%" align=left><B>Cameron Durrant</B> <BR>#90
      Fairmount Road West <BR>Califon, NJ 07830-3330 </TD>
    <TD bgColor=#ffffff width="25%" align=right>1,000,000 <SUP>3</SUP> Direct
      <BR><BR></TD>
    <TD bgColor=#ffffff width="25%" align=center>3.83% <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>Common Stock <BR><BR></TD>
    <TD bgColor=#ffffff width="25%" align=left><B>Alison Ayers</B> <BR>27
      O&#146;Connor Circle <BR>West Orange, NJ 07052 </TD>
    <TD bgColor=#ffffff width="25%" align=right>200,000 <SUP>4</SUP> Direct
      <BR><BR></TD>
    <TD bgColor=#ffffff width="25%" align=center>0.79% <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left>Common Stock <BR><BR></TD>
    <TD bgColor=#ffffff width="25%" align=left><B>David Tousley</B> <BR>14610
      Pawnee Lane <BR>Leawood, KS 66224 </TD>
    <TD bgColor=#ffffff width="25%" align=right>241,665 <SUP>5</SUP> Direct
      <BR><BR></TD>
    <TD bgColor=#ffffff width="25%" align=center>0.95% <BR><BR></TD></TR>
  <TR vAlign=top>
    <TD bgColor=#ffffff align=left><BR><BR></TD>
    <TD bgColor=#ffffff width="25%" align=left><B>Directors &amp;
      Executive</B> <BR><B>Officers as a group (5</B> <BR><B>persons)</B> </TD>
    <TD bgColor=#ffffff width="25%" align=right><B>2,241,665</B> <BR><BR></TD>
    <TD bgColor=#ffffff width="25%" align=center>8.37%
<BR><BR></TD></TR></TABLE></DIV>
<P align=justify><SUP>1</SUP> Percentage of ownership is based on 25,127,226
shares of our common stock issued and outstanding as of December 20, 2010.
Except as otherwise indicated, we believe that the beneficial owners of the
common stock listed above, based on information furnished by such owners, have
sole investment and voting power with respect to such shares, subject to
community property laws where applicable. Beneficial ownership is determined in
accordance with the rules of the Securities and Exchange Commission and
generally includes voting or investment power with respect to securities. Shares
of common stock subject to options or warrants currently exercisable, or
exercisable within 60 days, are deemed outstanding for purposes of computing the
percentage ownership of the person holding such option or warrants, but are not
deemed outstanding for purposes of computing the percentage ownership of any
other person. <BR><SUP>2 </SUP>Includes 600,000 shares of common stock and
200,000 stock options exercisable within 60 days. <BR><SUP>3</SUP>Includes
1,000,000 stock options exercisable within 60 days. <BR><SUP>4 </SUP>Includes
200,000 stock options exercisable within 60 days. <BR><SUP>5</SUP>Includes
241,665 stock options exercisable within 60 days.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_56></A>
<P align=center>52</P>
<P align=justify><B><I>Changes in Control </I></B></P>
<P align=justify>We are unaware of any contract or other arrangement the
operation of which may at a subsequent date result in a change of control of our
company. </P>
<P align=justify><B>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND
DIRECTOR INDEPENDENCE</B></P>
<P align=justify><B><I>Transactions with related persons </I></B></P>
<P align=justify>Other than as disclosed below and elsewhere, there has been no
transaction, since October 1, 2008, or currently proposed transaction, in which
we were or are to be a participant and the amount involved exceeds the lesser of
$120,000 or one percent of the average of our total assets at year end for the
last two completed fiscal years, and in which any of the following persons had
or will have a director or indirect material interest.</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%" BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(i) </TD>
    <TD>
      <P align=justify>any director or executive officer of our
  company;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(ii) </TD>
    <TD>
      <P align=justify>any beneficial owner of shares carrying more than 5% of
      the voting rights attached to our outstanding shares of common stock;
      and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(iii) </TD>
    <TD>
      <P align=justify>any member of the immediate family (including spouse,
      parents, children, siblings and in-laws) of any of the foregoing
      persons.</P></TD></TR></TABLE>
<P align=justify>On May 15, 2008, we terminated the services of Panos Kontzalis,
our former Chief Executive Officer and agreed to a severance package consisting
of the issuance of 65,000 shares of our common stock. In addition, we issued a
promissory note payable to him in the amount of $200,000. This promissory note
was without interest and had specified repayment terms. We repaid $100,000 in
accordance with the repayment terms. On February 2, 2010 we issued 49,505 shares
of our common stock, at their fair value of $2.02 per share pursuant to an
agreement with Mr. Kontzalis to settle the outstanding amount owed ($100,000).
</P>
<P align=justify><B><I>Compensation of Executive Officers and
Directors</I></B></P>
<P align=justify>For information regarding compensation of our executive
officers and directors, please see &#147;Item 11. Executive Compensation.&#148;</P>
<P align=justify><B><I>Director Independence </I></B></P>
<P align=justify>Under NASDAQ Rule 5605(a)(2), a director is not considered to
be independent if he or she is also an executive officer or employee of the
company or accepted any compensation from the company in excess of $120,000
during any period of twelve consecutive months within the three years preceding
the determination of independence. </P>
<P align=justify>We determined that Harvey Lalach, David Tousley, and Cameron
  Durrant are not independent as that term is defined by NASDAQ 5605(a)(2) because
  Mr. Lalach is our President and Chief Operating Officer, Mr. Tousley is our
  Chief Financial Officer and Dr. Durrant is our Executive Chairman and principal
  executive officer. We determined that Alison Ayers is independent as that term
  is defined by NASDAQ Rule 5605(a)(2).</P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_57></A>
<P align=center>53</P>
<P align=justify><B>ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</B></P>
<P align=justify><B><I>Fees Paid to Our Independent Registered Public Accounting
Firm</I></B></P>
<P align=justify>The following table sets forth the aggregate fees billed or
expected to be billed to our company for professional services rendered by our
independent registered public accounting firms, for the fiscal years ended
September 30, 2010 and 2009:</P>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=0 cellSpacing=0 cellPadding=0 width="100%">

  <TR vAlign=top>
    <TD align=left><B>Fees</B> </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right><B>2010</B> </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right><B>2009</B> </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD  width="2%">&nbsp;</TD>
    <TD  width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp; </TD>
    <TD  width="2%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>&nbsp; &nbsp;Audit fees </TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>86,656 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>80,838 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Audit related fees </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>Nil </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>Nil </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left>&nbsp; &nbsp;Tax fees </TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>6,537 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left>$</TD>
    <TD bgColor=#e6efff width="12%" align=right>3,850 </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;All other fees </TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>Nil </TD>
    <TD  width="2%" align=left>&nbsp;</TD>
    <TD  width="1%" align=left>&nbsp;</TD>
    <TD width="12%" align=right>Nil </TD>
    <TD  width="2%" align=left>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD bgColor=#e6efff align=left><B>Total Fees</B> </TD>
    <TD bgColor=#e6efff  width="1%" align=left><B>$</B></TD>
    <TD bgColor=#e6efff width="12%" align=right><B>93,193</B> </TD>
    <TD bgColor=#e6efff  width="2%" align=left>&nbsp;</TD>
    <TD bgColor=#e6efff  width="1%" align=left><B>$</B></TD>
    <TD bgColor=#e6efff width="12%" align=right><B>84,688</B> </TD>
    <TD bgColor=#e6efff  width="2%"
  align=left>&nbsp;</TD></TR></TABLE>
<P align=justify><B><I>Audit Fees</I></B><I>.</I> Consist of fees billed for
professional services rendered for the audits of our financial statements,
reviews of our interim financial statements included in quarterly reports,
services performed in connection with filings with the Securities and Exchange
Commission and other services that are normally provided by BDO Dunwoody LLP for
the fiscal years ended September 30, 2010 and 2009, in connection with statutory
and regulatory filings or engagements. </P>
<P align=justify><B><I>Policy on Pre-Approval by Audit Committee of Services
Performed by Independent Registered Public Accounting Firm</I></B></P>
<P align=justify>Our audit committee pre-approves all services provided by our
independent registered public accounting firm. All of the above services and
fees were reviewed and approved by our audit committee before the respective
services were rendered.</P>
<P align=justify>Our audit committee has considered the nature and amount of
fees billed by BDO Dunwoody LLP and believes that the provision of services for
activities unrelated to the audit was compatible with maintaining BDO Dunwoody
LLP&#146;s independence.</P>
<P align=center><B>PART IV</B></P>
<P align=justify><B>ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</B></P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD align=left ><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD width="90%" align=left><BR><B>Description</B> </TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
      ><B>(3)</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left>
      <P align=justify><B>Articles of Incorporation and Bylaws</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >3.1 </TD>
    <TD width="90%" align=left>
      <P align=justify>Articles of Incorporation (incorporated by reference to
      an exhibit to our Registration Statement on Form SB-2 filed on January 13,
      2005) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >3.2 </TD>
    <TD width="90%" align=left>
      <P align=justify>Bylaws (incorporated by reference to an exhibit to our
      Registration Statement on Form SB-2 filed on January 13, 2005)
  </P></TD></TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_58></A>
<P align=center>54</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD align=left >
      <P align=justify><B>Exhibit</B> <BR><B>Number</B> </P></TD>
    <TD width="90%" align=left>
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=center >
      <P align=justify>3.3 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Articles of Merger filed with the Secretary of State of
      Nevada on January 10, 2007 and which is effective January 25, 2007
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on January 25, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center >
      <P align=justify><B>(4)</B> </P></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left>
      <P align=justify><B>Instruments defining rights of security holders,
      including indentures</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=center >
      <P align=justify>4.1 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Specimen Stock Certificate (incorporated by reference to
      an exhibit to our Registration Statement on Form SB-2 filed on January 13,
      2005) </P></TD></TR>
  <TR vAlign=top>
    <TD align=center >
      <P align=justify>4.2 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Form 8-K filed on April 3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=center >
      <P align=justify>4.3 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>8% Convertible Loan Agreement dated June 3, 2009
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=center >
      <P align=justify>4.4 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>8% Convertible Loan Agreement dated June 19, 2009
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right >
      <P align=justify><B>(10)</B> </P></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left>
      <P align=justify><B>Material Contracts</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >
      <P align=justify>10.1 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Agreement between Anavex Life Sciences Corp. and Dr.
      Alexandre Vamvakides dated January 31, 2007 (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on February 7, 2007)
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >
      <P align=justify>10.2 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Abstract of Disclosure of Greek Patent Number 1002616
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >
      <P align=justify>10.3 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Abstract of Disclosure of Greek Patent Number 1004208
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >
      <P align=justify>10.4 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Abstract of Disclosure of Greek Patent Number 1004868
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >
      <P align=justify>10.5 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Written description of Greek Patent Application Number
      20070100020 (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on February 7, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >
      <P align=justify>10.6 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Stock Option Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on February 22,
      2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >
      <P align=justify>10.7 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Shares for Services and Subscription Agreement dated
      September 11, 2007 between our company and Eurogenet Labs S.A.
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on September 27, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >
      <P align=justify>10.8 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>2007 Stock Option Plan (incorporated by reference to an
      exhibit to our Current Report on Form 8-K filed on September 28, 2007)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >
      <P align=justify>10.9 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Consulting Agreement with Cameron Durrant dated May 20,
      2008 (incorporated by reference to an exhibit to our Quarterly Report on
      Form 10-QSB filed on August 18, 2008 </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >
      <P align=justify>10.10 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on April
      3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >
      <P align=justify>10.11 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Consulting Agreement with Tariq Arshad dated March 2,
      2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on April 3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >
      <P align=justify>10.13 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Consulting Agreement with Dr. Mark Smith dated January
      13, 2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on April 3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >
      <P align=justify>10.14 </P></TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on April 3, 2009)
      </P></TD></TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_59></A>
<P align=center>55</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number </B></TD>
    <TD width="90%" align=left><BR><STRONG>Description</STRONG> </TD></TR>
  <TR vAlign=top>
    <TD align=left >10.15 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on April 3, 2009)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.16 </TD>
    <TD width="90%" align=left>
      <P align=justify>Amended Consulting Agreement with Cameron Durrant dated
      May 14, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.17 </TD>
    <TD width="90%" align=left>
      <P align=justify>CEO Consulting Agreement with Dr. Herve de Kergrohen
      dated June 12, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.18 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Private Placement subscription agreement dated
      June 15, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.19 </TD>
    <TD width="90%" align=left>
      <P align=justify>Shares for Services Agreement with Andreas Eleuthariadis
      dated June 10, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.20 </TD>
    <TD width="90%" align=left>
      <P align=justify>Shares for Services Agreement with Vasileios Kourafalos
      dated June 10, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.21 </TD>
    <TD width="90%" align=left>
      <P align=justify>Shares for Services Agreement with George Kalkanis dated
      June 10, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.22 </TD>
    <TD width="90%" align=left>
      <P align=justify>Stock Option Agreement with Alexandre Vamvakides dated
      June 11, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.23 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Private Placement Subscription Agreement
      Convertible Loan (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.24 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Private Placement Subscription Agreement for
      Units (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.25 </TD>
    <TD width="90%" align=left>
      <P align=justify>Consultant Services Agreement with NAD Ltd. dated July 1,
      2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on November 24, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.26 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on November 24,
      2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.27 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on August 12, 2009)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.28 </TD>
    <TD width="90%" align=left>
      <P align=justify>Stock Option Agreement with Alexander Vamvakides dated
      October 19, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on November 24, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.29 </TD>
    <TD width="90%" align=left>
      <P align=justify>Promissory note issued to Stonehedge Limited on January
      1, 2010 (incorporated by reference to an exhibit to our Quarterly Report
      on Form 10-Q filed on March 31, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.30 </TD>
    <TD width="90%" align=left>
      <P align=justify>Second Amended Consulting Agreement with Dr. Cameron
      Durrant dated January 2, 2010 (incorporated by reference to an exhibit to
      our Current Report on Form 8-K filed on April 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.31 </TD>
    <TD width="90%" align=left>
      <P align=justify>Contract Lease Agreement with Euro Genet Labs SA dated
      February 1, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on April 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.32 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on April 9, 2010)
      </P></TD></TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_60></A>
<P align=center>56</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number </B></TD>
    <TD width="90%" align=left><BR><STRONG>Description</STRONG> </TD></TR>
  <TR vAlign=top>
    <TD align=left >10.33 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on April 9, 2010)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.34 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on April
      9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.35 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Subscription Agreement for US subscribers
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.36 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Subscription Agreement for non-US subscribers
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.37 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Warrant Certificate for US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.38 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Warrant Certificate for non-US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.39 </TD>
    <TD width="90%" align=left>
      <P align=justify>Shares for Services Agreement dated July 5, 2010 with
      Eurogenet Labs SA (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on July 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.40 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Warrant Certificate for non-US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.41 </TD>
    <TD width="90%" align=left>
      <P align=justify>Agreement for Services with Genesis Biopharma Group LLC
      dated August 10, 2010 (incorporated by reference to an exhibit of our
      Current Report on Form 8-K filed on August 18, 2010) <I>(portions of the
      exhibit have been omitted pursuant to a request for</I> <I>confidential
      treatment)</I> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.42 </TD>
    <TD width="90%" align=left>
      <P align=justify>Agreement for Services with ABX-CRO Advanced
      Pharmaceutical Services dated August 10, 2010 (incorporated by reference
      to an exhibit of our Current Report on Form 8-K filed on August 18, 2010)
      <I>(portions of the exhibit have been omitted pursuant to a</I> <I>request
      for confidential treatment)</I> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.43 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Subscription Agreement (US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.44 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Subscription Agreement (Canadian and Offshore
      Purchasers) (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.45 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Warrant Certificate (US warrant
      holders)(incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.46 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Warrant Certificate (Canadian and Offshore
      warrant holders) (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.47 </TD>
    <TD width="90%" align=left>
      <P align=justify>Consulting Agreement dated August 2, 2010 with Tom
      Skarpelos (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.48 </TD>
    <TD width="90%" align=left>
      <P align=justify>Independent Contractor Agreement dated September 1, 2010
      with David Tousley (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.49 </TD>
    <TD width="90%" align=left>
      <P align=justify>Sublease Contract with Genesis Research LLC dated
      September 15, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left >10.50 </TD>
    <TD width="90%" align=left>
      <P align=justify>Form of Subscription Agreement (US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on November 22, 2010) </P></TD></TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_61></A>
<P align=center>57</P>
<DIV>
  <TABLE
style="BORDER-COLOR: black; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; "
border=1 cellSpacing=0 borderColor=#000000 cellPadding=3 width="100%">
    <TR vAlign=top>
      <TD align=left > <P align=justify><B>Exhibit</B> <BR>
          <B>Number</B> </P></TD>
      <TD width="90%" align=left> <P align=justify><BR>
          <B>Description</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=center > <P align=justify>10.51 </P></TD>
      <TD width="90%" align=left> <P align=justify>Form of Subscription Agreement
          (non-US Purchasers) (incorporated by reference to an exhibit to our
          Current Report on Form 8-K filed on November 22, 2010) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=center > <P align=justify>10.52 </P></TD>
      <TD width="90%" align=left> <P align=justify>Form of Warrant Certificate
          (US Warrant Holders) (US Purchasers) (incorporated by reference to an
          exhibit to our Current Report on Form 8-K filed on November 22, 2010)
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=center > <P align=justify>10.53 </P></TD>
      <TD width="90%" align=left> <P align=justify>Form of Warrant Certificate
          (non-US Warrant Holders) (US Purchasers) (incorporated by reference
          to an exhibit to our Current Report on Form 8-K filed on November 22,
          2010) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=center > <P align=justify>10.54 </P></TD>
      <TD width="90%" align=left> <P align=justify>Shares for Service and Subscription
          Agreement dated November 1, 2010 with Eurogenet Labs SA (incorporated
          by reference to an exhibit to our Current Report on Form 8-K filed on
          November 22, 2010) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=center > <P align=justify>10.55 </P></TD>
      <TD width="90%" align=left> <P align=justify>Subscription Agreement with
          Stonehedge Limited dated November 17, 2010 (incorporated by reference
          to an exhibit to our Current Report on Form 8-K filed on November 22,
          2010) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=center > <P align=justify>10.56 </P></TD>
      <TD width="90%" align=left> <P align=justify>Form of Subscription Agreement
          (incorporated by reference to an exhibit to our Current Report on Form
          8-K filed on November 30, 2010) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=center> <P align=justify>10.57 </P></TD>
      <TD width="90%" align=left> <P align=justify>Form of Warrant Certificate
          Form of Subscription Agreement (incorporated by reference to an exhibit
          to our Current Report on Form 8-K filed on November 30, 2010) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=center > <P align=justify>10.58 </P></TD>
      <TD width="90%" align=left> <P align=justify>Shares for Services Agreement
          Form of Subscription Agreement (incorporated by reference to an exhibit
          to our Current Report on Form 8-K filed on November 30, 2010) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left > <P align=justify><B>(14)</B>
        </P></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left> <P align=justify><B>Code
          of Ethics</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left > <P align=justify>14.1 </P></TD>
      <TD width="90%" align=left> <P align=justify>Code of Conduct (incorporated
          by reference to an exhibit to our Current Report on Form 8-K filed on
          September 28, 2007) </P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left > <P align=justify><B>(21)</B>
        </P></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left> <P align=justify><B>Subsidiaries</B>
        </P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left > <P align=justify>21.1
        </P></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left> <P align=justify>Anavex
          Life Sciences (France) SA, incorporated under the laws of France </P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left > <P align=justify><B>(31)</B>
        </P></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left> <P align=justify><B>Section
          302 Certifications</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left > <P align=justify><a href="exhibit31-1.htm">31.1*
          </a></P></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left> <P align=justify><a href="exhibit31-1.htm">Section
          302 Certification of Dr. Cameron Durrant </a></P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left > <P align=justify><a href="exhibit31-2.htm">31.2*
          </a></P></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left> <P align=justify><a href="exhibit31-2.htm">Section
          302 Certification of David Tousley </a></P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left > <P align=justify><B>(32)</B>
        </P></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left> <P align=justify><B>Section
          906 Certifications</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left > <P align=justify><a href="exhibit32-1.htm">32.1*
          </a></P></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left> <P align=justify><a href="exhibit32-1.htm">Section
          906 Certification of Dr. Cameron Durrant </a></P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left > <P align=justify><a href="exhibit32-2.htm">32.2*
          </a></P></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left> <P align=justify><a href="exhibit32-2.htm">Section
          906 Certification of David Tousley </a></P></TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left > <P align=justify><B>(99)</B>
        </P></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" width="90%" align=left> <P align=justify><B>Additional
          Exhibits</B> </P></TD>
    </TR>
    <TR vAlign=top>
      <TD align=left > <P align=justify>99.1 </P></TD>
      <TD width="90%" align=left> <P align=justify>Insider Trading Policy Adopted
          August 27, 2010 (incorporated by reference to an exhibit to our Current
          Report on Form 8-K filed on September 27, 2010) </P></TD>
    </TR>
  </TABLE>
</DIV>
<P align=justify>* Filed herewith. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center color=black SIZE=5
width="100%" noShade>
<!--$$/page=--><A name=page_62></A>
<P align=center>58</P>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.</P>
<P align=justify><B>ANAVEX LIFE SCIENCES CORP. </B></P>
<P align=justify>By:</P>
<P align=justify><u>/s/ Dr. Cameron Durrant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><BR>
  Dr. Cameron Durrant<BR>
Executive Chairman and Director <BR>(Principal Executive Officer)
<BR>
Date: December 23, 2010 </P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons on behalf of
the registrant and in the capacities and on the dates indicated.</P>
<P align=justify>By:</P>
<P align=justify><u>/s/Dr. Cameron Durrant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</u><BR>
  Dr. Cameron Durrant
<BR>Executive Chairman and Director <BR>(Principal Executive Officer)
<BR>
Date: December 23, 2010 </P>
<P align=justify>&nbsp;</P>
<P align=justify>By</P>
<P align=justify><u>/s/David Tousley&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u><BR>David Tousley <BR>Chief
Financial Officer and Director<BR>(Principal Financial Officer and Principal
Accounting Officer) <BR>
Date: December 23, 2010 </P>
<P align=justify>&nbsp;</P>
<P align=justify>By:</P>
<P align=justify><u>/s/Harvey
Lalach&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><BR>
  Harvey
Lalach<BR>President, Chief Operating Officer, Secretary and Director
<BR>
Date: December 23, 2010 </P>
<HR align=center color=black SIZE=5 width="100%" noShade>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
